Exploiting Oxidative Stress as a Therapeutic Option in Rhabdomyosarcoma by Brack, Eva
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
Exploiting Oxidative Stress as a Therapeutic Option in Rhabdomyosarcoma
Brack, Eva
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-162951
Dissertation
Published Version
Originally published at:
Brack, Eva. Exploiting Oxidative Stress as a Therapeutic Option in Rhabdomyosarcoma. 2018, Univer-
sity of Zurich, Faculty of Medicine.
Exploiting Oxidative Stress 
as a Therapeutic Option in Rhabdomyosarcoma 
 
 
 
 
Dissertation 
 
zur 
 
Erlangung der naturwissenschaftlichen Doktorwürde 
(Dr. sc. nat.) 
 
vorgelegt der 
 
Mathematisch-naturwissenschaftlichen Fakultät 
 
der 
 
Universität Zürich 
 
von 
 
Eva Brack 
 
aus Deutschland 
 
 
 
Promotionskommission 
Prof. Dr. Beat Schäfer (Vorsitz) 
Prof. Dr. Martin Pruschy 
Prof. Dr. Alex Hajnal 
 
 
Zürich, 2018  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
STATEMENT OF AUTHORSHIP 
 
The experimental work presented in this thesis was performed at the Department of 
Oncology and Children’s Research Center, University Children's Hospital Zurich. I declare 
that I have used no other sources and aids other than those indicated. All passages quoted 
from publications or paraphrased from these sources are indicated as such, i.e. cited and/or 
attributed. This thesis was not submitted in any form for another degree or diploma at any 
university of other institution of tertiary education. 
 
Zurich, May 2018 
Eva Brack  
 
  
 
 
 
 
 
 
To Christoph and Antonie who supported me along my journey 
- and to my patients, who just deserve better 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Any living cell carries with it the experiences of a billion years of 
experimentation by its ancestors. You cannot expect to explain so 
wise an old bird in a few simple words.  
Max Delbrück, geneticist, 1966 
 
 
 
 
Summary 
Rhabdomyosarcomas are the most common soft tissue sarcomas and account for around 7% of 
childhood malignancies. Within this group, alveolar rhabdomyosarcoma (aRMS) is a highly 
malicious subtype, which is characterized by a specific chromosomal translocation encoding the 
oncogenic transcription factor PAX3-FOXO1. Standard treatment for children with aRMS 
comprises surgery, chemotherapy, and radiotherapy. Despite this aggressive treatment approach, 
survival rates remain poor, especially in the case of recurrences. Further, due to the high toxicity 
of the different treatment modalities, short-, as well as long-term side-effects are common, which 
subsequently greatly influence the patients’ quality of life.  
In an attempt to find new therapeutic agents from a large drug library screen, we have previously 
identified the compound fenretinide (retinoic acid p-hydroxyanilide), to affect both PAX3-FOXO1 
expression as well as aRMS cell viability. Fenretinide is a Vitamin A derivate and already in 
clinical use since many years but has up-until-now not been used in the context of 
rhabdomyosarcoma.  
In this thesis my aim was to characterize the mode of action of fenretinide in aRMS in detail and 
to find treatment modalities that act in combination with fenretinide.  
We were able to show that fenretinide induced the production of reactive oxygen species (ROS). 
Further exploration revealed that the fenretinide-induced ROS derived from an interaction of 
fenretinide downstream of complex II of the mitochondrial respiratory chain, leading to 
mitochondrial ROS (superoxides) which were able to trigger cell death, as ROS scavenging 
completely abolished cell death.  
To identify the mode of cell death involved, we next co-treated cells with commonly used 
pharmacological inhibitors of specific cell death pathways including Z-vad (pan-caspase inhibitor-
apoptosis inhibitor), Necrostatin-1 (RIP-1 kinase inhibitor-necroptosis inhibitor), 3-Methyadenine 
(3-MA) (phosphatidylinositol 3-kinase inhibitor-autophagy inhibitor) and Ferrostatin-1 
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(ferroptosis inhibitor). Interestingly, none of these inhibitors was able to rescue cells from cell 
death. Moreover, CRISPR/Cas9 mediated depletion of key players in the apoptotic and necroptotic 
pathway (Bak, Bax and RIPK1) confirmed our pharmacological data. These findings indicate that 
a different, less well characterized cell death pathway might be involved. Surprisingly, electron 
microscopic images of fenretinide treated cells revealed an excessive accumulation of cytoplasmic 
vacuoles. Morphologically, these vacuoles were distinct from autophagosomes and swollen 
endoplasmic reticulum, as observed during autophagy, oncosis, or paraptosis.  
Subsequent flow cytometry and fluorescence microscopy experiments pointed at a 
hyperstimulated macropinocytosis which shows accumulation of enlarged early and late 
endosomes due to impaired endosomal trafficking. However and most notable, pharmacological 
inhibition of the classical endosomal pathways (clathrin and caveolae mediated endocytosis) did 
not influence cell death. In contrast, pharmacological inhibition as well as genetic knockdown of 
the large GTPase dynamin completely abolished the fenretinide induced vacuolization, indicating 
a new form of dynamin-dependent cell death.  
In the second part of this thesis, we concentrated on treatment modalities that would enhance cell 
death in combination with fenretinide. To expand the treatment regime in this difficult to treat 
tumours is one of the main ambitions connecting laboratory and clinical research. We focused on 
ionizing radiation (IR), as this treatment form is already part of the standard treatment regime of 
patients with aRMS. However, IR is prone to induce many side-effects including growth-
restriction, infertility and the development of secondary malignancies. Hence, identification of 
radio sensitizers is highly desirable and would allow to reduce the applied doses. Our study 
showed, that the combinatorial treatment potentiated cell death and led to an impaired clonogenic 
growth. This was due to an enhanced production of a different type of ROS, namely production of 
hydrogen peroxide whereas fenretinide mainly induces superoxides. Further, we detected 
 II 
Summary / Zusammenfassung 
augmented DNA damage and impaired cell cycle progression in the co-treated cells, most likely 
due to enhanced ROS damage.  
Finally, we analysed the underlying cell death mechanisms and found an induction of apoptosis 
together with increased macropinocytosis. However, IR alone did not influence macropinocytosis 
which is specific for fenretinide.  
 
Taken together, our data identify fenretinide to demonstrate high potential for treatment of aRMS, 
as it induces a new form of dynamin dependent cell death mediated through the production of 
ROS. Further in combination with IR, fenretinide is a very promising radio-sensitizer able to 
significantly enhance cell death.  
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Zusammenfassung 
Das Rhabdomyosarkom ist der häufigste Tumor aus der Gruppe der Weichteilsarkome und hat in 
etwa einen Anteil von 7% an allen kindlichen Krebserkrankungen. Eine Untergruppe dieser 
Tumore ist das hochmaligne alveoläre Rhabdomyosarkom welches durch eine spezifische 
chromosomale Translokation und den dadurch codierten onkogenen Transkriptionsfaktor PAX3-
FOXO1 charakterisiert ist.  
Das Standardbehandlungsregime für Kinder welche an aRMS erkranken beinhaltet Operation und 
Strahlentherapie für die lokale Kontrolle und Chemotherapie als systemische Behandlung. Trotz 
dieses aggressiven Vorgehens sind die Überlebensraten noch immer schlecht, dies vor allem, wenn 
es zu einem Krankheitsrückfall (Relapse) kommt. Darüber hinaus haben die unterschiedlichen 
Behandlungen, aufgrund ihrer hohen Toxizität, häufig Kurzzeit- und Langzeitnebenwirkungen, 
welche einen grossen Einfluss auf die Lebensqualität der Patienten haben. In unserer 
Arbeitsgruppe wurde im Rahmen eines Medikamentenscreens der Wirkstoff Fenretinide (retinoic 
acid p-hydroxyanilide) als ein Therapeutikum identifiziert, dass in den durchgeführten Versuchen 
sowohl die Expression von PAX3-FOXO1 als auch das Zell Überleben von aRMS Zellen 
beeinflusst. Fenretinide, welches zur Familie der A-Vitamine gehört, ist bereits seit vielen Jahren 
im klinischen Gebrauch und wurde auch in multiplen Studien integriert, eine Anwendung zur 
Behandlung des Rhabdomyosarkoms ist bis dato noch nicht beschrieben.  
Ziel dieser Doktorarbeit war es die genaue Wirkungsweise von Fenretinide auf aRMS-Zellen im 
Detail zu untersuchen und zudem die Kombination von Fenretinide mit weiteren 
Behandlungsmodalitäten auf eine synergistische Wirkung hin zu evaluieren. 
 
In unseren Versuchen konnten wir zeigen dass Fenretinide die Produktion von reaktiven 
Sauersoffradikalen (reactive oxygene species, ROS) induziert. Weitere Untersuchungen zeigten 
dass Sauerstoffradikale durch eine Interaktion von Fenretinide mit dem Komplex-II der 
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mitochondrialen Atmungskette hervorgerufen wurden und so für die Entstehung von 
mitochondrialen ROS (Superoxiden) sorgen. Weiter zeigte sich, dass diese Superoxide den 
eintretenden Zelltod induzieren. Dies konnte durch anschliessende Neutralisationsversuche 
bewiesen werden, da die Induktion des Zelltods komplett aufgehoben werden konnten. Um den 
genauen Zelltodmechanismus der diesen Beobachtungen zugrunde liegt zu identifizieren, 
behandelten wir unsere Zellen zusätzlich mit pharmakologischen Inhibitoren der gängigsten 
Zelltod Wege zusammen mit Fenretinide. Zu diesen Inhibitoren der verschiedenen 
Zelltodmechanismen zählen Z-vad (pan-caspase Inhibitor-Apoptose Inhibitor), Necrostatin-1 
(RIP-1 kinase Inhibitor- Nekroptose Inhibitor), 3-Methyadenine (3-MA) (Phosphatidylinositol 3-
kinase Inhibitor- Autophagy Inhibitor) und Ferrostatin-1 (Ferroptose Inhibitor). Interessanterweise 
konnte keiner dieser Inhibitoren den Zelltod verhindern. Darüber hinaus konnten wir mit Hilfe der 
CRISPR/Cas9 vermittelten Ausschaltung von Schlüsselmolekülen des apoptotischen, als auch des 
nekroptotischen Zelltods (Bak, Bax und RIPK1) unsere pharmakologischen Daten bestätigen. 
Diese Forschungsergebnisse weisen darauf hin, dass voraussichtlich ein weniger gut 
charakterisierter Zelltod an der Wirkung von Fenretinide beteiligt ist. Elektronenmikroskopische 
Aufnahmen von Fenretinide behandelten Zellen zeigten eine exzessive Anhäufung von Vakuolen 
im Zytoplasma. Morphologisch stellten sich diese Vakuolen jedoch unterschiedlich zu 
Autophagosomen oder zum geschwollenem endoplasmatischen Retikulum dar, wie sie während 
Autophagy, Oncosis oder Paraptosis beobachtet werden können.  
Weiterführende Durchflusszytometrie und Fluoreszenzmikroskopie Untersuchungen deuteten in 
die Richtung einer überstimulierten Makropinozytose. In diesem Fall führt eine eingeschränkte 
Beweglichkeit von vergrösserten frühen-als auch späten Endosomen zu einer Anhäufung 
derselben. Am bemerkenswertesten war jedoch dass eine pharmakologische Inhibition der 
klassischen endosomalen Wege, via Clathrin und Caveolin vermittelte Endozytose, keinen 
Einfluss auf den induzierten Zelltod hatten. Unsere weiterführenden Experimente zeigten, dass 
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eine pharmakologische Inhibition als auch das genetisches Abschalten der grossen GTPase 
Dynamin den durch Fenretinide induzierten vakuolisierenden Zelltod komplett aufheben konnten, 
was auf einen neuen Dynamin-abhängigen Zelltod Mechanismus hinweist.  
 
Im zweiten Teil meiner Doktorarbeit habe ich mich auf die Untersuchung von 
Behandlungsmodalitäten konzentriert die zusammen mit Fenretinide die Wirkung auf aRMS 
Zellen noch verstärken. Das Behandlungsregime für diesen schwer zu behandelnden Tumor 
auszuweiten und damit eine direkte Verbindung der Laborarbeit und der klinischen Behandlung 
und Wissenschaft zu schaffen war eines meiner Hauptziele meiner Doktorarbeit.  
Wir fokussierten uns hier auf die Strahlentherapie da diese Behandlungsform bereits Teil der 
Standardbehandlung bei Patienten mit aRMS ist. Gerade die Strahlentherapie ist zwar effektiv, 
weisst jedoch ein hohes Risiko für verschiedenste Nebenwirkungen je nach Lokalisation der 
Applikation aus. Hierzu zählen Wachstumseinschränkung, Unfruchtbarkeit, bis hin zur 
Entwicklung von Zweitmalignomen. Aus diesem Grund ist es besonders wünschenswert 
Therapeutika zu finden die als Sensibilisatoren für die ionisierende Strahlung fungieren um die zu 
applizierende Strahlendosis möglichst reduzieren zu können.  
Wir konnten zeigen dass die kombinierte Behandlung den induzierten Zelltod analog zur 
Behandlungsintensität potenzierte und das klonale Wachstum einschränkte. Dies ist 
zurückzuführen auf eine verstärkte Produktion von verschiedenen reaktiven Sauerstoffradikalen. 
Eine detaillierte Analyse dieser Mechanismen ergab dass Strahlentherapie vor allem die 
Produktion von Wasserstoffperoxid, und Fenretinide, wie bereits erwähnt, vor allem die 
Produktion von Superoxiden hervorruft. 
Des Weiteren beobachteten wir eine verstärkte DNA Schädigung und ein eingeschränktes 
Voranschreiten des Zellzyklus in den kombiniert behandelten Zellen, dies am wahrscheinlichsten 
auch hervorgerufen durch ROS Schäden. Als letztes haben wir noch den zugrunde liegenden 
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Zelltodmechanismus im Detail analysiert. Hier konnten wir zum einen die Induktion von Apoptose 
und zum anderen eine vermehrte Makropinozytose in den kombiniert behandelten Zellen 
nachweisen. Die Strahlentherapie allein hatte jedoch keinen Einfluss auf die Makropinozytose und 
somit ist dieses Phänomen einzigartig für Fenretinide.  
 
Zusammenfassend, zeigen unsere Daten dass Fenretinide ein hohes Potential als ein zusätzliches 
Therapeutikum in der Behandlung des alveolären Rhabdomyosarkoms hat. Hier zeigte sich auf 
molekularer Basis eine neue Form des Zelltods basierend auf der Anhäufung von Vakuolen im 
Plasma, welcher durch Sauerstoffradikale aus der mitochondrialen Atemkette induziert wird. Des 
Weiteren präsentiert sich Fenretinide als vielversprechender Partner für die Strahlentherapie, da 
es als Sensibilisator für ionisierende Strahlung wirkt wodurch es aufgrund der kombinatorischen 
und synergistischen Wirkung zu einer Potenzierung des induzierten Zelltods und damit der 
Wirkung auf den Tumor kommt. 
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I. Introduction 
1. Cancer 
1.1 Classification 
The term cancer does not defines just one disease, but comprises a collection of diseases with one 
common feature: the uncontrolled division and invasion of certain cells. The first recorded cases 
of cancer can be traced back to 2500BC, when the Egyptian physician Imhotep described “a 
bulging mass in the breast”. Yet, it took another 2000 years, until cancer got its current name, 
given by the Greek physician Hippocrates who first named a mass of cancerous cells karkinos, the 
Greek word for crab. Neoplasms can be classified either by the site of origin or based on the 
histological type of the tumour, after the “International Classification of Diseases for Oncology 
(ICD-O)”. According to the latter, neoplasms may be classified into four major categories: 
Carcinomas are malignant neoplasms of epithelial origin and account for 80 to 90% percent of all 
cancer cases. Sarcomas are neoplasms that originate in supportive and connective tissues such as 
bones, tendons, cartilage, muscle, and fat and commonly occur in adolescents and young adults. 
Then neuroectodermal tumours, which originate from the embryonal neural crest. And lastly, the 
hematopoietic malignancies, which comprise solid lymphomas that arise in the lymphatic system 
and leukaemias, also referred as "liquid cancers" or "blood cancers". Hematopoietic malignancies 
originate in the bone marrow and are associated with the overproduction of immature blood cells. 
There is still an ongoing debate around the origin of tumour cells. The most popular model 
hypothesize a monoclonal origin of tumour cells, i.e., the cells start with a single mutated cell and 
gradually acquire more and more mutations [1]. This hypothesis, however, has lately been 
challenged by publications claiming a polyclonal origin for at least in some cancer types [2]. 
Another well recognized model is the cancer stem cell (SC) model, which states that normal SCs 
Introduction 
may suffer an initial oncogenic transformation followed by more and more mutations and 
eventually become cancer stem cells [3]. Undebatable is the role of oncogenes and tumour 
suppressor genes in the development of cancer. During genome wide sequencing studies, 125 
driver gene mutations were discovered, of which 71 affect tumour suppressor genes and 54, 
oncogenes. Further sub classification allowed the allocation of these driver gene mutations into 12 
major pathways affecting cell fate, cell survival, and genome maintenance [4].  
1.2 Hallmarks of Cancer 
Cancer is a dynamic and heterogeneous disease, with each malignancy possessing certain 
characteristics of malignant cells. First described by Hanahan and Weinberg in 2000 [5], the 
hallmarks and definition of cancer have been revised and extended by the two authors through 
subsequent researches leading to a better understanding of the genomic landscape of tumours and 
the role of the immune system in cancer development [6]: “Evading growth suppressors, avoiding 
immune destruction, enabling replicative immortality, tumour promoting inflammation, activating 
invasion & metastasis, inducing angiogenesis, genome instability & mutation, resisting cell death, 
deregulating cellular energetics and sustaining proliferative signalling”. This 10-piece set of 
functional capabilities allows the tumour uncontrolled proliferation. Hence, recognition of this 
skill set, will help the researcher develop new strategies to fight cancer.  
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Figure 1 The Hallmarks of cancer, adapted from [6] 
1.3 Epidemiology  
According to the World Health Organization WHO, cancer is the second leading cause of death 
globally, and is responsible for approximately 8.8 million deaths annually. Each year, 35,000 
people are diagnosed with cancer in Switzerland, of which, 16,000 will die. This is more than one 
quarter (26.3 %) of the total number of annual deaths (NICER, Nationales Institut für 
Krebsepidemiologie und -registrierung).  
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2 Childhood Cancer 
2.1 Overall incidence and mortality 
Childhood cancers are markedly different from those occur in adults [7]. According to the ICD-
O-3 classification of tumours in adults, the International Classification of Childhood Cancer, third 
edition (ICCC-3), classifies tumours into 12 main groups, which are further subdivided into 47 
subgroups [8]. Childhood cancer is relatively uncommon, with approximately 1 to 2 per 10000 
children aged 14 years and younger affected annually. However, it remains the leading cause of 
disease-related mortality among children 1 to14 years of age. For children under one year, the most 
common malignancy was neuroblastoma (28.6%), followed by leukaemia (14.4%). For the age 
group 1 to 14, leukaemia is the most common malignancy (25%), followed by neoplasm of the 
central nervous system (CNS) (17%) [9].  
 
 
 
 
 
 
 
 
 
 
Figure 2 The frequency of cancer types 
in children (above) and adults (below) on 
the basis of 2012 Surveillance, 
Epidemiology and End Results (SEER) 
data [7]. 
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Since the 1960s, when the estimated five-year cancer survival rate was 28%, the cancer survival 
rate in children 0 to 14 years has dramatically improved. Currently the overall ten-year survival 
rate for children diagnosed with cancer is approximately 87%. The increase in survival rate varied 
significantly among different diagnostic groups and was most striking for acute lymphoblastic 
leukaemia (ALL), which was considered incurable in the early sixties and nowadays has an overall 
survival rate of over 80%. As positive these statistics may sound, some malignancies, e.g., 
neuroblastomas and soft tissue sarcomas, still have a very poor prognosis with less than 70% cure 
rate - and worse after recurrence. (All data retrieved from Swiss Childhood Cancer Registry, 
Annual Report 2015-2016)  
 
  
Figure 3 Survival of patients in the SCCR. Swiss residents; age at diagnosis 0- 14 years; n = 7043. Left: Period of 
diagnosis 1976- 2016. Right: Survival according to type of cancer. 
2.2 Molecular and genetic basis 
Cancer is a genetic disease, and genetic aberrations can either be germline or somatic [4]. The 
proportion of paediatric cancers with clear hereditary background is small, with about 5% [10]. 
“Hereditary” refers to an inherited genetic alteration, which was passed on by the parents or 
occurred before fertilization in the oocyte or sperm cell. the most frequently recorded diagnoses 
with a hereditary background are: retinoblastoma (37% of all retinoblastoma cases), Wilms' 
tumour (7%), leukaemia- associated with Down's syndrome (3%), and brain tumours - associated 
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with neurofibromatosis (2%) [10], however the list of other inherited predispositions to cancer is 
long [11]. 
Childhood malignancies are often the products of somatic mutations. Such mutations frequently 
have gross chromosomal rearrangements (GCR) leading to interstitial deletions, amplifications, 
inversions, and translocations. These can subsequently result in the expression of proto-oncogenes, 
deletion of tumour-suppressor genes, or the generation of oncogenic fusion genes. Most of the 
chromosomal translocations can be found in hematologic malignancies and sarcomas [7, 12]. 
2.3 Treatment of childhood malignancies 
The multidisciplinary and standard approach over the last 40 years to treat childhood malignancies 
is multimodal, integrating chemotherapy, surgery, radiotherapy, and hematopoietic stem cell 
transplantation. The first pillar of treatment is chemotherapy, the goal of chemotherapy is to 
eradicate all cancer cells. It has been shown in the past that, chemotherapy is most efficient when 
administered in combination regimens. This is due to an overcoming of drug resistances to 
individual agents, that is already present in up to 50% at diagnosis [13]. Most of the conventional 
chemotherapeutic agents are non-selective cytotoxic substance that targets vital structures or 
pathways of the cancer cells. In the process, however, normal cells are also affected, leading to 
severe and undesirable toxic side effects.  
Surgery is the second pillar of cancer treatment. Better staging through advanced radiology 
technologies and sophisticated resection techniques have helped minimizing mutilating operations 
and surgery-associated mortality. Further, these new techniques have helped surgeons to more 
accurately take biopsies, which is essential for subsequent treatment. 
Radiotherapy, the third pillar of conventional anti-cancer treatment, is next to surgery the oldest 
treatment for cancer. Ionizing radiation interacts both directly and indirectly (through the 
production of reactive oxygen species) with the cells’ DNA [14]. Improvements in the techniques 
in delivering radiation have led to a significant reduction of radiation damages on normal tissues 
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[15-18]. A better understanding of radiobiology has also led to the development of multiple radio-
sensitizers that allow a reduction of the radiation dosage [19]. 
Targeted cancer therapy targets specific proteins involved in tumorigenesis. This form of treatment 
mainly focuses on specific molecular changes that are unique to the particular cancer. While 
targeted therapy is well established in the treatment of adulthood malignancies, several paediatric 
trials are now being conducted with compounds targeting multiple cancer pathways. These include 
the epidermal growth factor receptor pathway, the vascular endothelial growth factor pathway, 
anaplastic lymphoma kinase, insulin-like growth factor receptor (IGFR), hedgehog signalling, the 
mammalian target of rapamycin, protein kinase B, c-secretase, Janus kinase, fms-like tyrosine 
kinase and others [20, 21]. 
Gaining nowadays more importance in the treatment of paediatric malignancies is the use of 
immunotherapy. There is a wide variety of immunotherapies that work in different ways to either 
boost the body’s immune system or educate the immune system to fight malignant cells. For 
example, monoclonal antibodies are used to target certain tumour-associated antigens. This form 
of immunotherapy is well established in the treatment of neuroblastoma, with the use of 
monoclonal antibodies targeting GD2 - a tumour-associated disialoganglioside found on the 
surface of neuroblastoma cells or in the treatment of non-Hodgkin Lymphoma [22]. Other 
promising new therapies such as the recently FDA-approved CAR (chimeric antigen receptor) T-
cell therapy are also being developed. CAR T-cells are autologous T lymphocytes transduced with 
a modified lentiviral vector expressing CARs with an anti-CD19 scFv (single chain variable 
fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta). After transfusion back into the 
patient, the CAR-T-cells direct the host T lymphocytes to the CD19-expressing tumour cells, 
causing selective toxicity [23]. 
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3. Rhabdomyosarcoma 
3.1 Pathology and molecular biology 
Rhabdomyosarcomas are malignant tumours of mesenchymal origin, committed to the skeletal 
muscle lineage. RMS belong to the broad group of small round blue cell tumours. The 
characteristic feature of RMS is the skeletal myogenic origin with the identification of muscle-
specific proteins like myosin, desmin, myoglobin, Z-Band protein and Myo-D [24, 25]. In 1958 
Horn and Enterline first classified RMS into four histopathological groups (embryonal, botryoid, 
alveolar, and pleomorphic) [26]. Since then, multiple modifications to this classification have been 
made. Nowadays, histopathologically RMS are divided into four major subtypes, embryonal, 
alveolar, pleomorphic, and sclerosing/spindle cell RMS [27-29]. The embryonal (eRMS) and 
alveolar (aRMS) are the two most common subtypes with frequencies of 60%-70% and 20% , 
respectively [29]. The term embryonal refers to the fact that eRMS histopathologically contain 
features of embryonic rhabdomyogenesis, whereas the term alveolar refers to the morphological 
resemblance of aRMS histology to foetal lung alveoli. eRMS tumours show elongated and rather 
loose packed cells, compared to aRMS tumours with densely packed cells, organized in nests 
around fibrovascular stroma, resembling alveoli [24, 27]. The outcome of children with eRMS is 
much more favourable than the outcome of children with aRMS (5-year EFS 43% versus 29%) 
[30].  
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Figure 4 Cytological details of rhabdomyosarcoma. A) Embryonal rhabdomyosarcoma (eRMS). 
B, Alveolar rhabdomyosarcoma (ARMS) [27]. 
 
Advances in genetic techniques allowed karyotyping studies that revealed a series of genetic 
aberrations and non-random chromosomal translocations. Such events have caused the fusion of 
DNA sections, leading to a further subclassification of RMS. In eRMS cases, genetic aberrations 
such as loss of heterozygosity at 11p15.5, point mutations in TP53, NRAS, KRAS, HRAS, 
PIK3CA, CTNNB1, NF1, and FGFR4, as well as MDM2 amplifications and aneuploidy are 
commonly found [31, 32]. Whereas in aRMS two genotypes are mainly present, the more frequent 
chromosomal translocation PAX3/FOXO1 t(2;13) (q35;q14), and the less frequent variant 
PAX7/FOXO1 t(1;13)(p36;q14). PAX3, PAX7, and FOXO1 wild type all encode transcription 
factors. When either PAX3 or PAX7 gene is fused to the FOXO1 gene through translocation, 
chimeric transcription factors PAX3/7-FOXO1 are formed. At their N-termini, they contain the 
PAX-derived paired domain and homeodomain responsible for DNA binding, and at the C-termini, 
the FOXO1 transactivation domain [31]. Rarely, two additional rearrangements of the PAX3 gene 
can be found in aRMS tumours: The in-frame fusion with the nuclear receptor coactivator NCOA1 
t(2;2)(q35;p23) [33] or the fusion with the chromatin remodelling gene INO80D [31]. Along with 
the chromosomal translocation observed in these tumours, other genetic alterations in aRMS cases 
are rare and sometimes even the only genetic alteration. Occasionally observed alterations include 
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CDK4, miR-17-92 and MYCN amplifications, as well as the uniparental disomy 11p15.5 at the 
IGF2 locus [32]. This highlights the importance of chromosomal translocations as driver of 
tumorigenesis. It was shown, that introduction of PAX3-FOXO1 into chicken embryo fibroblast 
and expression of the protein in these cells leads to transformation and anchorage-independent 
growth [34]. Further, downregulation of PAX3-FOXO1 induced apoptosis [35] and decreased the 
proliferation rate in RMS cell lines [36]. 
 
 
Figure 5 The Genomic Landscape of paediatric RMS [31]. 
 
The ability of PAX3-FOXO1 to act as driver of tumorigenesis is at least partially due to its ability 
to alter transcription of its target genes. Microarray studies have revealed a whole battery of 
potential target genes, which are mainly myogenic signalling and differentiation genes such as the 
transcriptions factors MYOD1, MYOG, and SIX1 [37, 38]. In addition, several receptor tyrosine 
kinases involved in cell growth, such as FGFR4, ALK, and MET, were upregulated [32]. 
According to gene ontology criteria, several target genes were found downregulated which are 
involved in muscle development and regulation of muscle contraction [37]. 
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Comparing the genetic landscape of fusion positive and fusion negative RMS samples, 93% of all 
tumours revealed an overlap between some of the PAX3-FOXO1 target genes and genes mutated 
in eRMS. Both tumours through either mutation or translocation alter the function of the common 
receptor tyrosine kinase/RAS and receptor tyrosine kinase/PIK3CA axis [31].  
Previously, pathophysiological classification and subtype discrimination were the main factors for 
risk and outcome prediction, but nowadays, through the evaluation of patient data to include the 
genetic background of the tumour, it is believed that the fusion status rather than histology predicts 
the prognosis more accurately [30].  
3.2 Epidemiology and Outcome   
Soft tissue sarcomas are a heterogeneous group of malignancies comprising around 7.4% of all 
childhood malignancies. Within this group, Rhabdomyosarcoma (RMS) is the most frequent one, 
accounting for 50% of all soft tissue sarcomas. The annual incidence is estimated at 4.5 cases per 
million children, with a significant male dominance of 5.2 to 3.8 cases per million children. 70% 
of the cases involved children under ten years and the two main subtypes are the embryonal RMS 
(2.6 cases per million) and the alveolar RMS (1 case per million children) [39, 40]. The outcome 
of children with RMS differs significantly between subtypes. ERMS has a more favourable 
prognosis with a three year survival rate of around 75%, whereas aRMS is highly malignant with 
a poor overall survival rate of less than 30% [29]. 
Moreover, the recurrence rate in children with aRMS is high with more than 48%. Further, the 
remaining 5-year post-relapse survival rate is only about 21% [41-43]. 
3.3 Hereditary syndromes 
Several germ-line genetic disorders are associated with a higher risk to the development of 
sarcomas. 
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Li-Fraumeni syndrome, first described in 1969, has the highest predisposition to develop 
rhabdomyosarcoma. About 10% of RMS are associated with Li-Fraumeni syndrome, which is 
caused by germ-line mutations in the P53 tumour suppressor gene [44]. Further germ-line 
mutations in the retinoblastoma gene 1 not only predispose the subject to the development of 
bilateral retinoblastomas, but also to osteo- and rhabdomyosarcomas [45]. Costello syndrome, a 
condition caused by mutations of the HRAS gene at 11p15.5, is associated with the development 
of embryonal rhabdomyosarcomas. Another example is the Beckwith–Wiedemann syndrome, 
which causes overgrowth in children and a higher incidence of developing rhabdomyosarcomas. 
Here the genetic background is complex, with mutations mainly involving the 11p15.5 locus [12]. 
3.4 Clinical Presentation and risk stratification 
The term oncology - the field of medicine dealing with cancer - originates from ancient Greek. 
The word onkos describes in Greek theatre a tragic mask, which was worn by an actor as a symbol 
of physical burden. Oncology refers to the discipline of medicine that deals with patients with 
cancer.  
Patients with rhabdomyosarcoma usually present with a painless mass lesion or with a disturbance 
of a normal body function through an outwardly invisible tumour mass. 35-40% of tumours are 
found around the head and neck, 25% in the genitourinary tract, 20% at extremities, and the rest 
from truncal primaries [43]. Around 15% to 25% newly diagnosed patients already present with 
metastasis, mainly to the lungs and less common to the bone marrow, bones, and lymph nodes 
[46]. Staging is a critical step after the cancer diagnosis, as therapy and prognosis are directly 
linked to the tumour stage. Currently there is no international consensus on tumour staging and 
the European CWS studies mainly follow the postsurgical Intergroup Rhabdomyosarcoma study 
(IRS) staging [47]. The second commonly applied staging system is the pre-treatment, site-
modified TNM staging system (tumour-nodes-metastasis). 
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In order to predict the patient’s individual prognosis, several factors are considered. The main 
factor for risk stratification of rhabdomyosarcomas remains the histopathological confirmed 
diagnosis (aRMS vs eRMS). Further, the IRS and lymph node state (TNM state), the primary 
tumour site, size of the tumour (< 5cm vs. > 5cm) and the age of the patient (< 10 years vs. > 10 
years) are considered. According to these factors, the patients are assigned a risk group, which 
then determines their treatment strategy.  
3.5 Treatment 
As patient numbers are low, most children are treated according to risk-adapted, cooperative and 
multiinstitutional trials. These trials are designed to guide the treating physicians and to collect 
important patient data to improve treatment and quality of care. In Europe, the “Cooperative 
Weichteilsarkom Studiengruppe” (CWS) and the “European paediatric Soft tissue sarcoma study 
group” (EpSSG) are responsible to conduct these trials.  
As mentioned above, according to the patient’s risk group assignment, the patient is allocated to a 
treatment arm, which always consists of local surgical treatment and a vincristine, actinomycin 
based chemotherapy, and in case of higher stages, additional ifosfamide therapy. Radiotherapy 
belongs to the standard treatment and is only omitted in the very low risk group [48]. In patients 
with metastatic disease, high dose chemotherapy followed by autologous stem cell presentation 
was evaluated against standard chemotherapy with the addition of oral maintenance therapy in the 
HD CWS-96 trial. The study suggested that there was no role for high-dose chemotherapy in 
patients with metastatic RMS, but that maintenance chemotherapy might be beneficial [49] 
In case of recurrence, adapted regimens are given, including targeted agents such as bevacizumab 
or temsirolimus [50, 51]. But as direct targeting of transcriptions factors is considered impossible 
due to their low enzymatic activity and their huge interacting surface between transcription factor 
and DNA, alternative focuses have been set on targeting the involved signalling pathways [52,  
53].  
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Unfortunately, the EpSSG supported BERNIE phase II study, which evaluated the addition of 
bevacizumab to standard high risk treatment with ifosfamide, vincristine, actinomycin and 
doxorubicin or to maintenance chemotherapy with cyclophosphamide and vinorelbine in patients 
with metastatic RMS, did not see a benefit to the addition of bevacizumab [51]. Also, the COG 
supported trial that evaluated the addition of temsirolimus to cixutumumab in patients with RMS 
and other solid tumours, did not reveal any benefit.  
Taken together, there is an ongoing interest and effort to improve treatment strategies in patients 
with RMS. So far, besides standard chemotherapy and radiation therapy, no new and more targeted 
agents have been identified that significantly augment treatment outcome and survival.  
4. Fenretinide 
In late 1960’s, the pharmaceutical company Johnson & Johnson first developed fenretinide as a 
potential treatment for breast cancer, which was never brought to the market. In 2007, it was 
approved by the European Commission and the Food and Drug Administration (FDA) for the 
treatment of childhood sarcomas.  
4.1 Pharmacology 
Fenretinide is also known as N-(4-hydroxyphenyl) retinamide or 4HPR. Fenretinide is a synthetic 
phenylretinamide analogue of all-trans-retinoic acid (ATRA) also called just vitamin A (molecular 
formula: C26H33NO2). Upon exchanging the amide-linked 4-hydroxyphenyl group for the 
carboxyl group of ATRA, side effects such as skin and liver toxicity were markedly reduced 
(PubChem, open Chemistry database).  
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Figure 6 Molecular structure of fenretinide 
 
Fenretinide is administered either orally or intravenously. In vivo as well as in vitro, fenretinide is 
metabolized into different analogues including N-(4-methoxyphenyl)retinamide (4-MPR) through 
a structural change at the hydoxyphenyl ring and to 4-oxo-N-(4-hydroxyphenyl)retinamide (4-
oxo-4-HPR) through oxidation at the cyclohexenyl ring [54-56]. The metabolite 4-MPR 
accumulates mainly in fatty tissue but is also well detected in the plasma. Even though it is 
considered as non-toxic to cancer cells, it only accumulates in cells sensitive to fenretinide and so 
serves as an ideal biomarker [55, 56]. 4-oxo-4-HPR is present in much smaller concentrations as 
4-MPR and 4-HPR nevertheless, it is much more cytotoxic than 4-HPR in multiple cell lines, even 
in some that are resistant to 4-HPR [54, 57]. 
Despite the promising results from in vitro studies, the transition of 4-HPR into clinical use was 
difficult, as fenretinide has low bioavailability caused by poor solubility in aqueous solution and 
high affinity to plasma proteins and lipids [57-59]. Multiple attempts have been made to increase 
the bioavailability of fenretinide through chemical modifications. One of such modification is the 
coupling of fenretinide to nanoparticles, which enhanced its drug release and cell entry in vitro 
and resulted in better bioactivity [60, 61], however clinical trials using this formulation are 
pending. In another approach to increase the bioavailability, fenretinide was packed into a lipid 
matrix which enhanced the bioactivity in vitro. [62]. As a result of these promising data, a phase I 
trial of orally given fenretinide in this new organized lipid complex in children with relapsed 
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Neuroblastoma showed that this new formulation achieved higher plasma levels, minimal toxicity, 
and evidence of anti-tumour activity, compared to the old capsule formulation [63]. However, 
when this new formulation was evaluated in adults, the mean plasma levels of fenretinide using 
the LYM-X-SORB formulation were the same than the capsules, and gastrointestinal side effects 
caused a study drop out of 7 out of the 20 patients [64]. 
The addition of ketoconazole to fenretinide significantly increased the 4-HPR plasma levels 
through an inhibition of the metabolism of 4-HPR in mice [65]. This formulation is currently under 
clinical trial for usage in children with relapsed neuroblastoma, and as the study has just closed, 
results are pending (NCT02163356). Two other trials that administered fenretinide via intravenous 
infusion reported much higher plasma levels compared to the oral formulation and a promising 
anti-cancer activity [66, 67].  
The side effect profile of fenretinide is favourable, involves mainly the skin, (dermatitis), the eyes 
(development of nyctalopia), the liver (elevation of the liver enzymes and bilirubin), and the 
intestines (diarrhoea and nausea). Further pseudo tumour cerebri was also reported once. However 
grade four (limiting) toxicities are rare [58, 68]. 
4.2 Fenretinide-mediated anti-cancer activity: A literature summary 
The fat-soluble Vitamin A or all-trans-retinoic acid is essential for the maintenance of health. As 
it is not de novo synthetized in the body, it needs to be taken up through the diet.  
Vitamin A plays an essential role in the photosensitivity of the eye [69]. ATRA is a direct ligand 
for nuclear retinoic acid receptors (RARs), which belong to the steroid hormone receptor 
superfamily. So far six genes coding for different RARs have been identified. Their expression 
differs in different cells, but with the same functionality. Upon binding to the so called RAR 
elements (RARE) or retinoid X response elements (RXREs) located within the promoter of target 
genes, they function as heterodimers. More than 500 genes have been suggested to be regulatory 
targets of retinoic acid either directly or mediated by other transcription factors [69]. The target 
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genes play essential roles in the preservation of immune function, vision, and the development and 
maintenance of multiple body tissues during embryogenesis and later in life. The link between 
fenretinide and RARs is still a controversy according to the literature. Sheik et al reported that 
fenretinide was active in breast cancer cell lines resistant to RA and that binding of fenretinide to 
RARs was poor, hence only a minimal activation of the retinoic acid receptor element (RARE) 
and retinoid X receptor response elements (RXREs) was seen, implying a RAR independent 
mechanism of action [70]. Similar findings were seen in hematopoietic cell lines [71]. Other 
studies however, showed a direct interaction of fenretinide with RARs. Fanjul et al suggested that 
fenretinide is a highly selective activator of retinoid receptors [72] and Sani et al suggested that 
the hydroxyl group of fenretinide was responsible for the binding to RARs [73]. Further, 
fenretinide was able to induce apoptosis in liver carcinoma cells in a RAR beta dependent manner 
[74]. 
Most of the published data, suggest that the fenretinide induced cell death occurs mainly through 
apoptosis in most of the cell lines. This is achieved either through the production of reactive 
oxygen species (ROS) or the involvement of lipid second messengers.  
Due to the fact that in many cancer cell lines, fenretinide induced cell death can be inhibited by 
the addition of antioxidants such as Vitamin C and E and N-acetylcysteine (NAC), it is suggested 
that ROS and oxidative stress play an important role [67, 75-78]. The exact source of ROS is still 
being debated in the literature. However, most studies agree that the mitochondrial respiratory 
chain (MRC) must be the site of ROS production. Cuperus et all were able to show that ROS 
production occurred via complex II of the MRC [79], other groups suggested that rather complex 
III or sites between I and II were responsible [75, 80]. Several studies further report that the 
endoplasmic reticulum is rather a target of ROS than a source [81-84]  
Not only is the source of ROS controversial, what exact kind of ROS are produced is also under 
discussion. While Hail and Suzuki et al propose that fenretinide induces the production of 
 20 
Introduction 
hydrogen peroxide, others favour the production of mitochondria derived superoxides [67, 75, 79, 
85]. 
Downstream of ROS, multiple signalling pathways have been described for the induction of 
apoptosis. The activation of mitogen activated protein kinase (MAPK), c-Jun amino-terminal 
kinase (JNK), p38, extracellular signal-regulated kinase ERK1/2, GADD153, as well as nuclear 
factor-kappa B (NF-κB) have all been implicated in apoptosis induction [76, 81, 86-90]. Further, 
the members of the pro-apoptotic BH3 family and the anti-apoptotic BCL-2 family, survivin (a 
member of the inhibitor of apoptosis family), as well as the release of the downstream effector 
cysteine-dependent aspartate-directed proteases (caspases) 3, 8 and 9 play critical roles in 
fenretinide induced apoptosis [87, 89, 91-99]. Fang et al found recently that combining fenretinide 
with the BH3 mimetic ABT-737 further enhanced both the extrinsic and the intrinsic apoptosis 
pathway, suggesting fenretinide’s critical role in apoptosis induction [94]. Interestingly, Cao et al 
showed that fenretinide can either induce apoptosis or autophagy depending on the concentration 
used and therefore the amount of ROS produced. Here the DJ-1 (a multifunctional oxidative stress 
response protein) and the ASK-1-p38 MAPK pathway are the main regulators of either apoptosis 
or autophagy induction [100].  
Besides ROS production, lipid second messengers are thought to be targets of fenretinide. 
Ceramide, a sphingolipid second messenger, can either be de novo generated within a cell or 
through hydrolysis of sphingomyelin. Ceramides are implicated as signalling molecules during 
cell death [101]. Previously it was believed that fenretinide directly elevates ceramide, however 
newer studies using liquid chromatography-tandem mass spectrometry showed that fenretinide 
rather elevated dihydroceramide, the precursor of ceramide [102-104]. This is achieved through 
an inhibition of the dihydroceramide desaturase 1 (DES1) by fenretinide [105]. Two studies in 
pancreatic cancer cells and leukaemia cells showed that ROS and ceramide production are two 
independent events in fenretinide induced cell death [106, 107].  
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5 Reactive Oxygen Species (ROS) 
The role of reactive oxygen species and antioxidants in the development and maintenance of 
malignant cells and in the abatement of malignancies is still a centre of debate. ROS and oxidative 
stress are considered as a promoter of malignancies and antioxidants protective or even curative, 
but some newer studies suggest that ROS may be anti-cancer molecules.  
5.1 Biology and sources of reactive oxygen species and their regulation 
Molecular oxygen is relatively unreactive. ROS are derived from the incomplete reduction of 
molecular oxygen and may include: superoxide anion (O2-), hydrogen peroxide (H2O2), and 
hydroxyl radical (OH.)[108]. Intracellularly, ROS are generated mainly in the mitochondria and 
the membrane bound NADPH oxidase complex (NOXs) [109].  
In aerobic organisms and during cellular respiration, electrons are passed through a chain of 
mitochondrial complexes onto molecular oxygen, the final electron acceptor. In the mitochondria, 
10 different sites are known to produce ROS, whereupon complex I, II and III, produce the lion’s 
share [110]. Through the leakage of electrons from the electron transport chain (ETC), molecular 
oxygen can be reduced, giving rise to superoxide anions. Released into the mitochondrial matrix, 
superoxide anions are rapidly dismutased into hydrogen peroxide by superoxide dismutase 2 
(SOD2). Superoxide anions released into the mitochondrial intermembrane space are converted 
by superoxide dismutase 1 (SOD1) into freely diffusible hydrogen peroxide [111]. A third and 
extracellular superoxide dismutase (SOD3) is the major SOD in the vascular extracellular space 
and dismutases superoxides there [112]. Dismutases therefore prevent oxidation damage of 
macromolecules.  
The second source of ROS is the NOX complex, which catalyses the generation of superoxide 
anions from molecular oxygen and NADPH. NOX primarily locates in the plasma membrane, but 
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also can be found on the membrane of nucleus, mitochondria, and endoplasmic reticulum [113]. 
Also here, SOD 1 and 3 convert the superoxide anions to hydrogen peroxide [112].  
Last, a minor source for ROS production is the Fenton reaction. Here hydroxyl radicals are formed 
when hydrogen peroxide reacts with ferrous or cuprous ions through the Fenton reaction. Hydroxyl 
radicals are highly reactive and toxic leading to lipid, protein, and DNA damage [114].  
In an attempt to maintain redox homeostasis and avoid damage to macromolecules, the cell has 
developed a complex and sophisticated ROS scavenging network, besides the above-mentioned 
SODs. Spatially segregated in peroxisomes, the enzyme catalase converts hydrogen peroxide to 
water and molecular oxygen with an extremely high substrate turnover rate, scavenging around 6 
million molecules of hydrogen peroxide per minute [115].  
Glutathione peroxidases (GPXs), a group of five isoforms, catalyse the reaction between hydrogen 
peroxide and reduced glutathione (GSH) to form oxidized glutathione (GSSG). Glutathione 
reductase (GR), on the opposite, uses NADPH as an electron donor to reduce oxidized GSSG to 
GSH [116]. GSH, being the most abundant peptide in cells, is able to directly scavenge HO·, 
singlet oxygen, and plays an important role in the regeneration of other antioxidants such as 
vitamin C and E to their active forms [117].  
Peroxiredoxins (PRXs) are highly abundant and spatially distributed in the cytosol, peroxisome, 
endoplasmic reticulum, and mitochondria. Six isoforms of PRXs are known and their active 
cysteine site serves as an oxidant acceptor to reduce hydrogen peroxide [118]. Oxidized PRXs are 
further reduced by thioredoxin (TRX), which, as a result, becomes oxidized. Thioredoxin 
reductase (TR) also uses NADPH as an electron donor to reduce oxidized TRXs [119].  
Several transcription factors participate in orchestrating the activity and the production of the 
above described antioxidants. The key transcription factor is Nuclear Factor Erythroid 2-like 2 
(NRF2). Under normal condition, NRF2 is located in the cytoplasm and associated with Kelch-
like ECH-associated protein 1 (KEAP1) and the Cul3-based E3 ubiquitin ligase and so targeted 
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for proteasomal degradation [120, 121]. Under oxidative stress, KEAP1 is oxidized by H2O2 at its 
cysteine residues enabling a dissociation from NRF2 [122]. Subsequently stabilized NRF2 
translocates into the nucleus, where it binds to antioxidant-responsive elements (AREs) within the 
regulatory region of around 200 target genes including CAT, GPXs, PRXs, SOD2 and TRX [123, 
124]. Moreover, NRF2 is involved in the de novo synthesis of GSH through the NRF2-mediated 
expression of the cysteine/glutamate antiporter (xCT), which regulates the cysteine homeostasis 
and the expression of glutamylcysteine synthetase components [120]. Lastly, NRF2 induces the 
expression of regulatory enzymes in the pentose phosphate pathway (PPP) and serine biosynthesis, 
leading to an enhanced NADPH production, the substrate for TR and GR [125].  
 
 
Figure 7 Sites of ROS generation and regulation [126] 
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5.2 ROS and cancer 
Misbalance in the cellular redox state is associated with multiple diseases such as 
neurodegeneration, atherosclerosis, autoimmune diseases, and aging [127, 128]. The role of ROS 
in tumorigenesis has been debated for decades. ROS serve as important signalling molecules in 
normal as well as in cancer cells. Whereas low levels of ROS are responsible for controlled 
metabolic adaption, proliferation, and differentiation [129], high levels of ROS can hyper-activate 
signalling pathways and could eventually lead to transformation and tumorigenesis [130]. Multiple 
studies have shown an elevated level of intracellular ROS in many types of cancer cells [131]. The 
increased level of ROS reflects the disruption of redox homeostasis, either due to an upregulated 
ROS production or a reduced ROS-scavenging capacity, leading to persisting oxidative stress in 
cancer cells [132]. Multiple ways of increasing ROS level in cancer cells have been identified. 
Irani et al showed that, H-ras-transformed fibroblasts produce large amount of superoxides through 
the activation of NOX [133]. Other studies point out the association of the tumour suppressor p53 
in increased ROS production: Loss of the tumour suppressor p53 leads to an increased ROS 
production in Trp53-knockout mice, however, dietary supplementation with NAC in these mice 
prevented the occurrence of frequent lymphomas and further slowed the growth of lung cancer 
xenografts in these animals [134]. Likewise, breast cancer 1 (Brca1) and p53-heterozygous 
deficient animals showed increased levels of ROS and a higher incidence of carcinomas in their 
forestomach and oesophagus [135]. Conflicting findings suggest a complex redox regulation in 
cancer cells concerning the regulation of scavenging mechanisms. Cancer cells need to adapt to 
the increased levels of ROS, in order to promote proximal pro-tumorigenic signalling. However, 
in some cancer cells, an increase in ROS levels is associated with a decreased production of 
antioxidants such as SOD2, CAT and GPX1. This decrease helps the cancer cell to maintain high 
ROS levels [136-138]. Upregulation of NRF2 through mutations in NRF2 itself, in KEAP1, or in 
the oncogenes K-ras and Myc is a well-documented phenomenon in cancer cells. This upregulation 
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leads to an increased expression of ROS scavenging molecules, and so to the maintenance of ROS 
homeostasis in cancer cells. This ensures cancer cell survival through an inhibition of the otherwise 
ROS-activated JNK/p38 death-inducing pathway [139, 140]. This reflects an adaption of cancer 
cells to oxidative stress and allows cancer cells to activate proximal pro-tumorigenic signalling 
pathways, nonetheless oxidative stress can also have anti-tumorigenic effects.  
5.3 ROS signalling 
Superoxides are highly reactive with iron-sulfur clusters; however, when reacting with thiols, the 
rate is too low to be relevant for signalling [141]. Moreover, due to their negative charge and their 
poor stability, they are almost unable to travel through membranes [142]. Hydrogen peroxide are 
not as reactive as superoxides but more stable and diffuses easily through membranes, which 
renders them potent signalling molecules [141, 143].  
5.3.1 Pro-tumorigenic Role of ROS 
Higher level of ROS can lead to oxidative inactivation of the phosphatase and tensin homolog 
(PTEN), the protein tyrosine phosphatase (PTP), and MAPK phosphatases. As these phosphatases 
are all negative regulators of the PI3K/AKT and MAPK pathways, the PI3K/AKT/mTOR and 
MAPK/ERK signalling cascades are stimulated in a ROS dependent manner [133, 144-146]. The 
PI3K/AKT pathway is not only upregulated in various cancer types, AKT can further increase 
ROS production to promote proliferation and cancer cell survival [147]. Moreover, Weinberg et 
al was able to show that disruption of the mitochondrial function caused a lower level of ROS, 
which in turn led to reduced tumorigenesis in an oncogenic mouse model of lung cancer, and that 
increased level of mitochondrial ROS was responsible for K-ras-induced anchorage-independent 
growth of the lung cancer cells through the MAPK/ERK pathway [148]. ROS not only promoted 
survival through hyperactivation of the pro-survival pathways, it is capable of activating nuclear 
factor kappa B (NFκB) signalling pathway, which in return leads to an upregulation of genes, such 
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as caspase inhibitors or members of the B-cell lymphoma 2 family (BCL2), involved in cell 
survival [149-151].  
Last, ROS can promote angiogenesis and metastasis, which are often associated with an aggressive 
tumour growth. In fast growing tumours, limited blood supply translates into poor oxygen und 
nutrient supply- a condition that promotes ROS production. Through AMPK activation, NADPH 
production by one-carbon metabolism is enhanced, despite the impairment of the pentose 
phosphate pathway [152, 153]. Moreover, ROS stabilizes hypoxia induced factor alpha 
(HIFα) through the inhibition of prolyl hydroxylases (PHDs) under hypoxic stress: While PHDs 
under normal conditions mark HIFα for proteasomal degradation [154, 155], under hypoxic stress, 
HIFα dimerizes with its beta subunit, translocates to the nucleus and induces the expression of 
proangiogenic genes like vascular endothelial growth factor (VEGF), genes involved in glycolysis 
and cell survival [156-158].  
Neoangiogenesis allows cancer cells to migrate. Tochhawng et al showed that cancer cells are 
capable to detach from primary tumour through a series of cellular events, including cytoskeletal 
remodelling and degradation of the extracellular matrix, which requires the activation of several 
signalling pathways including MAPK, PI3K/Akt, and transcriptional activation of HIFα and Snail 
[159]. Moreover, ROS mediated oxidation and so activation of v-Src lead to a more aggressive 
cancer phenotype showing increased invasion and anchorage- and growth factor independent 
growth [160].  
5.3.1 Anti-tumorigenic Role of ROS 
When oxidative stress becomes too high, cell cycle arrest and cell death pathways are induced.  
As a sensor for redox stress, apoptosis signal-regulating kinase 1 (ASK1) mediates the activation 
of JNK and p38 MAPK, which eventually leads to cell death [161]. ASK1 is coupled to TRX1 in 
its inactive state. However, on TRX1 oxidation by ROS at two cysteine sites, ASK1 dissociates 
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from TRX1 and thus facilitates the suppression of anti-apoptotic factors through the activation of 
the downstream MAP kinase kinase (MKK)4/MKK7/JNK and MKK3/MKK6/p38 pathways [161, 
162]. However multiple human tumours harbour inactivating mutations in JNK and p38 and thus 
avoid cell death signalling [163].  
5.3.2 Exploiting oxidative stress as a therapeutic option in cancer 
In order to exploit the possibility of integrating ROS in a treatment option and taking into 
consideration the two opposite roles of ROS in cancer, several approaches have been applied in 
the past. As cancers cells have higher basal levels of ROS, they are more sensitive to a higher level 
of ROS compared to normal cells. Once a certain threshold is reached, cell death in induced (Figure 
9). Therefore, one option is to increase ROS levels in cancer cells either directly or indirectly 
through interference with their antioxidant system. The other option is to decrease ROS levels in 
hope to disable protumorigenic signalling.  
 
 
Figure 8 Cancer redox biology: a biological basis for therapeutic selectivity [131] 
 
 28 
Introduction 
Many classical chemotherapeutic agents and ionizing radiation, function by increasing the ROS 
level within the cancer cell. Drugs like taxanes, vincalkaloids, platinum, anthracyclines, and 
antimetabolites induce mitochondrial damage through interference with the ETC and thus induce 
superoxide production, which eventually leads to the release of cytochrome c and triggers cell 
death [164]. Alternatively, ROS levels can be indirectly increased through the inhibition of the 
scavenging pathways. As the GSH metabolism seems to be important in protecting cancer cells 
from cell death, targeting this scavenging pathway seems promising. A recent publication of Yun 
et al showed that high levels of Vitamin C in K-ras and B-raf muted cancer cells led to oxidative 
stress, as intracellular oxidised vitamin C was reduced to vitamin C by glutathione and thus 
depleted glutathione. Thus, reactive oxygen species accumulate and inactivate glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), which leads to metabolic crisis in the cancer cells [165]. 
Another compound, namely, Phenethylisothiocyanate (PEITC) conjugates with GSH through 
electrophile-nucleophile interactions and depletes GSH from the pool. In addition, PEITC is able 
to inhibit GPX activity. These two examples cited so far caused a build-up of ROS and led to cell 
death in a preclinical mouse model of H-ras transformed ovarian cancer cells [166, 167]. The 
compound L-Buthionine-sulfoximine (BSO) inhibits glutamylcysteine ligase (GCL) and so targets 
GSH synthesis. In combination with ROS inducing agents such as 2-deoxy-D-glucose or 
carboplatin, BSO serves as a sensitizer and enhances cell death [168, 169].  
The Glutathione pathway is not the only promising candidate for increasing redox stress; inhibitors 
against TRX, TR, and SOD1 also have been shown to be of great value [167, 170, 171].  
Lastly, NRF2, the key player in antioxidant regulation, presents an interesting target. NRF2 is 
stabilized by multiple oncogenes like K-ras, PI3K, and Myc, mutations in NRF2 or in its negative 
regulator KEAP1 are often found in cancer cells [172, 173]. Moreover, NRF2 is upregulated in 
multiple cancer types and responsible for chemotherapy and radiation therapy failure [174, 175]. 
So far, two different strategies have been employed that either inhibit or induce the production of 
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NRF2. NRF2 inhibitors may be effective against NRF2-addicted cancer cells in which NRF2 is 
abnormally activated. But due to insufficient specificity, these inhibitors are not established yet. 
Moreover drugs that induce NRF2 are in use for non-malignant conditions but are also not yet 
established for cancer [176, 177].  
6. Endocytosis 
Endocytosis is the process that cells use to internalize surface proteins and macromolecules. Once 
internalized, the molecules are sorted and transferred to different compartments depending on their 
composition and designated destination: Either they can be recycled and routed back to the plasma 
membrane, passed to late endosomes and lysosomes for degradation, to the trans Golgi network 
also for degradation, or even sent across endothelial cells at the blood-brain barrier in a process 
that is called transcytosis for the delivery of macromolecules to the brain [178, 179]. Under 
physiological conditions, endocytic processes are essential for the maintenance of cell polarity and 
the physiological composition of proteins and lipids in the plasma membrane, which are important 
for cell surface receptor regulation, signalling, and motility. Certain viruses, pathogens, and 
bacterial toxins exploit endocytosis as a mechanism for entering cells and cancer cells may use 
endocytic process to induce their motility leading to their metastasis transformation [180].  
Endocytic pathways can be broadly divided in to pinocytosis and phagocytosis. Particles larger 
than 500nm are usually taken up by phagocytosis or if soluble macropinocytosis. Pinocytosis can 
be further divided into clathrin-mediated endocytosis (CME), caveolae-mediated endocytosis, and 
those independent of clathrin (clathrin-independent endocytosis, CIE) [181] 
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Figure 9 Different endocytic pathways [182] 
 
6.1 Clathrin mediated endocytosis 
CME occurs through the initial formation of clathrin-coated pits (CCP) and ends with the 
formation of clathrin coated vesicles (CCV). This process involves the following steps: the 
initiation of CCP formation, selection of the cargo, clathrin coat formation, CCP maturation, 
membrane invagination, CCV scission, and finally, the release and the uncoating of the vesicles 
[183]. Each step requires certain key-components to proceed. The initiation of the CCP formation 
begins with the recruitment of the four subunits of the heterotetrameric adaptor protein 2 (AP2) 
complex to the plasma membrane [184]. The AP2 complex is on the one hand responsible for 
cargo-recognition and on the other hand for recruiting clathrin to the plasma membrane in the next 
step of CME. Clathrin consists of heavy and light chains that form heterodimers; which are then 
assembled into trimers, forming a triskeleton [185]. The triskeletons gather like a net around the 
CCV, interconnected with the AP2 complex. Besides clathrin and AP2, in total, about 150 proteins 
are involved in the CCV formation; they are subsumed as CLASPs (clathrin associated sorting 
proteins) and interact with both the cargo and the AP2 complex to increase the sorting capacity 
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[186]. In a next step, clathrin polymerization stabilizes the curvature of the pit. However, for 
complete curvature forming and CCP progression, other proteins are also necessary and these 
include the BAR (Bin-Amphiphysin-Rvs) domain-containing proteins endophilin, amphiphysin, 
sorting nexin 9, and epsin. Successful budding of the CCV requires, the coordinated effort of 
several proteins: The binding of the BAR proteins to the large dynamin GTPase via their SRC 
homology 3 (SH3) domain (details on dynamins see below). This binding not only activates but 
also enables dynamin to assemble around the necks of the CCV. This assembly in turn causes the 
GTP hydrolysis, which drives the budding of the CCV. Once released, the clathrin coat is 
disassembled and now the vesicle is free to fuse with endosomes [181, 186-189].  
6.2 Clathrin independent endocytosis 
The term clathrin independent endocytosis (CIE) summarizes several pathways where the 
endocytic vesicles do not have a distinct coating. These pathways can be either dynamin dependent 
or dynamin independent. Dynamin dependent pathways comprise the RhoA dependent pathway 
and the Caveolae-mediated endocytosis CavME pathway (see below). The RhoA dependent 
pathway was first identified to be involved in the uptake of Inteleukin 2 (IL2) receptor and was 
later shown to be also involved in the uptake of other cytokine receptors such as EGFR. Several 
other proteins involved in the formation of the vesicles are Rac1, Pak, and the phosphatidylinositol 
3-kinase (PI3K). As mentioned above, the vesicle budding occurs in a dynamin-dependent manner 
[182, 190].  
Dynamin independent pathways comprise the Cdc42 dependent pathway and a pathway involving 
the GTPase Arf6.  
The Cdc42 dependent pathway is responsible for the uptake of large amount of fluid into cells and 
leads to the formation of so-called clathrin-independent carriers (CLICs). The newly formed 
CLICs eventually fuse to specialized early endosomes which are enriched with 
glycosylphosphatidylinositol (GPI) anchored proteins called the GPI-AP enriched endosomal 
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compartments (GEECs). In that sense, this process is mainly termed the CLIC/GEEC pathway 
[182, 186, 190]. And last the Arf6-dependent pathway that was first associated with the uptake 
and recycling of the Major Histocompatibility Antigen I. However, other cargo like beta-1 integrin, 
E-cadherin and others followed. Arf6 activates phosphatidylinositol-4-phosphate-5-kinase to 
produce phosphatidylinositol-4,5-biphosphate which is involved in actin assembly and has been 
associated with regulating endosome recycling. However the role of Arf6 as an independently 
acting pathway is not yet fully established and might be greatly dependent of the cell type [182].  
6.3 Caveolae-mediated endocytosis 
Caveolae-mediated endocytosis (CavME) is involved in signalling, lipid metabolism, and cell 
surface tension sensing [186]. CavME is a highly regulated process and occurs after the binding 
of ligands to their respective receptors which accumulate in caveolae. Caveolae are hydrophobic 
membrane domains rich in cholesterol and sphingolipids. They are formed by the assembly of the 
integral membrane protein caveolin, which is inserted into the inner leaflet of the membrane 
bilayer in a wedge-like fashion that shapes the membrane curvature. Caveolin binds to cholesterol 
through its N-terminus and the rest serves as a scaffold for the binding of signalling proteins. The 
budding of the caveolae is not yet well understood but involves the regulated interplay of kinases 
and phosphatases. However, for the scission of the caveolae from the membrane the dynamin 
GTPases are the main drivers [181, 186, 191]. 
6.4 The large GTPase Dynamin 
The GTPase Dynamin was first discovered in 1989 [192] shortly after its role in endocytic 
processes was described [193]. In mammals, three different Dynamin genes are known, and the 
proteins share a homology of 80% with very different expression patterns spatially. Dynamin 1 is 
found solely in neuronal tissues; Dynamin 2 is expressed ubiquitously; and Dynamin 3 is expressed 
in the brain, the testes, and the lungs [194].  
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Dynamin is a 100kDa GTPase composed of a catalytic G domain that binds and hydrolysis GTP 
and a four helix bundle called bundle signalling element (BSE). The BSE is a flexible connector 
between the stalk and the G domain. Further a phosphinositide-4.5.-biphophate binding pleckstrin 
homology (PH) domain and at the C-terminus a proline- and arginine-rich domain (PRD) through 
which dynamin partners interact (Figure 10) make-up the whole molecule [195]. Under 
physiological conditions, the stalk of dynamin dimerizes to form a cross. The two G-domains of 
the dimer are oriented in opposite directions and form the basic dynamin unit. The PH domain is 
responsible for phospholipid and PI(4,5)P2 binding and the PRD contains multiple binding sites 
for SH3 domain containing proteins. These SH3 domain-containing proteins are responsible for 
guiding dynamins to endocytic sites and for its coordination with other factors during scission 
processes.  
Dynamins polymerize into helical structures, which is essential for their function. The 
polymerization of the dynamins results from the side-by-side apposition of the dimers through an 
interaction of the corresponding stalks. In that sense, the stalks shape the core of the dynamin ring 
and depending on their angle, the diameter of the ring is set. The BSE and G-domains reach 
towards the adjoining rungs of the dynamin helix. This is crucial, as the GTP hydrolysis of the G-
domains can only occur across adjoining rungs and explains the strong onset of GTP hydrolysis 
upon polymerization [196].  
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Figure 10 Structure and assembly of dynamin [187, 194] 
 
Concerning the dynamin’s fission mechanism, several models have been suggested. Generally 
researchers agree that dynamin helical oligomers use the energy derived from GTP hydrolysis to 
constrict and cut membrane tubules from the membrane. When bound to guanosine triphosphate, 
the opposing G domains dimerize and their GTPase activity is activated. Upon GTP hydrolysis, 
the position of the G domain changes relative to the BSE; the resulting mechanical energy is 
transferred to constrict the helix [197].  
The “two stage model for dynamin-catalysed fission” model suggests that in stage one, when G 
domains across the adjoining rungs have the highest affinity, the polymerized dynamins implement 
a super‐constricted state that causes the formation of hemi‐fission intermediates. In stage two, 
subsequent hydrolysis to the GDP‐bound form loosens the scaffold to a constricted state, leaving 
the hemi‐fission intermediates proceed to complete fission [198].  
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The “constrictase/ratchet model” suggests that the energy released from the hydrolysis of GTP 
drives dynamins, which act as a molecular motor, to mechanically slide the adjacent turns of the 
helix. This sliding of the helical turns would occur repeatedly leading to the constriction and 
twisting of the helix (association/power stroke/dissociation) [197].  
As mentioned above, dynamins are involved in multiple endocytic pathways. Even there are 
significant differences between the pathways, similarities exist when it comes to the function of 
dynamins. During early formation of the endosomal pit, several adapter proteins and scaffolding 
proteins are recruited to the PI(4,5)P2 enriched plasma membrane. The cargo is accumulated, and 
the vesicles grow and mature. At this stage, dynamins also accumulates around the growing 
vesicles. During CME, BAR-domain containing proteins bind dynamins and guides them to the 
neck of the vesicle to mediate the fission (see above) [196].  
Another poorly understood function of dynamins is their interaction with the cytoskeleton. 
Dynamins are directly linked to the cytoskeleton and colocalize to the actin meshwork and interact 
with their regulators N-WASP/WAVE and Arp2/3, which are important in the formation of 
lamellipodia, circular dorsal ruffle, invadopodia, and actin comets (see also the section on circular 
dorsal ruffles). Actin might play a role in guiding dynamins to the right position or it might do so 
by generating membrane tension at the neck of the endosomes to facilitate the dynamin-induced 
scission [196, 199].  
It has also been suggested that dynamin 2 modulates the function and localization of Rac, a Rho 
family member. Under normal conditions, Rac is involved in lamellipodia formation, transcytosis, 
and macropinocytosis. Schlunck et al showed, that disruption of the dynamin function impairs 
lamellipodia formation and thus inhibits cell spreading and platelet-derived growth factor-induced 
macropinocytosis. Rac was found misplaced into abnormal dorsal ruffles and led to the 
accumulation of abnormally shaped tubulated structures with membrane-bound Rac. The authors 
suggested that the disruption of dynamin function inhibits the internalization of Rac from the 
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plasma membrane which leads to the accumulation of activated Rac in abnormal membrane 
ruffles, depleting Rac from the pool [200].  
Armstrong et al also suggested that the interaction of dynamins, Rac, and actin are essential for 
transcytosis and that an inhibition of dynamin leads to the translocation of active Rac from the 
plasmalemma, leading to the loss of cortical actin and the formation of intercellular gaps [201]. 
Many studies on dynamin rely on the use of dynamin mutants, dynamin knock-out mice, or 
dynamin inhibitors [187, 195, 202]. Depending on the target site of the Dynamin inhibitors, the 
inhibitors alter different functions of the dynamin protein. Binding to the GTPase domain of 
dynamin decreases the GTPase activity and binding to the PH domain effects the recruitment of 
dynamin to the membrane.  
Multiple compounds have been developed over the last twenty years targeting different dynamin 
domains with different sensitivity and specificity[187]. The compound dynasore hydrate, or just 
dynasore was identified by Macia et al during a high-throughput screening of ~ 16 000 compounds 
for their ability to inhibit the GTPase activity of dynamin 1. They showed that Dynasore inhibited 
the GTPase activity of dynamin and abolished the uptake of the transferrin and low-density 
lipoprotein receptor [203]. The authors assumed that dynasore inhibits the basal and the stimulated 
rates of GTP hydrolysis in a non-competitive manner, without having an influence on GTP binding 
or dynamin assembly [203]. However, using a recently developed highly sensitive GTPase assay, 
Mohanakrishnan found that while dynasore had no influence on the basal GTPase activity of 
unassembled dynamin, it inhibited the GTPase activity of the assembled dynamin. These findings 
speak against the GTPase domain as the target of dynasore [204] and the exact target of dynasore 
remains to be elucidated.  
As it was shown that dynasore had some undesirable side-effects including the binding to serum 
proteins which depleted dynamin availability and a high affinity to the detergent tween, which 
reduced its potency. Further at higher concentrations, dynasore had some cytotoxic effects [187].  
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Several new compounds were developed to improve the efficacy of dynasore; for example dyngo-
4a. Dyngo-4a displayed a decreased cytotoxicity and a 32-fold higher inhibitory potency towards 
the assembly stimulated GTPase activity of dynamin [205].  
Multiple studies have proved the efficacy of dynasore and dyngo-4a in inhibiting endocytosis in 
various cell systems [206, 207]. However, new studies have now suggested dynamin-independent 
effects of dynasore and dyngo-4a. Park et al first described in murine dynamin 1-3 triple knockout 
(TKO) fibroblasts that fluid phase endocytosis was not inhibited, whereas addition of dynasore 
abolished the uptake [202]. Recently, Persaud et al showed that dynasore and dyngo-4a were able 
to inhibit the Ras-like GTPase RagA in dynamin TKO cells and so prevented an activation of 
mTORC1 signalling [208]. Although there is growing evidence suggesting that dynasore and 
dyngo-4a may interfere with cholesterol homeostasis and may target lipid rafts independent of 
dynamins, the exact mechanisms remain to be resolved [209]. 
7. Cell Death Mechanisms 
Cell death is part of life and crucial for all multicellular organisms. Cell death is essential in many 
processes, including tissue sculpting during embryogenesis, the maintenance of the immune 
system, and the destruction of aged, diseased, infected, or damaged cells.  
The first descriptions of programmed cell death mechanisms were published in the early 1950s 
[210, 211]. In 1973, Schweichel and Merker proposed the first classification on cell death based 
on morphological features [212]. According to this classification, three different forms of cell 
death could be distinguished: type I cell death, also called apoptosis; type II cell death, also called 
autophagy; and type III cell death, also called necrosis (Figure 11) [213].  
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Figure 11 Schematic diagram showing 3 possible pathways of cell death [213] 
 
The first classification relied on morphological features solely, but now with modern biochemical 
methods and techniques, the field has been revolutionised. Over the last 6 decades, scientists have 
gained profound insights into the molecular pathways on the initiation, regulation, and execution 
of different kinds of cell death. The majority of cell deaths do not proceed randomly but rather in 
a highly organised manner and are genetically programmed. Because of this, the term regulated 
cell death (RCD) or programmed cell death (PCD) was coined. This process is in clear contrast to 
accidental cell death (ACD), which is the sudden and catastrophic death of cells when exposed to 
severe, external insult [214]. Some features of the different PCD forms partially overlap and 
whether a cell dies from one or the other PCD form depends on the cell death stimulus, the tissue 
type and the cell’s microenvironment. The same stimulus may also trigger different forms of PCD 
in the same cell depending on the intensity of the stimulus; or the same stimulus could trigger 
different forms of PCD in different cells [215].  
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The Nomenclature Committee on Cell Death (NCCD) has so far defined 12 major kinds of PCD 
and surely more will follow (Figure 14) [216]. 
 
 
Figure 12 Major cell death subroutines. (RCD: regulated cell death, ADCD: autophagy-dependent cell death, ICD: 
immunogenic cell death, LDCD: lysosome-dependent cell death, MPT: mitochondrial permeability transition [217]. 
7.1 Apoptosis 
The term Apoptosis is derived from the Greek word “άπóπτωσις” - meaning falling off, which 
usually suggests “leaves falling from a tree”. It was first used by Kerr et al in 1972 to describe a 
morphologically distinct form of cell death [218]. Apoptosis is surely the best characterized form 
of cell death and can be subdivided into extrinsic apoptosis and intrinsic apoptosis. Apoptosis is 
initiated following an insult or preprogramed for certain physiological conditions, such as during 
embryogenesis and development [218-220].  
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The executioners of apoptosis are the caspases. This energy-dependent proteolytic cascade of 
cysteine-aspartate specific proteases (caspases) is the final step of apoptosis. Caspases are dimeric 
endoproteases that become activated through proteolysis by upstream caspases and once activated 
cleave downstream caspases themselves [221].  
7.1.1 Morphology of apoptosis 
During apoptosis, typical morphological changes can be visualized by light or electron 
microscopy. As early events, cell shrinkage and chromatin condensation (pyknosis) occur. The 
cells appear smaller, denser, and the organelles are tightly packed. The most characteristic feature 
of apoptosis is the condensation of the chromatin. As apoptosis proceeds, nuclear fragmentation 
(karyorrhexis), extensive plasma membrane blebbing and budding occurs which involves the 
separation of the cell fragments into apoptotic bodies (Figure 13). During this whole process, the 
organelle integrity and the plasma membrane are maintained. This is essential, as in that way 
hardly no inflammatory reaction will occur. Eventually, the apoptotic bodies are phagocytosed by 
macrophages and degraded within phagolysosomes [222, 223].  
 
Figure 13 Electron microscopy image of taurolidine induced apoptosis in a glioma cell [213, 224] 
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7.1.2 Extrinsic Apoptosis 
Extrinsic apoptosis is induced by extracellular stress signals that are transmitted through a battery 
of specific transmembrane receptors. The cell death program is initiated upon binding of death 
ligands to their corresponding death receptors, such as FAS/CD95 ligand (FASL/CD95L) to 
FAS/CD95, tumour necrosis factor α (TNFα) to TNFα receptor 1 (TNFR1), and TNF ligand 
superfamily member 10 (TNFSF10, also termed TRAIL), to the TRAIL receptor (TRAILR) [225, 
226].  
All different death receptors function by eliciting signals that lead to extrinsic apoptosis. In a 
similar way, upon ligand binding to its corresponding receptor, the receptor is stabilized and 
undergoes a conformational change. This facilitates the formation of a multiprotein complex at the 
cytosolic tail, the so-called death domain (DD) [227].  
Several proteins are subsequently recruited to the DD, causing the formation of the supramolecular 
death-inducing signalling complex (DISC). These proteins include receptor-interacting protein 
kinase 1 (RIP1), FAS-associated protein with a DD (FADD), c-FLIP, cellular inhibitor of 
apoptosis proteins (cIAPs), and pro-caspase-8 or 10 [228, 229]. Aggregation of the DISC causes 
conformational changes that unleash the catalytic activity of caspase-8 or 10.  
In type I cells, including lymphocytes and thymocytes, caspase 8 cleavage directly triggers the 
caspase 3 dependent executioner phase independent of mitochondria activation. Whereas in type 
II cells, including hepatocytes, pancreatic β cells and most of the cancer cells, caspase-8 cleavage 
induces the proteolytic cleavage of BH3-interacting domain death agonist (BID), to the truncated 
mitochondrion-permeabilizing fragment (tBID). TBID translocates to the outer mitochondrial 
membrane (OMM) and activates BCL2 associated X apoptosis regulator (BAX) and BCL2 
antagonist/killer 1 (BAK) [230-232].  
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This activation is controlled by pro-apoptotic and anti-apoptotic members of the apoptosis 
regulator (BCL2) protein family, a group of proteins containing one to four shared BCL2 
homology (BH) domains.  
Through the homodimerization of Bak and Bax, mitochondrial pore formation is initiated which 
leads to mitochondrial membrane permeabilization (MOMP) and the release of several proteins 
from the mitochondrial intermembrane space (IMS). These proteins include 
cytochrome c (CYTC), diablo IAP-binding mitochondrial protein (DIABLO or second 
mitochondrial activator of caspases (SMAC)), endonuclease G (ENDOG), and cytoplasmic 
adaptor protein APAF1 [233, 234].  
MOMP can be antagonized by anti-apoptotic members of the BCL2 family, including BCL2 and 
BCL2 like 1 (BCL-XL). They directly bind to and inhibit the pro-apoptotic BCL2 members [235, 
236].  
CYTC and APAF1 bind to procaspase 9 forming the supramolecular complex apoptosome, which 
activates caspase 9. The activated caspase 9 catalyses the proteolytic activation of the two 
executioner caspases 3 and 7, and thus completes the apoptotic demise of cells [214, 216, 237-
240].  
7.1.2 Intrinsic Apoptosis 
Intrinsic apoptosis is initiated by a multitude of internal stress factors, including oxidative stress, 
ER stress through accumulation of unfolded proteins or DNA damage [241, 242]. Multiple stress 
factors can initiate intrinsic apoptosis and they all share one common step, the irreversible MOMP. 
MOMP is thoroughly controlled by pro-apoptotic and anti-apoptotic members of the BCL2 family 
(see above) [231, 235, 236, 238, 240]. If the pro-apoptotic signals dominate, Bak and Bax 
homodimerize at the OMM and initiate the pore formation. Once the point of no return is reached, 
MOMP not only leads to the release of lethal proteins from the IMS (see above), it also leads to 
the dissipation of the mitochondrial transmembrane potential (Δψm), with cessation of 
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mitochondrial ATP synthesis through an inhibition of the MRC [238, 240, 243]. Then as described 
above, eventually the apoptosome is formed, which preludes the last steps of apoptosis.  
The release of proteins from the IMS is caspase-independent and is responsible for further pro-
apoptotic effects: The release of AIF and ENDOG and their relocation to the nucleus, leads to the 
cleavage of DNA into nucleosomal fragments (nucleosomal fragmentation) [244, 245]. 
SMAC/DIABLO is important for the activation of the caspases for its ability to eliminate the 
inhibitory effect of IAPs [246-248].  
In that sense the NCCD suggests to define ‘intrinsic apoptosis' as a cell death process that is always 
mediated by MOMP but may proceed in a caspase-dependent and caspase-independent manner 
[214]. 
  
Figure 14 Schematic overview of the apoptosis pathway [249] 
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7.2 Necroptosis 
For a long time, apoptosis was seen as the only form of RCD, and other cell death forms were 
considered unregulated accidental cell deaths (ACD)s, and therefore, subsumed as necrosis [218]. 
With the discovery of genetic, biochemical, and functional evidences, the term "necrosis" is 
understood as a molecularly controlled, regulated form of cell death (RCD), which includes 
various cell-death modalities such as parthanatos, ferroptosis, mitochondrial permeability 
transition (MPT)-dependent necrosis, and necroptosis [250, 251]. Among these, necroptosis is the 
best studied form of regulated necrosis and is clearly defined by a tightly regulated activation and 
inhibition process.  
7.2.1 Morphology of Necroptosis 
Necroptotic cell death was historically referred to as the type III cell death (Figure 11). It is 
characterized by early cellular rounding and swelling and an increased cytoplasmic granularity, 
while the nuclei remain intact. Towards the end, the disintegration and rupture of the mitochondrial 
and lysosomal plasma membrane is accompanied with the ejection of cellular contents in a 
ruptured balloon-like morphology [252].  
7.2.2 Molecular mechanism 
Apoptosis is not only the main form of induced RCD after an insult, it is also the main cell death 
form under physiological conditions [220]. The role of necroptosis during embryogenesis, 
differentiation, and maturation is limited to few reports. It is further not clear, if necroptosis is not 
only induced as a backup for an impaired apoptosis [253, 254].  
Necroptosis mainly occurs during pathophysiological conditions of infection and disease. Upon 
cellular stress, a range of proteins can trigger necroptosis. These include TNF, FasL, TRAIL, 
interferon (IFN), lipopolysaccharides, dsRNA, cytosolic DNA, ER stress, viral infection and 
chemotherapeutic agents. Their corresponding receptors (Fas, TNFR1, pathogen recognition 
receptors (PRRs) like toll-like receptor 3 and 4 (TLR 3 and 4) and Z-DNA binding protein 1 
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(ZBP1)) are responsible for signal transduction [255-264]. The key molecules during necroptosis 
are the RIP kinases (receptor-interacting protein kinases), a class of serine/threonine protein 
kinases. RIP1 possesses several domains which are capable to activate different signalling 
pathways. Its N-terminal kinase domain is required for canonical necroptosis, its death domain 
(DD) is essential for TRADD association and its C-terminal RHIM domain is responsible for the 
recruitment of RIP3. RIP3 is homologous to RIP1, also containing an N-terminal kinase domain 
and a C-terminal RHIM domain [265].  
One prototypic signalling pathway is mediated through TNF stimulation: TNF induces the 
recruitment of RIP1 and TRADD to TNFR1, which is then called complex 1. Ubiquitination and 
phosphorylation of RIP1 hinders a dissociation of complex 1 from the receptor, resulting in an 
inhibition of cell death and a pro-survival NF kappa B signalling [266].  
Whereas, upon dissociation of complex I from the receptor, different pro-cell death complexes 
(complex IIa, IIb and the necrosome) are formed depending on the availability and abundance of 
accompanying proteins, which can either induce apoptosis or necroptosis [267]. If caspase 8 is 
available, it associates with complex II and induces apoptosis, however if caspase 8 is not available 
or dysfunctional, RIP3 is recruited to form the necrosome.  
Complex IIa further recruits FADD, TRADD, and RIP1, whereas complex IIb can be formed 
independent of TRADD. In order to activate RIP3 by RIP1 through phosphorylation, their physical 
interaction between their RHIM domains is essential. [260, 268-270]. After its activation, RIP3 
phosphorylates mixed lineage kinase domain-like (MLKL) at several sites (Figure 15) [271-273]. 
The exact mechanism of action of MLKL is still unknown and controversially discussed. Common 
understanding is that MLKL delocalizes to the plasma membrane once phosphorylated, where it 
binds specific phosphatidylinositol phosphate species and prompts an influx of ions, either directly 
by the formation of ion channels or pores or indirectly through the interaction with ion channels. 
This ion influx will eventually lead to the cell’s demise [273-275].  
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Figure 15 Signal transduction complexes in TNF-induced necroptosis [276]. 
 
Alternatively to the canonical necrosome formation, RIP3 can be activated through the TLR3, 
TLR4 and ZBP1. Here dsRNA, cytosolic DNA and pathogen associated molecular patterns 
(PAMPs) are the inducing molecules. Once RIP3 is activated, MLKL is phosphorylated 
independent of the RIP1 kinase activity and necroptotic cell death can proceed [256, 277].  
7.3 Ferroptosis 
Ferroptosis, a new form of RCD, was described by Dixon et al in 2012 [278]. Ferroptosis is an 
oxidative, iron-dependent form of cell death leading to lethal accumulation of toxic lipid ROS 
through lipid peroxidation and the depletion of plasma membrane polyunsaturated fatty acids [279, 
280]. At the genetic, biochemical, and morphological level, ferroptosis can be distinguished from 
other RCDs, [278]. Up to now, ferroptosis has been associated with normal physiological functions 
such as embryogenesis and differentiation [281].  
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7.3.1 Morphology of Ferroptosis  
Morphologically, ferroptotic cell death has only few distinct cellular features. In the early phase, 
the mitochondria become smaller with increased membrane density, reduced or no cristae, and 
ruptured OMM (Figure 16). As the process progresses, the cells show a necrotic and rather 
indistinct appearance [251, 278].  
 
Figure 16 Transmission electron microscopy of BJeLR cells treated with erastin and undergoing ferroptosis. 
Single white arrowheads indicate shrunken mitochondria [278] 
 
7.3.2 Molecular mechanism 
Ferroptosis can be triggered by small molecules that inactivate the cellular glutathione (GSH)-
dependent antioxidant defence system [282]. The reduced glutathione (GSH)-dependent enzyme 
glutathione peroxidase 4 (GPX4) is the most important ferroptosis inhibitor. It catalyses the GSH-
dependent reduction of lipid hydroperoxides to lipid alcohols [283]. Compounds that affect 
Glutathione homeostasis seem promising as agents that induce ferroptosis. The first ferroptosis 
inducing compound Erastin inhibits the cysteine/glutamate antiporter system xc- and so 
consequently depletes cysteine [278]. Tyrosine kinase inhibitor sorafenib seems to have the same 
function. Sorafenib also depletes cysteine via inhibiting the cysteine/glutamate antiporter system 
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xc- and induces ferroptotic cell death in multiple cancer cell lines [284]. Kagan et al was able to 
show that lipid peroxidation preferentially occurred at certain phosphatidylethanolamine-
containing polyunsaturated fatty acids (PUFAs). Here, lipid peroxidation is catalysed by 
lipoxygenases (LOX). Lipid peroxides further decompose into reactive derivatives, which target 
proteins, nucleic acids and other macromolecules [285, 286].  
The iron-dependency of ferroptosis has been shown in several ways: Iron depletion by iron 
chelators abrogates ferroptosis whereas increased iron availability through an increased import by 
the iron carrier transferrin or increased degradation of the iron storage pool ferritin promotes 
ferroptosis [278, 283, 287, 288]. This iron-dependency might be explained by two different 
mechanisms. First LOX contain a di-iron centre at their catalytic sites, which renders them iron 
dependent [289] and second heavy metals are prone to promote non-enzymatic lipid oxidation via 
the Fenton reaction [290, 291]. Which of the two mechanisms is the most important one remains 
to be elucidated.  
7.4 Autophagy 
Autophagic cell death is historically referred to as type II cell death. The term autophagy-
dependent cell death (ACD) is somehow misleading as autophagic responses mediate 
cytoprotection rather than cell death. It was shown that inhibition of the autophagic machinery 
accelerates rather than prevents cell death [292, 293]. ACD is involved in physiological cell death 
as observed during the development of D. melanogaster [294] and has been observed in some 
cancer cells as a response to chemotherapeutic agents. The latter seems to be especially true when 
the cells lack key proteins of the apoptotic pathway such as Bak, Bax, and caspases [295].  
7.4.1 Morphology of autophagy 
During ACD, much of the cytoplasm are sequestered into autophagosomes. These large 
autophagosomes are responsible for the cell’s characteristic vacuolated appearance (Figure 17) 
[214]. Autophagosomes are double-membraned and may contain cytosol and intact cytoplasmic 
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organelles such as mitochondria and ER. After the fusion of autophagosomes with lysosomes, 
these develop into autolysosomes with a single layer of membrane that contain degraded 
cytoplasmic organelles [296].  
 
Figure 17 Human epithelial cancer (HeLa) cell treated thapsigargin and undergoing autophagic cell death. 
Accumulation of double-membraned cytoplasmic vacuoles containing organelles or parts of the cytosol [297]. 
7.4.2 Molecular mechanism 
The autophagic process can be divided into distinct steps, each involving different key proteins. 
Key players of the autophagic machinery are the autophagy-related (Atg) genes, that orchestrate 
the autophagic process [298]. The degradative autophagy pathway is induced during cellular stress, 
which can be caused by conditions such as nutrient and growth factor deprivation [298]. The 
protein kinases mTOR negatively regulates autophagy through inhibitory phosphorylation of the 
Unc-51-like kinases ULK1 and ULK2 (mammalian homologues of Atg1) while AMPK activates 
autophagy through phosphorylation of ULK 1&2 and by inhibiting mTOR [299-301]. Upon 
induction of autophagy ULK is dephosphorylated, which leads to the phosphorylation of Beclin-1 
(mammalian homologue of Atg6) and eventually to the generation phosphatidylinositol 3-
phosphate (PtdIns(3)P) [302, 303]. Autophagosome formation requires two ubiquitin-like 
conjugation systems, which are directly linked with expansion of autophagosomal membranes 
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[304, 305]. These complexes activate Atg3, which covalently attaches microtubule-associated 
protein 1 light chain 3 (better known as LC3/Atg8) onto the surface of autophagosomes [306]. 
Lipidated LC3 is essential for the closure of the autophagosomes and assists the attachment of 
specific cargos and adaptor proteins [307, 308]. The regulation and timing of the fusion of the 
autophagosome with a lysosome is essential and requires among others SNARE proteins and Ras-
like proteins from rat brain (Rab) protein [298]. Finally, bit by bit, the contents of the autolysosome 
are degraded, and their building blocks recycled [309].  
7.5 Methuosis 
Methuosis is derived from the Greek word methuo, which means to drink to intoxication. Maltese 
and Overmayer used the word to describe a novel type of cell death, which occurs in cells 
accumulating large fluid-filled cytosolic vacuoles [310]. Although methuosis can be initiated by 
various triggers, such as genetic manipulation, small molecules, and antibodies, these triggers 
share the same feature of an increased macropinocytosis [311-321]. In the latest NCCD review, 
methuosis was not considered as a form of RCD, as it has not been described yet in a physiological 
context [216].  
7.5.1 Morphology of methuosis 
The most prominent feature of methuosis is the congestion of the cytoplasm with large clear, fluid-
filled vacuoles of different sizes. The membrane of the vacuoles is single-layered, in contrast to 
the double-membraned autophagosomes. The nucleus stays intact without signs of chromatin 
condensation or fragmentation. At the final stage, the cell membrane ruptures, resembling the final 
stage of necroptosis [310, 311]. 
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Figure 18 GBM cells undergoing methuosis triggered by ectopic expression of activated Ras [322]. 
7.5.2 Molecular mechanism 
7.5.2.1 Macropinocytosis during physiological processes  
Macropinocytosis is a regulated clathrin-independent from of endocytosis that mediates the 
internalization of soluble molecules, nutrients, and antigens. Macropinocytosis is involved in cell 
motility, migration, and metastasis [323]. Evolved from surface membrane ruffles, the so called 
macropinosomes are formed by closure of the plasma membrane through an actin-dependent 
process [323]. First described by Lewis in 1931, macropinocytosis is caused by external stimuli 
such as CSF-1, epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) 
signalling through receptor-tyrosine kinase signalling [324-327].  
Two distinct forms of macropinocytosis can be distinguished: Macropinocytosis derived from 
peripheral ruffle (PR) formation, referred to as macropinocytosis, and macropinocytosis derived 
from circular dorsal ruffle formation, referred to as circular dorsal ruffles (CDR). While 
macropinocytosis is very well studied, CDR is less explored, and many open questions remain.  
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7.5.2.1.1 Macropinocytosis from peripheral ruffles  
Once formed, the macropinosomes undergo a maturation process, which is different for different 
cells. Here, key molecules are various Rab GTPases. Known as the Rab cascade, upstream Rab 
GTPases recruit certain GEFs (guanine nucleotide exchange factors) that activate and recruit a 
downstream Rab GTPase. The downstream Rab GTPase then recruits a GAP (GTPase-activating 
proteins) to the upstream Rab, which is consequently deactivated [186].  
Most of the cargo is directly recycled back to the plasma membrane via early endosomes with 
Rab5 GTPase as the key endosomal component. The remaining early endosomes mature to late 
endosomes. The formation of a new late endosomes is preceded by acquisition of a Rab7 GTPase. 
This leads to the transient formation of a hybrid Rab5/Rab7 endosome. The removal of Rab5 and 
its replacement with Rab7 require its GAP activity. The Rab7 positive late endosomes become 
more and more acidified (the luminal pH drops from 6 down to 4.9) and finally fuse with 
lysosomes. During this stage, the late endosomes accumulate Lamp1, a late endosomal/lysosomal 
protein. Nearly all of the cargo in the late endosomes is degraded within the lysosome and only a 
minority serves for the maintenance and generation of lysosomes themselves [328]. 
Phosphatidylinositol phospholipids (PIP) are important components of the membranes and are 
heavily involved in endocytosis. Phosphorylation and dephosphorylation at the 3, 4, and 5 
positions of the inositol ring directs certain binding proteins to the PIPs. PI(4,5)P2 is mainly 
present on the plasma membrane and prominent binding partners include AP2 and dynamin, 
whereas PI(3)P is enriched in endosomes with their own binding partners. [329]. PIPs and Rab 
GTPases are closely connected. PIPs are able to recruit GEFs and GAPs to the Rab GTPases and 
either activate or inactivate the Rab GTPase. PIPs are therefore crucial for the directional flow of 
membrane cargoes [186].  
Besides the above mentioned Rab GTPases, other members of the RAS superfamily are 
significantly involved in macropinocytosis [330]. Rac1 and Cdc42 are essential for membrane 
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ruffling and macropinosome formation [326, 331-333], while RhoB localizes to intracellular 
endosomes, where it controls vesicle transport through regulating actin assembly on vesicle 
membranes. Last, RhoG, is involved in the formation of dorsal membrane ruffles [326, 331-335]. 
The involvement of Ras in membrane ruffling and macropinocytosis has gained more and more 
importance since it has been shown to be involved in membrane ruffling and macropinocytosis but 
also driving methuosis [310, 311, 317, 336-340]. Last, the Arf GTPases are also involved in 
membrane trafficking. Arf6 guides Rac1 to the plasma membrane and initiates the activation of 
phospholipase D1, which is required for macropinosome formation [341, 342].  
7.5.2.1.2 Circular dorsal ruffles  
Suggested functions of CDRs embrace the directed internalization of receptors and the gross 
internalization of soluble substrates and molecules through macropinocytosis. Further CRD is 
involved in cell motility in a specific mode, namely mesenchymal migration [333, 343]. 
CDRs are phenomena observed on the dorsal surface of cells. They extend vertically from the cell 
membrane to form closed, ring-shaped vesicles. After TRK stimulation, they appear, constrict, 
enclose, and disappear within 30minutes [344]. The signalling events are not fully understood. 
However, the phosphatidylinositol 3-kinase (PI3K) and the small GTPase Rac seem to be involved 
downstream of TRK stimulation [345]. After growth factor stimulation, expression of guanosine 
diphosphate (GDP)-bound dominant negative forms of Ras, Rac and Rab5 inhibit the induction of 
CDRs. Further members of the Arf family have been found localized to CDR and overexpression 
of their GAPs strongly inhibits CDR formation [346, 347]. 
The regulation of actin polymerization is controlled by a group of interacting proteins. The key 
step is N-WASP 1 or Cortactin mediated activation of Arp 2/3 [199, 348]. More than 20 
membrane-binding proteins are associated with CDR. Among these, Dynamin 2 plays an essential 
role. While Dynamin 2 overexpression strongly induces CDR formation, dominant-negative 
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mutant Dynamin 2 expression and Dynamin 2 depletion abolishes CDR formation [199, 200, 346, 
349-351].  
7.5.2.2 Macropinocytosis during methuosis  
The first description of hyperstimulated macropinocytosis dated back to 1999 when Chi and 
Kitanka observed a caspase-independent form of cell death. They reported such cell death to be 
accompanied by massive accumulation of fluid-filled vesicles after ectopic expression of the 
constitutively active oncoprotein, H-Ras (G12V) in glioblastoma cells [337, 352]. They 
misinterpreted the vesicles to be autophagosomes. 
Almost 10 years later, Overmayer and Maltese showed that ectopic expression of oncogenic H-
Ras induces the formation of single-membraned non-acidic vacuoles. These vacuoles resemble 
macropinosomes in that they incorporate fluid-phase tracer dextran 488, via increased 
macropinocytosis. Further, they showed that these macropinosomes contained Rab 7 and Lamp1 
but failed to fuse with lysosomes, indicating an impaired maturation. To further pin down the 
involved pathway, they expressed mutant and constitutively active Rac1 in glioblastoma cells and 
saw that this mutant also induced an increased fluid-phase dye uptake and eventually cell death, 
indicating its relevance [310, 311]. Moreover, they were able to show that this new phenotype was 
distinct from autophagy, apoptosis, and necroptosis. The macropinosomes did not contain the 
autophagosomal marker LC3, however, caspase 3 activation was observed, but the phenotype 
could not be inhibited by either knockdown of Beclin-1 (autophagy essential protein), 
pharmacological inhibition with the pan-caspase inhibitor Z-vad, nor the necroptosis inhibitor 
Necrostatin (NS-1) [310].  
Two follow up studies in glioblastoma and osteosarcoma cell lines revealed that methuosis occurs 
independent from activation of phosphatidylinositol-3-kinases (PI3K), Cdc42 and Raf signalling 
[311]. Further, they showed that active Rac1 stimulates GIT1, a negative regulator of the GTP-
binding protein Arf6, which is a well-known regulator of endosomal recycling. Pharmacological 
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inhibition of Rac1 or shRNA-dependent silencing of GIT1 prevented the vacuolization and loss of 
cell viability [336].  
Since these early descriptions of methuosis in cancer cells with ectopic H-Ras expression, several 
groups have demonstrated induction of methuosis through different compounds in various cell 
systems. After application of methamphetamine to neuroblastoma cells, Nara et al observed the 
formation of large cytoplasmic vacuoles that were not co-localized with autophagosome or the ER 
markers. Co-localization experiments revealed Ras and Rac1 on the vacuoles and co-treatment 
with the Ras inhibitor, farnesylthiosalicylic acid (FTS), and the Rac1 inhibitor, EHT1864 inhibited 
the formation of macropinosomes. Further an increase in the lysosomal marker LAMP1 and a 
decrease in Cathepsin L were observed, indicating either an impaired endosomal maturation or an 
impaired lysosomal function triggered by Ras/Rac1 [353, 354]. 
Chunhui et al, found that a combination of ectopic expression of TrkA and nerve-growth factor 
(NGF) treatment in medulloblastoma cells also hyperstimulated macropinosomes. However, these 
vacuoles carried the autophagosomal marker LC3, whereas knock-down experiments of autophagy 
key players did not block the NGF-induced macropinocytosis. Interestingly, the Casein Kinase 1 
(CK1) inhibitor D4476 completely blocked the observed phenomenon and induction of cell death 
[355]. Their follow-up study then showed that RhoA is activated by Src. Further CK1 
phosphorylates RhoB, leading to the release of actin stress fibres, which enables the activated 
RhoA to reorganize actin required for generation of macropinosomes [356].  
Other small molecules have been shown to induce macropinocytosis through various pathways. 
These include the indol-based chalcone-related small molecules MIPP and MOMIPP in different 
cancer cell lines and in a Ras and Rac1 independent fashion. Nevertheless, also here a block in 
endosomal maturation is suggested [313, 357]. Further development of these chalcones identified 
some agents that induce massive accumulation of vacuoles, however fail to induce cell death. This 
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unexpected uncoupling of vacuolization and cell death suggests that other pathways and key 
molecules must be involved than the ones explored so far [315, 358, 359].  
Another compound studied in the context of methuosis is Vacquinol, which further decreases ATP 
levels and induces a rupture of the cell membrane. An unbiased shRNA screen showed that the 
activity of MAP kinase kinase 4 (MKK4) was required, however its exact role remains unclear 
and the publication was later retracted due to unreproducible animal studies [360]. Despite being 
promising in the cell culture setting, this compound failed to effectively reduce tumour size or 
prolong overall survival in a glioblastoma mouse model [319, 361].  
Last, Manara et al discovered that upon CD99 mAB triggering, methuosis is induced in Ewing 
sarcoma through activation of Insulin Growth Factor Receptor 1 (IGFR1), Ras and Rac1 [317].  
Although multiple studies have by now well documented methuosis in malignant cancer cells, 
many questions remain. Are tumour cells in general more prone to disruptions of the endocytic 
pathway as they often rely on sustained growth factor signalling? What are the exact signalling 
pathways involved and at which step is the endosomal maturation blocked? Most importantly, how 
does increased macropinocytosis lead to the induction of cell death?  
 
 
 
 
 
 
 
 
 
 
Figure 19 Overview of signalling 
pathways involved in hyperstimulation of 
macropinocytosis [362] 
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8 Ionizing Radiation 
8.1 Physics and Chemistry 
The German physicist Wilhelm Conrad Röntgen was the first to discover that x-ray exposure 
blackens photographic films in 1895. One year later, the first medical use of x-ray was published 
(Lancet, 1896) [363]. Radiation oncology is the clinical field dealing with the application of 
radiation as a therapeutic option in the treatment of malignancies. Alongside with surgery, 
radiation therapy was the first established treatment for cancer patients. 
The term radiobiology refers to the study of ionizing radiation and its effect on living organisms. 
Depending on the amount of energy, radiation either elevates an electron in an atom to a higher 
energy level (excitation) or if the energy level is higher, ejects orbital electrons from the atom 
(ionization). Along with the ejection of the electrons a large amount of energy is released [364]. 
The delivered radiation dose is internationally measured in Gray (Gy) and defined as the amount 
of radiation depositing 1 Joule of energy in 1 kilogram of matter. Different kind of ionizing 
radiation can be distinguished; these include electromagnetic radiations (x-rays and gamma-rays) 
and particulate radiations (electrons, protons, α-particles, heavy charged particles, neutrons). All 
charged particles cause direct radiation effects, meaning that the radiation directly excites or 
ionizes the target atom through a high linear energy transfer (LET). X-rays, gamma-rays, and 
neutrons, on the other hand, indirectly interact with the target: they react with molecules in the cell 
(e.g., hydrolysis of water) and cause the production of free radicals that eventually damage the 
target [14]. Hydrolysis of the water results in a hydrogen and a hydroxyl (free radical) molecule. 
Upon recombination of two hydroxyl molecules, unstable hydrogen peroxide is formed. Hydrogen 
peroxide eventually decays into a peroxide hydroxyl, which combines with an organic compound 
to form a stable organic hydrogen peroxide molecule, which damages the cell [14, 365].  
Fractionated radiation means the delivery of the required radiation dosage in multiple smaller 
doses, over several weeks. Through this protracted application, the differences between healthy 
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and tumour tissue are best utilized in the sense of damage repair and response of the 
microenvironment [15]. To be able to describe effects of different fractionation regimes, the linear 
quadratic model is applied and shows the effects of fractionated radiation on cell survival. By 
reducing the dose per application, higher cumulative dose levels can be administered. This spares 
the normal tissue without reducing the radiation effect on cancerous tissue [366, 367]. This model 
has lately been challenged by the observation that target cells show a hypersensitivity to dosages 
below 0.5Gy and radio resistance to higher doses. Differences in DNA damage repair might be 
responsible for this observation. Interestingly, tumour cells that are generally more radio resistant 
show the greatest sensitivity to low dose radiation [368].  
8.2 Five R’s of Radiobiology 
The five R’s of radiobiology are used to explain the biological factors that influence treatment 
response of different patients to fractionated radiation. Originally described as the four R’s of 
radiobiology by Withers in 1975, the four key principles upon which radiation parameters are 
based are explained: repair of normal cells to sublethal doses of radiation damage, redistribution 
of cells within the cell cycle, repopulation of surviving tumour cells, and reoxygenation of hypoxic 
areas within in the tumour [369].  
Repair after sublethal doses of radiation mainly involves the repair of single and double strand 
breaks (SSB/DSB). Healthy tissues have greater capability to launch the repair program compared 
to irradiated tumorous tissue. Redistribution refers to the different sensitivity of cells during cell 
cycle and the different repair programs that are started depending on the cell cycle phase (see 
below). Repopulation is the observation that surviving tumour cells accelerate in regrowth after 
radiation. To avoid this, short radiation intervals have to be chosen.  
Reoxygenation exploits the capability of tumour cells to enhance their intratumoral oxygenation, 
which significantly improves the radiation efficacy.  
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The fifth R was later added by Steel in 1989, highlighting the importance of radio sensitivity of 
cells [370]. Radiation sensitivity is dependent on intrinsic and extrinsic factors. Actively dividing 
cells are more radiosensitive than non-dividing cells. Cell cycle can be divided into four phases: 
mitosis or M phase (division of cells), gap 1 or G1 phase (preparation for replication), synthesis 
or S phase (DNA synthesis by replication), and gap2 or G2 phase (preparation for re-entering 
mitosis). M and G2 phase are the most radiosensitive phases, when chromosomes are condensed 
and paired [371]. Further radio sensitivity correlates with a cell’s ability to start its DNA repair 
program or its activation of apoptotic pathways. Other factors that influence radiation sensitivity 
are the microenvironment and the vasculature that determine oxygenation and nutrient availability. 
Oxygen supply is one of the main factors determining radio sensitivity. The relative radio 
sensitivity of euoxic to hypoxic cells is about 1.5 to 2.5, meaning that the dose required to achieve 
a certain effect must be 1.5 to 2.5 higher for euoxic than hypoxic cells [372]. Oxygen is needed 
for the formation of reactive oxygen species. Further, it is believed that oxygen transfers free 
radical–induced DNA damage into a more permanent state. Intratumoral regions with poor oxygen 
supply are relatively radio resistant and tend to be more aggressive. Hypoxia can select for tumour 
cells harbouring p53 mutations which are so associated with a bad prognosis [373-375].  
8.3 DNA and Chromosome Damage Repair and cell death 
Ionizing radiation produces a range of DNA lesions, which eventually can cause cell death and 
mutations. In mammalian cells, 1 to 2 Gy causes around 1000 base damages and single-strand 
breaks (SSBs) and around 40 double-strand breaks (DSBs) [376]. Low dose radiation or indirect 
radiation causes mainly SSBs damages through hydroxyl radicals, generated from the hydrolysis 
of water [377], whereas direct radiation mainly causes DSBs and thus the cleavage of DNA in two.  
SSBs are by far less important compared to DSBs to cause cell death. DSBs are thought to be the 
most important lesions as one single double strand break can already engage the damage-sensing 
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process that can lead to cell death. Large lesions causing the formation of dicentric and acentric 
DNA fragments can induce mitotic cell death during division [366]. 
To handle DNA damage, cells developed sophisticated DNA damage repair mechanisms. SSBs 
and base damages are usually repaired by base excision repair (BER) and DSBs by either 
nohomologous end joining (NHEJ) or by homologous recombination repair (HRR) [376]. During 
BER the undamaged complementary strand functions as a template. First, the damaged base along 
with the associated sugar is removed by an endonuclease, followed by the insertion and ligation 
of a replacement nucleotide by the DNA polymerase beta [376]. If several SSBs more than three 
nucleotides apart are present on opposing strands of DNA, BER can accidently cause a double-
strand break. This mechanism is thought to be responsible for the indirect radiation damage 
through ROS [377]. 
When a DSB occurs during S or G2 phase the HRR is launched, while during G1 phase NHEJ 
repair program is initiated. During NHEJ, a sensor repair program is triggered that guides the 
sensors ATM (ataxia telangiectasia mutated) and MRN (mammalian complex of Mre11-Rad50-
Nbs1) to the DSB. To guide repair, microhomologies (short homologous DNA fragments present 
in single-stranded DNA overhangs at the end of the DSB) are used. After recruitment of the DNA-
dependent protein kinase catalytic subunit (DNA-PKcs), processing or end-bridging and ligation 
is performed. A precise repair can occur only when the overhangs are compatible, otherwise 
translocations and telomere fusions can occur [376, 378].  
For HRR, a complement DNA strand is required as a template. This can be found during S/G2 
phase when a sister chromatid is available. ATM and MRN are also recruited to the site of the 
DSB. The DNA is resected by the endonuclease MRE11, resulting in two 3’-single stranded DNA 
(ssDNA), that serves as binding sites for Rad51. ATM phosphorylates BRCA1 leading to the 
recruitment of BRCA2. BRCA2 in return recruits Rad51 that is responsible for the strand exchange 
with the undamaged chromosome leading to so called Holliday junctions. In this model, the 
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ssDNA strands first invade and base-pair with the undamaged sister chromatid. The ssDNA strands 
from the damaged chromatid are then elongated by a DNA polymerase, using the sister chromatids 
as templates. Once the Holliday junctions are resolved, the gap filling and DNA ligation can be 
performed [379].  
As discussed above, the main target of radiation therapy is DNA. Nevertheless, the so called 
bystander effect demonstrates that neighbouring unirradiated tissues are also affected by their 
irradiated neighbour tissue and display chromosomal damage in up to 30% after radiation [380]. 
It is thought that the bystander effect is mediated through cytokines, for example, tumour necrosis 
factor, interleukin 8, or reactive oxygen species. A direct cell-to cell contact was not needed, 
whereas gap-junctions play an important role [381]. The bystander effect has also been observed 
in vivo: Khan et al reported upper lung damage in rats that had only received radiation to the lower 
parts of the lung. It is believed that this effect was also mediated by ROS [382].  
If a cell experiences lethal radiation and damages can no longer be repaired, different kinds of cell 
death programs can be triggered.  
Mitotic cell death or mitotic catastrophe is the most commonly observed cell death after radiation. 
It occurs when large DNA lesions lead to the formation of dicentric and acentric DNA fragments 
or through failure of the mitotic checkpoints. Morphological changes that can be observed are 
unique nuclear changes, like multinucleation and macronucleation as consequences of 
chromosomal missegregation. Further micronucleation most likely resulting from the persistence 
of acentric chromosomes can be observed [217]. The molecules involved in sensing the impaired 
mitosis and eventually triggering mitotic death are still unclear, but most likely p53 plays a role 
[383]. The fate of cells experiencing mitotic catastrophe is either mitotic cell death or senescence. 
However, according to recommendations of the Nomenclature Committee on Cell Death, neither 
mitotic death nor senescence are considered RCD [217].  
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During senescence, cells stop proliferation, but remain metabolically active and viable. 
Morphologically, their cytoplasm flattens, and nuclei enlarge. Further, an intracellular 
vacuolization and altered chromatin structure can be observed [384]. In the German language we 
refer to them as “fried eggs, sunny side up”. The molecular steps leading to senescence include the 
inhibition of multiple cyclin-dependent kinases (CDKs), a dephosphorylation and activation of 
retinoblastoma (RB) proteins and ARF, and the activation of p53 [385]. As they stay metabolically 
active, senescent cells may secrete a variety of immunomodulatory and mitogenic cytokines and 
growth factors. These in return can promote the growth of neighbouring tumour cells [385].  
Along with mitotic cell death, radiation can further induce apoptosis. Here changes in 
mitochondria, followed by caspase activation and MOMP can be observed. Initiation of the 
apoptotic pathways mainly occurs through direct and indirect DNA damage and p53 activation, 
which in turn leads to an upregulation of proapoptotic proteins like BAK and BAX, cell death 
ligands or receptors [366].  
8.4 Radiation induced toxicity 
Radiation effects can be divided into acute reactions, subacute reactions, and late effects. Acute 
reactions occur within seconds to days after radiation, while the timing of subacute reactions and 
late effects is dependent on the dosage per fraction and the total dose administered. The time course 
and severity of clinical signs and symptoms are a function of the overall body volume irradiated 
and the radiation intensity [386]. Radiation fast-responding cells are mainly cells that are actively 
dividing. Epithelial and mucosa cells, stem cells, and haematopoietic cells are examples [386]. 
Here, as acute radiation induced side-effects, dermatitis, mucositis and neutropenia can be 
observed.  
Besides the radiation intensity and total dosage, patient-specific factors may also influence the 
degree of toxicity. Such factors include the individually associated therapeutic regimen, nutritional 
status, and individual genetic background. Patients with Ataxia teleangiectatica, Nijmegen-
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Breakage-Syndrome or Fanconi’s Anaemia in general have a significantly increased vulnerability 
to radiation, most likely due to their impairment in DNA repair [387].  
Depending on the age of the patient and the treatment site, the long-term side effects may vary. 
These include cardiomyopathy, neurocognitive sequelae, growth restriction through growth 
hormone deficiency, infertility, and the development of secondary malignant neoplasms (SMN) 
[388-392].  
The likelihood to develop secondary malignancies is much higher in children than in adults, as the 
risk remains throughout their entire lifetime. SMNs are best studied in children with Hodgkin’s 
disease and leukaemia. In Hodgkin’s disease an overall incidence of up to 25% within 30 years 
after radiation has been recorded [393], and in women with radiation to the chest, the incidence of 
developing breast cancer can reach 35% [394].  
8.5 Types of radiation devices and radiosensitizing agents 
To reduce or to avoid side effects, multiple strategies have been developed. More precise 
radiotherapy techniques, such as the three-dimensional conformal radiotherapy was first 
developed in Japan by Shinji Takahashi in the 1960s. With this new technique, a better 
conformation of the radiation doses to the target, while sparing the surrounding tissue, was 
achieved [16, 395]. Since then further improvements of these techniques have led to the 
development and implementation of intensity-modulated radiotherapy (IMRT) and image-guided 
radiotherapy (IGRT) [396, 397]. IMRT treatment uses a flexible shielding and multiple radiation 
beams coming from different directions. This allows a precise sculpturing of the radiation beams 
around the shape of the tumour, and therefore, the high-dose area is confined to the tumour while 
sparing the surrounding tissue [398].  
Proton therapy uses protons instead of photons as the source of radiation to treat malignancies. 
Due to their large mass, protons have minimal side scatter in the tissue. The penetration range of 
protons depends on their intrinsic energy and only small amounts penetrate beyond their calculated 
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range. Furthermore, protons reach a maximum peak dose (Bragg peak) only within the last 
millimetres of their range, which is localized to the target tissue [17]. Therefore, protons reach 
maximum effect in the target, which decreases the dose in the surrounding tissue. First studies in 
children on treatment outcome and treatment related side effects after PT have been promising 
[18]. 
In order to increase the efficiency and reduce the side effects of RT, radiosensitizers may be 
administered simultaneously with the therapy [399]. Radiosensitizing agents are compounds that 
render cancer cells more vulnerable to radiation therapy. Further radiosensitizing agents are 
capable of broadening the therapeutic window and selectively augment radiation effects in tumour 
cells while sparing the surrounding tissue.  
According to their chemical structures, radiosensitizers can be classified into three categories, 
namely, small-molecule chemicals, nanostructures, and macromolecules [19]. A broader approach 
to explain different ways to combine medication with radiotherapy was proposed by Bentzen et al 
[400]. They proposed five potential exploitable mechanisms: spatial cooperation, cytotoxic 
enhancement, biological cooperation, temporal modulation, and normal tissue protection. Through 
cytotoxic enhancement, the combinatorial treatment “aims to enhance the cell killing by 
modulating the induction or repair of cellular DNA damage” [400].  
8.6. Radiation therapy in the treatment of rhabdomyosarcoma 
As previously mentioned, radiotherapy is the third pillar of treating children with RMS [401-404]. 
Depending on the IRS risk group allocation, the timing, duration, and radiation dose administered 
changes. Due to the dismal prognosis of children with aRMS, they are all allocated to radiotherapy 
treatment [404].  
Since the addition of RT to the treatment regimen in the Intergroup Rhabdomyosarcoma Study I 
and III, event free survival (EFS) and overall survival have substantially improved. The best 
improvement was observed in IRS-III when RT was used in conjunction with intensified 
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chemotherapy [401]. Nevertheless, radiation-induced side effects and toxicity remain a major 
problem [405]. In an attempt to reduce radiation induced morbidity, the Intergroup 
Rhabdomyosarcoma Study-IV focused on hyperfractionated radiation to determine if dose 
escalation would improve outcomes without increasing late side-effects. The study resulted in 
observing no difference in local or regional control, and a comparison of the late effects was not 
done [43, 406]. On the contrary, Wolden et al. showed that IMRT in parameningial aRMS resulted 
in an excellent local tumour control with IRS-comparable acute toxicity rates despite the use of 
reduced margins [407]. A newer study from Combs et al evaluated the outcome and toxicity profile 
of IMRT and fractionated stereotactic radiotherapy (FSRT) in children with head-and-neck-
rhabdomyosarcoma. They reported excellent outcomes with low incidence of treatment-related 
side effects. A difference in outcome between aRMS and eRMS was not observed [408].  
Since proton beam therapy has become more accessible, it has gained importance in the treatment 
of aRMS. Dosimetric studies show an enhanced conformity through proton administration and 
increased sparing of the healthy surrounding tissues [409]. First results from proton therapy in 
patients with orbital RMS, showed a superior dose conformation to the tumour and a reduced 
radiation exposure of the adjacent normal structures [410], with the 5-years overall survival rate 
comparable to that of photon therapy [18].  
Although there is ongoing research on new radiosensitizing agents for the treatment of aRMS, up 
to now no compound is permanently established in the international treatment protocols. 
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Even though survival rates and outcome of children with cancer has significantly improved over 
the last 50 years, the current treatment strategies are still accompanied with high toxicity and often 
low specificity. Further, treatment failure due to resistance development is still a major problem. 
Hence to improve treatment strategies, agents with less toxicity and more targeted focus have to 
be found. Many paediatric malignancies harbour genetic aberrations, giving rise to oncogenic 
transcription factors. ARMS also belong to these group of malignancies with the oncogenic fusion 
protein PAX3-FOXO1. Being able to directly target these would be highly desirable, but as 
transcription factors are considered undruggable due to their lack of an enzymatic binding pocket, 
other strategies have to be exploited. Therefore, a small-compound library screen was previously 
performed in our laboratory, to find drugs which target the fusion protein without being generally 
toxic. Here, fenretinide was identified as top hit.  
Hence my first aim was to characterize the mode of action of fenretinide in aRMS cells, with a 
specific focus on its possible interaction with the fusion gene/protein. The second aim was to 
identify and characterize the induced cell death, since we observed that fenretinide triggered a new 
and not yet described form of cell death. Finally, we aimed to identify other treatment modalities 
that work in concert with fenretinide and characterize their combinatorial effect. This work will 
help to potentially place fenretinide into one of the international treatment trials to augment 
outcome and decrease treatment-related side-effects in patients with aRMS.  
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Abstract 
Alveolar rhabdomyosarcoma (aRMS) is a highly malicious childhood malignancy characterized 
by a specific chromosomal translocation encoding the oncogenic transcription factor PAX3-
FOXO1 and therefore also referred to as fusion-positive RMS (FP-RMS). Previously, we have 
identified the compound fenretinide (retinoic acid p-hydroxyanilide) from a large drug library 
screen, to affect both PAX3-FOXO1 expression levels as well as FP-RMS cell viability. Here, we 
characterized the mode of action of fenretinide in more detail. First, we demonstrate that 
fenretinide induced the generation of reactive oxygen species (ROS) depending on complex II of 
the mitochondrial respiratory chain. ROS scavenging as well as complexing of iron ions 
completely abolished cell death.  
To identify the mechanisms of cell death, we co-treated cells with fenretinide and a range of 
pharmacological inhibitors of specific cell death pathways including Z-VAD (apoptosis), 
Necrostatin-1 (necroptosis), 3-Methyadenine (3-MA) (autophagy) and Ferrostatin-1 (ferroptosis). 
Surprisingly, none of these inhibitors was able to prevent cell death. Genetic depletion of key 
players in the apoptotic and necroptotic pathway (Bak, Bax and RIPK1) with CRISPR/Cas9 
confirmed the pharmacological data. Interestingly, electron microscopic examination of 
fenretinide treated cells revealed an excessive accumulation of cytoplasmic vacuoles which were 
distinct from autophagosomes. Further flow cytometry and fluorescence microscopy experiments 
suggested a hyperstimulation of macropinocytosis, leading to an accumulation of enlarged early 
and late endosomes. Surprisingly, pharmacological inhibition as well as genetic depletion of the 
large GTPase dynamin completely abolished fenretinide induced vacuolization and subsequent 
cell death, suggesting a new form of dynamin-dependent programmed cell death.  
Taken together, our data identify a new form of cell death mediated through the production of ROS 
by fenretinide treatment. Hence, this data further underscore the value of fenretinide for treatment 
of sarcoma patients including FP-RMS. 
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Introduction 
Rhabdomyosarcoma (RMS) is the most common soft tissue malignancy of children and young 
adolescents accounting for 5-10% of all cancers in this age group [1]. RMS are highly malignant 
tumors of mesenchymal cell origin and can be subdivided into two major subtypes, of which the 
alveolar rhabdomyosarcoma (aRMS) is the most unfavorable one [2]. The majority of aRMS are 
characterized by a tumor-specific chromosomal translocation, giving rise to the chimeric 
transcription factor PAX3/7-FOXO1 and are therefore referred to as fusion-positive RMS (FP-
RMS) [3]. The overall survival rate of patients suffering from this malignancy is poor with less 
than 30%, and the recurrence rate is high with more than 48%. Further, the remaining 5-year post-
relapse survival rate is only about 21% [2, 4]. Resistance of FP-RMS to conventional treatments 
including chemotherapy and radiation therapy, which mainly lead to induction of apoptosis, is a 
main cause of failure [5-8]. Hence, one of the major resistance mechanisms is the intrinsic or 
acquired ability to prevent apoptosis [9].  
Importantly, during the last decade a range of non-apoptotic cell death pathways have been 
described [10], opening the exciting possibility to eliminate cancer cells via alternative routes. 
Besides apoptosis, regulated necrosis comprising among others necroptosis and ferroptosis are the 
best studied and understood alternative forms of cell death [11]. A number of agents have been 
discovered that are capable to reactivate such alternative death pathways in several different cell 
types [12-17] and therefore have an anti-neoplastic action.  
Several types of cell death are associated with accumulation of cytoplasmic vesicles including 
methuosis, paraptosis or oncosis [18-25]. Methuosis is a rather new form of cell death and is 
characterized by an accumulation of phase lucent vesicles generated by increased 
macropinocytosis. This type of cell death is widely investigated in several types of cancers and 
can be induced through multiple compounds such as vacuolin-1 [18-21]. However, a cell death 
mode characterized by accumulation of vacuoles has not yet been reported for FP-RMS. 
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To explore alternative forms of cell death in FP-RMS, we previously screened a library of 1280 
mostly FDA approved compounds using PAX3-FOXO1 activity as read-out [26]. From this 
screen, we identified fenretinide (retinoic acid p-hydroxyanilide) as the most effective small-
molecule compound. Importantly, fenretinide treatment also induced a strong reduction of FP-
RMS tumor growth in mouse xenograft experiments.  
Here we describe the detailed mechanism of cell death provoked by fenretinide treatment in FP-
RMS cells. Fenretinide activated a novel form of non-apoptotic cell death which was associated 
with extensive accumulation of cytoplasmic vesicles [18, 27]. Strikingly, this novel cell death 
mechanism is pharmacologically and genetically dependent on the function of the GTPase 
dynamin which controls endocytosis. These findings, together with a long experience of 
fenretinide treatment in clinics for the treatment of multiple malignancies, rejuvenate the 
application of this drug in FP-RMS. 
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Results  
We previously demonstrated that fenretinide-induced cell death is associated with a reduction in 
PAX3-FOXO1 levels in FP-RMS cells [26]. Since expression of PAX3-FOXO1 is essential for 
survival [28], we first explored whether the effect of fenretinide is dependent of fusion protein 
depletion. For this, we used a doxycycline inducible lentiviral shRNA vector system directed 
against endogenous PAX3-FOXO1 together with a CMV-promoter driven vector for expression 
of an shRNA-insensitive variant of PAX3-FOXO1 (P3F mut) in Rh4 cells (Supplementary Figure 
1A). Upon induction of shRNA, endogenous P3F protein levels were reduced to about 20 percent, 
while levels of ectopic PAX3-FOXO1 matched the ones of the endogenous protein 
(Supplementary Figure 1B). As expected, treatment of these cells with fenretinide did not induce 
a decrease in exogenous PAX3-FOXO1 protein levels, demonstrating that they are not regulated 
at the post-translational level. Furthermore, ectopic expression of PAX3-FOXO1 reduced the 
levels of cleaved PARP, suggesting that it indeed can rescue cells from apoptosis. Unexpectedly 
and most importantly however, ectopic PAX3-FOXO1 did not protect from fenretinide induced 
cell death as measured by WST assay and by Western blot (Figure 1A). Taken together, these 
results suggest that induction of apoptosis after fenretinide treatment is linked to a reduction in 
PAX3-FOXO1 levels, while under conditions of sustained PAX3-FOXO1 expression fenretinide 
might induce an alternative mode of cell death.  
 
To further explore this hypothesis, we next studied different well characterized cell death pathways 
to evaluate their relevance for fenretinide mediated cytotoxicity using a pharmacological approach. 
We treated two FP-RMS cell lines (Rh4 and Rh30) with fenretinide in combination with the 
apoptosis inhibitor Z-VAD, the necroptosis inhibitor Necrostatin (NS1), the autophagy inhibitor 
3-Methyadenine (3-MA), the ferroptosis inhibitor Ferrostatin-1 (FS) and the iron chelator 
Deferoxamin (DFO) [29, 30] and assessed cell viability after 48h. Surprisingly, none of the 
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specific cell-death inhibitors was able to rescue from cell death (Figure 1B), suggesting that neither 
induction of apoptosis, necroptosis, ferroptosis or autophagy play a major role in fenretinide 
induced cell death. Interestingly however, the iron chelator DFO almost completely rescued cell 
viability. While both FS and DFO act as reactive oxygen species (ROS) scavengers, FS is lipid-
soluble and claimed to protect from membrane lipid-peroxidation during ferroptosis, while DFO 
has a broader ROS-protecting activity, suggesting that more broadly produced ROS species might 
play an important role.  
Since pharmacological inhibition is prone to certain off-target effects, we aimed next to confirm 
these results using a genetic approach. We used the CRISPR/Cas9 system in both cell lines to 
knockout essential apoptotic/necroptotic pathway genes to create death pathway ablated tumour 
cells. To block apoptosis, we combined sgRNAs directed against BAK and BAX, two key players 
in the intrinsic apoptotic pathway, and to inhibit necroptosis we used sgRNAs directed against 
RIPK1, the central kinase in the necroptotic pathway. We achieved nearly complete knockouts for 
BAK and BAX and a significant reduction of RIPK1 as determined by Western Blot 
(Supplementary Figure 1C). In parallel, we also combined the different sgRNAs and depleted all 
three genes in one single cell population. All knockout cells were then treated with fenretinide. In 
Rh4 cells, combined knockout of BAX and BAK resulted in a nearly complete inhibition of 
Caspase-7 and PARP-1 cleavage, while in Rh30 cells both PARP-1 and Caspase-9 cleavage were 
less affected by the genetic manipulations, suggesting that other apoptotic pathways are (also) 
involved. Similar results were seen for the triple-knockouts of BAK/BAX/RIPK1 (Figure 1C). 
Interestingly, we found that Rh4 cells do not express Caspase-8, while Rh30 cells do 
(Supplementary Figure 1D) which might explain the difference in apoptotic downstream effects 
between the two cell lines. Next, we determined dose-response curves with all knockout cells after 
treatment with fenretinide. In agreement with the pharmacological approach, we observed only a 
very small, non-significant rescue from cell death in deleted versus wild-type cells, which was 
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slightly more pronounced in the triple knockout cells (Figure 1D) and in Rh30 cells compared to 
Rh4 cells. Nevertheless, these results suggest that while fenretinide engages some apoptotic 
features including caspase activation, cells execute mainly an alternative death pathway if 
apoptosis is blocked.  
 
Based on the ability of the ROS inhibitor DFO to rescue FP-RMS cells from fenretinide-induced 
cell death, we wondered whether and what kind of ROS might be induced and whether these would 
be responsible for induction of cell death. 
First, we confirmed ROS accumulation after 20hrs of fenretinide treatment with the fluorogenic 
pan-ROS probe CellRox by observing a strong perinuclear accumulation in the treated compared 
to control cells (Figure 2A). To evaluate the kinetics of ROS accumulation, we captured time lapse 
fluorescence microscopy images of fenretinide treated and untreated Rh4 cells stained with 
CellRox (Supplementary Figure 2A). This revealed that cells stained positive for ROS already 
20hrs after fenretinide treatment, and started to detach and undergo cell death 6hrs later, 
demonstrating that ROS production precedes initiation of cell death. Similar time lapse 
experiments with BAK/BAX/Rip1 knock out cells and propidium iodide (PI) as marker for cell 
death showed that knock-outs delay onset of cell death for about 10 hours (Supplementary Figure 
2A), validating that fenretinide is able to initiate apoptosis, but cells undergo a different mode of 
cell death if apoptosis is blocked. 
To quantify induced ROS, we measured CellRox fluorescence after 18hrs of fenretinide treatment 
by flow cytometry (Figure 2B). This analysis showed that ROS levels increased by about 2.5-fold. 
Staining of cells with a mitochondria specific ROS probe (MitoSox) revealed a similar increase of 
about three-fold (Figure 2B), suggesting that at least a part of fenretinide-induced ROS species 
originate from mitochondria.  
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To determine the relevance of ROS for induction of cell death, we used different ROS inhibitors 
including the antioxidant Vitamin C, DFO, FS and the mitochondria-specific ROS scavenger 
MitoTempo. The extent of reduction in ROS levels differed between the different inhibitors, with 
DFO and MitoTempo reducing ROS levels below 50 percent, while Vitamin C and FS were 
considerably less effective (Figure 2C and D and Supplementary Figure 2B). In agreement with 
these scavenging potencies, similar to DFO (Figure 1B) also MitoTempo was able to completely 
inhibit fenretinide induced cell death (Figure 2D), while Vitamin C and FS had only minor effects. 
Taken together, these findings suggest that fenretinide induces mitochondrial ROS generation 
which are involved in the induction of cell death.  
 
One of the major sources of ROS production is the mitochondrial respiratory chain (MRC). As the 
MRC is the major source of ATP production in the cell, any interference is fatal for the tumour 
cell and reduces the mitochondrial membrane potential (Δψm). Hence, we next evaluated whether 
the mitochondrial ROS induced by fenretinide are produced by one of the MRC complexes. We 
co-treated Rh4 cells with fenretinide and different inhibitors targeting the five complexes of the 
MRC and measured the amount of produced ROS. Inhibitors against complex I (Rotenone), III 
(Antimycin), IV (Sodium Azid) and V (CCCP) did not cause a decrease in ROS levels 
(Supplementary Figure 3A). Instead, inhibitors of complex II, namely TTFA and Carboxin 
significantly reduced ROS production in both Rh4 and Rh30 cells (Figure 3A and B). These 
findings indicate that the main target of fenretinide for ROS production lies downstream of 
complex II of the MRC.  
 
To further characterize fenretinide induced cell death, we next investigated morphological changes 
at the ultrastructural level using electron microscopy (EM). For this, we treated Rh4 and Rh30 
cells with fenretinide in combination with Z-VAD for 48hrs (Figure 4A). Interestingly, this 
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analysis revealed that fenretinide induced an enormous vacuolization within the cytoplasm which 
was even further enhanced in combination with Z-VAD. The vacuoles had different sizes, were 
phase lucent and contained only one single membrane, suggesting that they do not represent 
autophagosomes. In contrast, features of apoptosis were only rarely detected, most pronounced 
with a combination of fenretinide and Necrostatin (data not shown), whereas we could readily 
identify chromatin condensation and membrane blebbing after treatment with the PLK1 inhibitor 
Volasertib, which is known to induce apoptosis in RMS cells [31] (Supplementary Figure 4A). 
These findings further strengthen our hypothesis that fenretinide is able to trigger multiple types 
of cell death.  
The observed features of the phase lucent vesicles were consistent with macropinosomes and 
reminiscent of cell death forms which are associated with accumulation of endosomes [18, 27]. 
We therefore wondered whether fenretinide induced cell death involves disturbance of 
macropinocytosis or endocytosis. To study macropinocytosis, we followed the uptake of fluid 
phase dyes like Acridine Orange and Lucifer Yellow [21] by flow cytometric analysis. Fenretinide 
indeed induced the uptake of Acridine Orange and Lucifer Yellow (>4fold increase, Figure 4B 
and Supplementary Figure 4B and 4C). Co-treatment with the ROS scavengers Vitamin C and 
MitoTempo almost completely abolished this uptake, indicating that the fenretinide induced 
increase in dye uptake is downstream of ROS induction and mediated through macropinocytosis. 
Addition of Z-VAD to fenretinide treated cells did not further enhance this effect. Validation of 
these results by fluorescent microscopy after 48hrs of fenretinide treatment confirmed the strong 
increase in Lucifer Yellow uptake (Figure 4C). Hence, these findings are in accordance with the 
EM images and suggest that the observed vesicles derive from an increased accumulation of 
endosomes, similar to the ones described for other cytoplasmic vacuolization associated cell death 
forms [18, 27, 32].  
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To further characterize the endosomal origin of the vesicles, we stained fenretinide treated cells 
with antibodies directed against the early endosomal marker Rab5, the late endosomal marker 
Rab7, and the lysosomal marker LAMP-1. Compared to untreated control, an accumulation of 
early and late endosomes but not of lysosomes was observed (Figure 5A and 5B). Interestingly, 
even though the vesicles are acidic enough to allow Acridine Orange emission to change from 
green to red (Figure 4B, 5C Supplementary Figure 4B, 5C), they are unable to further mature and 
fuse with lysosomes, indicating that later maturation steps are blocked.  
Based on this, we next aimed to further substantiate the relevance of disturbed endocytosis for 
fenretinide induced cell death. We blocked the different endocytosis processes by chemical 
compounds and measured cell viability. Neither inhibition of macropinocytosis by EIPA, clathrin-
independent endocytosis by Filipin and Genistein nor clathrin-mediated endocytosis by 
Chlorpromazin influenced cell viability upon fenretinide treatment (Supplementary Figure 5A). 
Interestingly however, the Dynamin inhibitors dynasore and dyngo-4a nearly completely rescued 
from cell death (Figure 5C and 5D and Supplementary Figure 5B), both at the physiological 
(Figure 5C) and the morphological level (Figure 5D). Moreover, we also observed a significant 
inhibition of Acridine Orange uptake by co-treatment with dynasore (Figure 5E and 
Supplementary Figure 5 C).  
To exclude, that dynasore acts via ROS scavenging, we co-treated Rh4 and Rh30 cells for 48hrs 
and measured mitochondrial ROS by flow cytometry. In Rh4 cells ROS levels were unaffected by 
dynasore, while we measured an almost 50 percent reduction in ROS levels in Rh30 cells 
(Supplementary Figure 5D), suggesting that dynasore does not generally act as ROS scavenger 
and the reduction of ROS levels in Rh30 cells might occur indirectly.  
To evaluate whether dynasore specifically rescued fenretinide mediated cell death, we screened a 
small molecule library with 204 mostly FDA-approved drugs in Rh4 cells alone and in 
combination with dynasore or Vitamin C and assessed cell viability (Supplementary Figure 5E). 
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Within the top cytotoxic drugs (reducing viability to 10-50%), we identified 12 drugs that exerted 
a ROS dependent cytotoxic effect (cell viability change >25%), including MLN2238, MLN9708, 
Rigosertib, Verdinexor, BI-847325, Ponatinib, MK-1775, VX-680, Doxorubicin, Ispinesib, 
Elesclomol and OTX015. In none of these cases however, dynasore could significantly enhance 
survival, indicating that dynasore acts specifically on fenretinide induced cell death and not simply 
as ROS scavenger.  
 
In order to validate the involvement of the GTPase Dynamin in fenretinide induced accumulation 
of endosomes, we used the CRISPR/Cas 9 system to knock-out Dynamin-1 and -2 in both Rh4 
and Rh30 cells. As determined by Western Blot analysis, the knock out in Rh4 cells was nearly 
complete for both Dynamins, while knock-out efficiency was reduced in Rh30 cells 
(Supplementary Figure 6A). Examining the uptake of Acridine Orange after fenretinide treatment 
into the Dynamin knock-out cells revealed a significant lower uptake compared to scrambled 
control cells (Figure 6A and F and Supplementary Figure 6B and C), demonstrating significant 
reduction of endocytic processes in knockout cells. Importantly, upon treatment of these knockout 
cells with different concentrations of fenretinide we also detected a significant rescue from cell 
death using a cell viability assay (Figure 6B, Supplementary Figure 6D). Rescue was further 
confirmed by phase contrast images (Figure 6C). Taken together these findings indicate that the 
vesicle accumulation during fenretinide treatment is directly dependent on the Dynamin GTPases. 
Furthermore, these results suggest that the accumulation of the endosomes is causally and directly 
linked to cell death. 
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Discussion 
One of the biggest therapeutic challenges in FP-RMS treatment is intrinsic or acquired resistance 
towards conventional therapies, which is the main cause for the high recurrence rates of this type 
of tumor. Since survival rates of patients with relapsed FP-RMS are still very poor [4], there is an 
urgent need to identify new agents that are effective against such resistant cells. Drugs that re-
sensitize cells towards chemotherapy induced apoptosis as well as compounds that activate 
alternative, non-apoptotic cell death pathways represent potential opportunities in this context [33, 
34]. 
Here, we characterized the cytotoxic effect of fenretinide on FP-RMS cells. Originally, fenretinide 
was detected as hit in a large compound library screen designed to identify drugs affecting PAX3-
FOXO1 activity [26]. While fenretinide indeed affects PAX3-FOXO1 transcript levels, the more 
detailed characterization of the mechanism of action performed in this study suggests that its 
cytotoxic effects in FP-RMS cells do not depend on reduction of PAX3-FOXO1 levels and 
therefore this effect might be a more downstream event following induction of cell death. 
Interestingly, fenretinide induced cell death was found to include a mechanism other than 
apoptosis, necroptosis, autophagy and ferroptosis, as neither commonly used inhibitors directed 
against these pathways nor their genetic ablation of key molecules had a positive influence on 
survival of cells after fenretinide treatment. In contrast, inhibition of ROS completely protected 
FP-RMS cells from fenretinide mediated toxicity, as already described in other cellular systems 
[35-38]. While it is not clear at this point how fenretinide treatment leads to ROS induction, our 
study clearly demonstrates that ROS originating from the mitochondria plays an important and 
early role in fenretinide mediated cell death in FP-RMS cells. Downstream of ROS, fenretinide 
induces the formation and accumulation of cytoplasmic vesicles. These vesicles are surrounded by 
a single membrane and therefore do not originate from the autophagy pathway which gives rise to 
double membrane autophagosomes. Instead, the vesicles morphologically resembled endosomes, 
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an interpretation which was further substantiated by fluid phase dye uptake studies showing strong 
enhancement of these processes by fenretinide. Furthermore, pharmacologic as well as genetic 
interference with Dynamins blocked vesicle accumulation and rescued from fenretinide induced 
cell death. The Dynamin family of GTPases are major mediators of endosome fission at the plasma 
membrane. They are involved in both clathrin-dependent and -independent endocytosis, but some 
evidence suggests that they also play a role in a specific macropinocytosis pathway involving 
circular dorsal ruffles (CDR) [39, 40] We found that inhibitors of clathrin and caveolin-mediated 
endocytosis like Chlorpromazin, Filipin und Genistein failed to block fenretinide mediated cell 
death. Furthermore, ultrastructural analysis by EM showed that fenretinide induced vesicles have 
a variable size with a dimeter of up to 7 μm, which is comparable to the described diameter of 
macropinosomes of 0.2 to 5 μm [19]. Taken together, these data indicate that these vesicles most 
likely derive through an increased or impaired macropinocytosis.  
Interestingly, blocking of Caspase activity by Z-VAD further enhanced the number of vesicles in 
presence of fenretinide. Hence, a part of the cells might succumb by an apoptotic mechanism but 
shift the mode of cell death cell when this route is blocked. This is in accordance with a delay in 
the onset of cell death in presence of Z-VAD by about 10 hours as seen in our time lapse 
experiments. When compared to other cell death mechanisms, apoptosis has been shown to be a 
relatively fast process [41, 42]. Accordingly, non-apoptotic regulated modes of cell death such as 
necroptosis have only been detected after specific inhibitors of apoptosis became available [43, 
44].  
For induction of this vesicle associated type of cell death in FP-RMS cells a special type of ROS 
stress seems to be relevant, since induction of ROS-dependent cell death with other drugs 
including the proteasome inhibitors MLN2238 and MLN9708, the microtubule-destabilizing agent 
Rigosertib or the tyrosine-kinase inhibitor Bosutinib were not blocked by Dynamin inhibitors. The 
mechanisms behind this difference needs further clarification in the future.  
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The role of reactive oxygen species as important regulators of tyrosine kinase receptor signalling 
cascades [45-48], might be another possible explanation to the formation of CDRs after fenretinide 
treatment.  
Importantly, similar cellular phenotypes have been described in the context of different relatively 
vaguely described cell death mechanisms called paraptosis, oncosis and methuosis [25, 27, 32]. In 
case of methuosis vesicle accumulation has been associated with disturbance of endosomal 
maturation and/or recycling. Several different stimuli have been described that induce this 
phenotype. These include different small molecules with less understood links to macropinocytosis 
as well as activation of Ras, which stimulates marcopinosmome formation via over-activation of 
Rac1 and concomitant decline in Arf6 and at the same time impedes their recycling (for review 
see Maltese et al [18]). Ultimately, this manifests as vesicle accumulation as seen in different cells 
like glioblastoma, Ewing sarcoma and epithelial cells [21, 27, 49]. Whether Ras mutant tumors 
compensate this effect and are less prone for methuosis is currently unclear. FP-RMS tumors 
anyway are not associated with Ras mutations. Similar to methuosis, we observed an impaired 
recycling of endosomes with a maturation stop at the level of early/late endosome formation, as 
the vesicles acquire markers such as Rab5 and Rab7 but not the lysosomal marker LAMP-1. 
However, since pharmacological inhibition and knock-out of Rac1 as well as Arf6 in FP-RMS 
cells neither affected fenretinide mediated cell death nor dye uptake (data not shown), this pathway 
does not seem to play a role in these cells. Hence, while the exact mechanism leading to the 
maturation stop of the endosomes in FP-RMS cells needs further characterization, it seems that 
different upstream pathways might be able to induce the same vacuolization phenotype associated 
with cell death. Importantly however, while in all the described cases vesicle accumulation and 
cell death correlate, a causal link of the two effects has not been established yet. 
Overall our results provide evidence that fenretinide induced mitochondrial ROS interferes with 
regulation of Dynamin-dependent macropinocytosis leading to vesicle accumulation in the 
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cytoplasm of the cells. This is associated with strong cytotoxic effect in FP-RMS cells. The fact 
that fenretinide engages a novel form of cell death which is not exploited by conventional 
chemotherapy agents defines it as a promising combinatorial partner for the treatment of FP-RMS 
patients. Agents for a potential combination treatment might be drugs that induce canonical 
apoptosis or necroptosis or even other forms of cell death like autophagy or ferroptosis. Since 
fenretinide is already in clinical use in children (Clinicaltrials.gov ID NCT02163356) and has only 
moderate side-effects both in short and long term treatment regimens [50, 51] our findings might 
stimulate expansion of the clinical application of fenretinide to FP-RMS therapy in the future. 
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Material and Methods 
Cell culture 
The alveolar rhabdomyosarcoma cell lines RH4 and Rh30 (provided by Peter Houghton, Greehey 
Children’s Cancer Research Institute, San Antonio, Texas, USA) and the HEK293T (ATCC, LGC 
Promochem, Wesel, Germany) were maintained in Dulbecco's Modified Eagle Medium (DMEM, 
Sigma-Aldrich-Aldrich, Buchs, Switzerland), with 100 U/mL penicillin/streptomycin (Invitrogen, 
ThermoFisher, Waltham, Massachusetts, USA), 2 mM L-glutamine ((BioConcept, Allschwil, 
Switzerland) or Glutamax (Gibco, ThermoFisher, Waltham, Massachusetts, USA) and 10% fetal 
bovine serum (FBS) (Sigma-Aldrich-Aldrich, Buchs, Switzerland), in 5% CO2 at 37°C. ARMS 
cell lines were regularly tested for Mycoplasma infection, authenticated by short tandem repeat 
analysis (STR profiling) in 2011/2014 and positively matched with reference data [52]. 
 
Cell proliferation assay 
Cells were seeded at a concentration of 150’000 cells/ml (Rh4) or 100’000 cells/ml (Rh30) in 384 
well polystyrol microplates (Greiner Bio One, Kremsmünster, Austria) format in 20µL medium.  
For determination of dose response curves with single compounds (see Table 1 in Supplementary 
Material and Methods), drugs were added to the cells using a HP D300 digital dispenser (Hewlett-
Packard Development Company, L.P., Houston, Texas, USA).  
To assess metabolic activity 10µL colorimetric water-soluble tetrazolium (WST-1) (Sigma-
Aldrich-Aldrich, Buchs, Switzerland), diluted 1:1 with DMEM, was added. After 30 minutes of 
incubation at 37°C in the dark, absorbance at 440 and 640 nm were measured with a Synergy™ 
HT multi-detection microplate reader (BioTek, Winooski, Vermont, USA). The difference of the 
two values was calculated (delta optical density; ΔOD) and values from pure medium were 
subtracted as background.  
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Small molecule library screen 
Cells were seeded at a concentration of 150’000 cells/ml (Rh4) or 100’000 cells/ml (Rh30) in 384 
well polystyrol microplates (Greiner Bio One, Kremsmünster, Austria) format in 20µL medium.  
Drugs were diluted to a final concentration of 500nM and manually added in duplicates to the cells 
(see Table 5 in the Appendix), 12 DMSO controls were included. After 48 hours treatment, effects 
of drugs were determined by cell viability assay.  
 
Flow Cytometry 
For all Flow Cytometry experiments, 150000 cells/ml (Rh4) or 100000 cells/ml (Rh30) were 
seeded in Corning Costar 6-well plates (Sigma-Aldrich-Aldrich, Buchs, Switzerland). After 
treatments, cells were detached from the plates using Trypsin, washed once with PBS and re-
suspended in 0.5 ml indicated buffer. Data was acquired with the LSRII Fortessa (BD Biosciences, 
San Jose, California, USA) flow cytometer or the BD FACS Canto system (BD Biosciences, San 
Jose, California, USA).  
The data was analysed with FlowJo Software, Version 9.9.6 (Tree Star Inc., Ashland, Orlando, 
USA). The used fluorescent stains can be found in Table 2 in Supplementary Material and 
Methods.  
 
Pan ROS measurement 
Cells were seeded and treated with compounds according to table 1 in Supplementary Material 
and Methods for 20-48 hours. At the same time, CellROX Deep red (ThermoFisher, Waltham, 
Massachusetts, USA) solution (4µM) was added to the media. Cells were collected, washed in 
PBS (Sigma-Aldrich-Aldrich, Buchs, Switzerland) and resuspended in FluoroBrite DMEM live 
cell fluorescence imaging medium (ThermoFisher, Waltham, Massachusetts, USA). CellRox 
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(ThermoFisher, Waltham, Massachusetts, USA) signal (50’000 events per sample) was acquired 
with Excitation laser 640 nm and Emission filter 670/14.  
 
Mitochondrial ROS measurement 
Cells were seeded and treated with the desired compounds according to table 1 in Supplementary 
Material and Methods for 20-48 hours. Cells were collected, washed in PBS and resuspended in 
MitoSox (ThermoFisher, Waltham, Massachusetts, USA) Solution (10µM MitoSox in PBS) for 
30min at 37°C in the dark. MitoSox signal (50’000 events per sample) was acquired with 
Excitation laser 561 nm, and Emission filter 570 LP, 525/50. 
 
Acridine Orange (AO) and Lucifer Yellow (LY) Uptake 
Cells were seeded and treated with compounds according to Table 1 in Supplementary Material 
and Methods for 48 hours. Acridine Orange (2.7 μM, Sigma-Aldrich-Aldrich, Buchs, Switzerland) 
and Lucifer Yellow (820 μM, ThermoFisher, Waltham, Massachusetts, USA) in FluoroBrite 
DMEM live cell fluorescence imaging medium (ThermoFisher, Waltham, Massachusetts, USA) 
was added to the cells 4 h prior to their preparation for flow cytometry after removal of the culture 
medium. Cells were collected, washed in PBS and resuspended in PBS. Signals (50’000 events 
per sample) were acquired with Excitation laser 488 nm and 561, Emission filter 505 LP, 530/30 
and 635LP, 670/30 for AO and with Excitation laser 405nm, Emission laser 505LP, 525/50 for 
LY.  
 
Epifluorescence microscopy 
All images were taken with the Zeiss Axio Observer (Zeiss, Oberkochen, Germany) equipped with 
the Hamamatsu Orca Flash 4.0 V2, sCMOS, (Hamamatsu, Hamamatsu City, Japan) cooled 
fluorescence camera and an objective with 20x magnification. The violet and green fluorescent 
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filters were used for the imaging of DAPI, Lucifer Yellow, Rab5/7 and Lamp1 stained structures, 
respectively. Fluorescent stains are listed in Table 2 in Supplementary Material and Methods. 
For Data Processing, the images were exported as TIFF files and the mean integrated density was 
quantified with the image processing program Fiji [53]. The integrated density value of an image 
was divided by the number of cells (counted on the phase image). A minimum of four pictures 
were taken for each treatment.  
 
Rab 5, Rab7 and Lamp-1 immunofluorescence staining 
50000 cells/ml were seeded in 4 well-Falcon™ chambered cell culture slides (Thermo Scientific, 
ThermoFisher, Waltham, Massachusetts, USA) and treated with 3µM fenretinide for 48 h. After 
washing, cells were fixed with 4 % paraformaldehyde (PFA) (CarlRoth, Karlsruhe, Germany) 
washed and quenched with 0.1 M Glycin (Sigma-Aldrich-Aldrich, Buchs, Switzerland) in PBS. 
After fixing, cells were permeabilized with 0.1% Triton X-100 (Sigma-Aldrich-Aldrich, Buchs, 
Switzerland) in PBS and then blocked with 4% horse serum (Sigma-Aldrich-Aldrich, Buchs, 
Switzerland) in 0.1% Triton X-100/PBS before they were incubated with the respective primary 
antibody in 0.1% Triton X-100 in PBS and 4% horse serum at 4°C overnight in a humid chamber. 
Primary Antibodies used for immunofluorescence localization of rabbit anti-Rab 5 (Cat #2143) 
and rabbit anti-Rab 7(Cat #9367) were obtained from Cell Signaling Technology (Danvers, 
Massachusetts, USA) and mouse anti-LAMP1 was obtained from the Developmental Studies 
Hybridoma Bank (University of Iowa, Ames, Iowa, USA) respectively. After three washing steps, 
cells were incubated with donkey anti-rabbit IgG-Alexa 488 (Rab 5/7) or chicken anti-mouse IgG-
Alexa 488 (Lamp1) 2° Antibody (1:200) (both from ThermoFisher, Waltham, Massachusetts, 
USA) in PBS with 4% horse serum for 1 hour at RT. After washing, the chamber walls were 
removed and Vectashield mounting medium with 4′, 6-Diamidin-2-phenylindol (Vector 
Laboratories, Burlingame, California, USA) was added. 
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Live cell time-lapse microscopy  
80000cells were seeded in 400µl of a 8-well 15u- Ibidi chambered cell culture slide (Ibidi GmbH, 
Planegg, Germany) and treated with or without 3µM fenretinide and different stains in FluoroBrite 
DMEM with 10% FBS and 1% Pen/Strep and Glutamin. CellRox (4µM) was used for panROS 
detection, propidium iodide (1µg/ml) (Sigma-Aldrich-Aldrich, Buchs, Switzerland) was used for 
detection of dead cells. For time lapse image acquisition, the slides were kept in a thermally 
stabilized and CO2 controlled chamber incubator (5% CO2 at 37 °C) (Ibidi GmbH, Planegg, 
Germany) and images were automatically taken every 20 min over a 60 hours period.  
 
LY fluorescence microscopy 
50000 cells were seeded per well of a 4-well Falcon™ chamber slide and treated with 3/4µM (for 
Rh4/Rh30) fenretinide for 48h and subsequently stained with Lucifer Yellow (820µM) in 
FluoroBrite DMEM for 4 h at 37°C, 5% CO2. Afterwards, cells were washed with PBS and fixed 
with 4 % PFA for 15 min at room temperature. After three PBS washes, the chamber was removed 
and the cells were mounted in Vectashield mounting medium with 4′, 6-Diamidin-2-phenylindol. 
 
Electron microscopy 
300000 (Rh4) or 200000 cells (Rh30) cells were seeded per well of a Corning Costar 6-well plate 
(Sigma-Aldrich-Aldrich, Buchs, Switzerland) and treated with 3 or 5µM fenretinide in 
combination with either 100µM Z-VAD-FMK, 30µM dynasore, 25µM Necrostatin or 0.0065µM 
Volasertib for 48h at 37°C, 5% CO2. Treated and untreated control cells were then fixed with 2.5 
% glutaraldehyde (EMS Electron Microscopy Sciences, Hatfield, Pennsylvania, USA) in 0.1 M 
cacodylate buffer (pH 7.35) (Merck AG, Zug, Switzerland) for at least on hour. Adherent cells 
were scraped off the culture dish using a cell scraper, combined with floating cells, pelleted by 
centrifugation and sequentially treated with 1% OsO4 in 0.1 M cacodylate buffer for 1 hour at 0°C 
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and 2% uranyl acetate (Merck AG, Zug, Switzerland) in H2O overnight at 4°C. The final pellet 
was immobilized with 2% of Difco Noble Agar (BD Biosciences, Allschwil, Switzerland) in H2O, 
subsequently dehydrated in an ethanol absolute series (VWR International GmbH, Dietikon, 
Switzerland) and embedded in Epon/Araldite (Sigma-Aldrich-Aldrich, Buchs, Switzerland). 
Ultrathin (50 nm) sections were contrasted with uranyl acetate and examined with a CM100 
transmission electron microscope (Thermo Fisher Scientific, Eindhoven, The Netherlands) at an 
acceleration voltage of 80 kV using an Orius 1000 digital camera (Gatan, Munich, Germany), or 
a Talos 120 transmission electron microscope at an acceleration voltage of 120 KV using a Ceta 
digital camera and the MAPS software package (Thermo Fisher Scientific, Eindhoven, The 
Netherlands). 
 
Immunoblotting 
Whole cell extracts were prepared from cells lysed with RIPA buffer (50 mM Tris-Cl (pH 7.5), 
150 mM NaCl, 1% NP-40, 0.5% Na-deoxycholate, 1 mM EGTA, 0.1% SDS, 50 mM NaF, 10 mM 
sodium β-glycerolphosphate, 5 mM sodium pyrophosphate, 1 mM sodium orthovanadate and 
supplemented with Complete Mini Protease Inhibitor cocktail (all from Sigma Aldrich, Buchs, 
Switzerland). Proteins were separated using NuPAGE™ Novex™ 4-12% Bis-Tris gels 
(ThermoFisher, Waltham, Massachusetts, USA) and transferred to nitrocellulose membranes (GE 
Healthcare Life Sciences). Membranes were blocked with 5% milk powder in TBS/0.05% Tween 
and subsequently incubated with respective primary antibodies overnight at 4°C. After three time 
washing in TBS-0.05% tween, membranes were incubated with horseradish peroxidase (HRP)-
linked secondary antibody for 1h at RT. After three additional washing steps with TBS/0.05% 
Tween, proteins were detected by chemiluminescence using either the Pierce™ ECL Western 
Blotting Substrate or Supersignal Western blotting reagent (both ThermoFisher, Waltham, 
Massachusetts, USA) and a ChemiDoc MP (BioRad Laboratories AG, Cressier, Switzerland) or 
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Fujifilm LAS-3000 (Biocompare, San Francisco, USA) imager. The images were analyzed with 
the software Image Lab Version 6.0. (BioRad Laboratories AG, Cressier, Switzerland). All used 
antibodies used are listed in table 3 in Supplementary Material and Methods. 
 
CRISPR/Cas9-mediated knockout  
Multi-coloured lentiCRISPR plasmids with EGFP (Addgene Cat #75159), TagBFP (Addgene Cat 
#75160) or mCherry (Addgene Cat #75161) fluorescent markers were kindly provided by Scott 
McComb. The sgRNAs sequences were designed on http://crispr.mit.edu (accessed on 9.2.2017) 
and ordered as complementary oligos from Microsynth AG (Balgach, Switzerland) (for sgRNA 
sequences see Table 4 Supplementary Material and Methods). 100µM complementary oligos were 
annealed in Tango Buffer (ThermoFisher, Waltham, Massachusetts, USA) by heating for 5 min to 
95°C, followed by a slow cool down over 1 hour to RT. Vectors, annealed sgRNA oligos, 
(ThermoFisher, Waltham, Massachusetts, USA), Esp3I (BsmBI) (ThermoFisher, Waltham, 
Massachusetts, USA) and T4 ligase (ThermoFisher, Waltham, Massachusetts, USA) were 
combined in T4 Ligase buffer and the following reaction was run on a T3000 thermocycler 
(Biometra, Biocompare, San Francisco, USA): 10 cycles of 37°C for 5 minutes and 16°C for 10 
minutes for restriction and ligation, respectively. 4µl of the ligation reaction was then used to 
transform StellarTM competent bacteria (Clontech, Takara, Saint-Germain-en-Laye, France) by 
heat shock at 42°C for 45 sec (Clontech, Takara, Saint-Germain-en-Laye, France). Colony PCR 
using RedTaq PCR mixture (Sigma-Aldrich-Aldrich, Buchs, Switzerland) and sgRNA specific 
primers was performed to identify positive clones. For the production of lentiviral particles, 293T 
cells were transfected with the LentiCRISPR plasmid together with pVSV.G (Addgene Cat# 8454) 
and pPAX (Addgene Cat# 12260) plasmids in a ratio of 2.6:1:1 using either polyethylenimine 
(Polysciences, Warrington Township Pennsylvania, USA) or calcium phosphate (Sigma-Aldrich-
Aldrich, Buchs, Switzerland). Medium was changed after 4 hours, and virus was harvested 48 
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hours later. Viral supernatants were concentrated using Amicon Ultra tube Ultracel 100k 
(Millipore, Merck, Schaffhausen, Switzerland). For transduction of target cells, viral particles and 
16µg/ml hexadimethrine bromide (Sigma-Aldrich-Aldrich, Buchs, Switzerland) were added to 
culture medium and left over night on the cells. 72 hours later, transduction efficiency was 
evaluated by flow cytometry, and positive cells were isolated by FACS sorting with a BD Aria III 
4L (BD Biosciences, San Jose, California, USA). Several different sgRNAs per target gene were 
evaluated individually for their knock-out efficiency and the two most efficient ones were selected 
for further experiments.  
 
ShRNA-mediated knockout  
Custom lentiviral shRNA constructs containing a U6-tet promoter driven shRNA (scrambled (sc) 
or directed against PAX3/FOXO1 (target sequence: GGCCTCTCACCTCAGAATTCA)) as well 
as a PGK promoter driven GFP and puromycine expression cassette were purchased from Cellecta 
(Cellecta Inc. Mountain View, California, USA). For constitutive expression of PAX3-FOXO1, 
the cDNA was cloned into the multiple cloning site (NheI) following the EF1 promoter in the 
lentiviral plasmid pRR-CMV-Bleo-EF1-MCS (Cellecta) also carrying a Bleomycin resistance 
under a CMV promoter. Generation of lentiviral particles in HEK293T cells and transduction of 
the target cells was performed as described above for the CRISPR/Cas9 knock-outs.  
 
Statistical analysis 
The software GraphPad Prism (La Jolla, California, USA) was used for all statistical analysis 
(parametric paired t-test). The data were considered significant when p≤0.05. 
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Figure legends 
Figure 1. Fenretinide activates a distinct and non-classical cell death pathway. a Cell viability 
of indicated engineered Rh4 cells treated with Doxycycline and increasing concentrations of 
fenretinide as determined by WST assay. Western Blot using whole cell lysates from indicated 
modified Rh4 cells after treatment or not with 5µM fenretinide for 48h. b Cell viability assay of 
Rh4 and Rh30 cells treated with increasing concentrations of fenretinide in combination with 
different cell death inhibitors (Z-VAD (100µM), NS-1 (25µM), 3-MA (2.5µM), FS (4µM), DFO 
(50µM) c Western Blot using whole cell lysates from Rh4 and Rh30 cells carrying the indicated 
knock-outs treated with increasing concentrations of fenretinide. PARP cleavage and Caspase 7 or 
9 activity was assessed. d Cell viability assay of indicated knockout-cells treated with increasing 
concentrations of fenretinide as assessed by WST assay.  
Figure 2. Fenretinide triggers the production of reactive oxygen species. a-d Fluorescence 
microscopy analysis and flow cytometry of fenretinide treated Rh4 cells. a Light microscopy 
images of fenretinide (3µM) treated Rh4 cells stained with a fluorogenic Pan-ROS detectant 
(CellRox 4µM) b Mean fluorescence index analysis of the flow cytometry data of Rh4 (upper) and 
Rh30 cells lower panel) treated with fenretinide (3/4µM). Cells were stained with CellRox 4µM 
and MitoSox 10µM for the detection of total ROS and mitochondrial ROS levels, respectively c 
Mean fluorescence index analysis of the flow cytometry data of Rh4 (upper) and Rh30 cells, lower 
panel) treated with fenretinide (3/4µM) and different ROS inhibitors including Vitamin C (50µM), 
Deferoxamin (50µM) and Ferrostatin (4µM). Cells were stained with MitoSox for the detection of 
mitochondrial ROS levels d Mean fluorescence index of the flow cytometry data of normalized 
ROS levels in Rh4 and Rh30 cells (upper and lower panel, respectively) after indicated treatments 
(right panel) and cell viability (left panel) of Rh4 and Rh30 cells treated with fenretinide (3/4µM) 
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in presence or absence of the mitochondria specific ROS scavenger MitoTempo (300µM) as 
determined by WST assay.  
Figure 3. Fenretinide interferes with complex II of the mitochondrial respiratory chain. Flow 
cytometry analysis of fenretinide (3/4µM) treated Rh4 and Rh30 cells (upper and lower panel, 
respectively) in combination with two different inhibitors of complex II of the respiratory chain. 
Assessed was mitochondrial ROS by staining with MitoSox (10µM). a Mean fluorescence index 
of flow cytometry data measured in Rh4 and Rh30 cells treated with fenretinide in combination 
with 1500µM of complex II inhibitor Carboxin (left panel) and 500µM respectively 1000µM 
TTFA (right panel).  
Figure 4. Fenretinide induces accumulation of cytoplasmic vesicles and uptake of fluid phase 
dyes. a Electron microscopy images of untreated or fenretinide (3/4µM) treated Rh4 and Rh30 
cells (left and right panel) for 48 hours (lane one and three). Lane two and four show Rh4 and 
Rh30 cells treated with fenretinide (3/4µM) and Z-VAD (100µM) for 48 h. b Mean fluorescence 
index of the flow cytometry data of fenretinide (3/4µM) treated Rh4 and Rh30 cells in combination 
with different inhibitors Vitamin C (50µM), Z-VAD (100µM) and MitoTempo (300µM), stained 
with Acridine Orange (2.7µM) using two different bandpass filters 530/30 and 670/30 (See 
Suppl.Fig.4B). c Light fluorescence microscopy images of Rh4 and Rh30 cells treated or untreated 
with fenretinide (3/4µM) and stained with Lucifer Yellow (820µM). Graphs on the right show 
quantification of the relative mean density index assessed with Fiji software. Total integrated 
density value of an image was divided by the number of cells. 
Figure 5. Fenretinide causes accumulation of early and late endosomes. a Cell viability assay 
of Rh4 and Rh30 cells (upper and lower panel, respectively) treated with increasing concentrations 
of fenretinide in combination with 30µM of dynasore. b Electron microscopy images of untreated 
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or fenretinide (3/4µM) treated Rh4 and Rh30 cells (upper, respective lower panel) for 48hours 
(lane one and three). Lane two and four show Rh4 and Rh30 cells treated with fenretinide (3/4µM) 
and dynasore (30µM) for 48h. c Relative mean fluorescence index of the flow cytometry data of 
fenretinide (3/4µM) treated Rh4 and Rh30 cells (upper, respective lower panel) in combination 
with the Dynamin inhibitor dynasore (30µM), stained with Acridine Orange (2.7µM) using two 
different bandpass filters 530/30 and 670/30 (See Supl.Fig.5C). d Light fluorescence images of 
Rh4 cells treated or untreated with fenretinide (3µM) and stained with antibodies against either 
Rab 5, Rab 7 or Lamp1. Further nuclear staining with Dapi. e Quantification of the relative mean 
density index assessed with Fiji software. Total integrated density value of an image was divided 
by the number of cells. 
Figure 6. Inhibition of the Dynamin GTPases rescues from Fenretinide induced cell death. 
a-c: Crispr/Cas9 Dynamin depleted cells by different sgRNAs a Mean fluorescence index of the 
flow cytometry data of fenretinide (3µM) treated Rh4 and Rh30 Dynamin depleted cells (upper 
and lower panel, respectively), stained with Acridine Orange (2.7µM) using two different 
bandpass filters 530/30 and 670/30 (See Supplementary Fig 6B). b Cell viability assay of Rh4 and 
Rh30 Dynamin mutants (upper and lower panel, respectively), treated with different 
concentrations of fenretinide. c Phase contrast images of Rh4 and Rh30 Dynamin depleted cells 
treated or with fenretinide (3µM /4µM). 
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Supplementary Data and Figures 
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Sup. Fig. 2 
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Sup. Fig. 3 
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Sup. Fig. 4 
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Sup. Fig. 5 
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Sup. Fig. 6 
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Legends supplementary figures 
 
Supplementary Figure 1. Fenretinide induced cell death is not dependent on PAX3-FOXO1 
expression. a Scheme of the two-vector system designed to simultaneously silence endogenous 
PAX3-FOXO1 (Doxycycline-inducible) while overexpressing PAX3-FOXO1. b Western Blots 
using extracts from indicated modified Rh4 cell treated with Doxycycline (0.1ug/ml) or not to 
induce shRNA-mediated silencing of endogenous PAX3-FOXO1. Blots were probed for PAX3-
FOXO1 and PARP cleavage (shP3F-EV: empty expression vector, P3F Mut: pRR plasmid driving 
expression of shRNA-insensitive form of P3F, shsc-EV: shRNA vector with control shRNA, 
shP3F: Silencing vector driving expression of P3F-directed shRNA). c Western Blot using whole 
cell lysates from Rh4 cells having the indicated knock-outs of key players of the apoptotic and 
necroptotic pathway (Bak, Bax, RIPK1 and RIPK3). d Western Blot using whole cell lysates from 
Rh4, Rh3, Rh30 and Jurkat control cells. Caspase 8 presence was assessed. 
 
Supplementary Figure 2. Fenretinide triggers the production of reactive oxygen species. a 
Light microscopy time lapse images of fenretinide (3µM) treated Rh4 cells or control cells stained 
with a fluorogenic Pan-ROS detectant (CellRox 4µM) (upper two rows). Mid two rows show 
fenretinide (3µM) treated Rh4 cells or control cells stained with Propidum Iodide (3µl/ml) – a cell 
death marker; lower two rows show Rh4 Bak/Bax/Rip knockout cells, treated or untreated with 
fenretinide (3µM) and stained with Propidum Iodide (3µl/ml). b Mean fluorescence index analysis 
of the flow cytometry data of Rh4 and Rh30 cells (left and right panel) treated with Fenretinide 
(3/4µM) and different ROS inhibitors including Vitamin C (50µM), Deferoxamin (50µM) and 
Ferrostatin (4µM). Cells were stained with CellRox (4µM) for the detection of Pan ROS levels. 
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Supplementary Figure 3. Fenretinide does not interfere with other complexes of the 
mitochondrial respiratory chain than complex II. Flow cytometry analysis of fenretinide (3µM) 
treated Rh4 cells in combination with inhibitors of each complex of the respiratory chain. a Mean 
fluorescence index analysis of flow cytometry data measured with Rh4 cells treated with 
fenretinide in combination with 0.25µM of complex I Inhibitor Rotenone, 2.5µM of complex III 
Inhibitor Antimycin, 15µM of complex IV inhibitor Sodium Azid (SA) and 0.5µM of the 
uncoupler CCCP. Staining with MitoSox (10µM) to assess mitochondrial ROS.  
 
Supplementary Figure 4. Fenretinide induces accumulation of cytoplasmic vesicles and 
induces the uptake of fluid phase dyes. a Electron microscopy images of untreated and 
Volasertib (6.5nM) treated Rh4 cells for 48 hours. b Mean fluorescence index analysis of the flow 
cytometry data of fenretinide (3/4µM) treated Rh4 and Rh30 cells (left and right panel) in 
combination with different inhibitors Vitamin C (50µM), Z-VAD (100µM) and MitoTempo 
(300µM), stained with Acridine Orange (2.7µM) using two different bandpass filters 530/30 and 
670/30 (See.Fig.4B). c Mean fluorescence index analysis of the flow cytometry data of fenretinide 
(3/4µM) treated Rh4 and Rh30 cells (left and right panel) in combination with different inhibitors 
Vitamin C (50µM), Z-VAD (100µM) and MitoTempo (300µM), stained with Lucifer Yellow 
(820µM). 
 
Supplementary Figure 5. Fenretinide treatment induces accumulation of fluid phase dyes in 
early and late endosomes. a Cell viability assays of Rh4 cells treated with increasing 
concentrations of fenretinide in combination with different inhibitors of the different endocytic 
pathways (EIPA-Macropinocytosis, Filipin/Genistein-Clathrin independent endocytosis, 
Chlorpromazin-Clathrin mediated endocytosis) in increasing concentrations as depicted. b Cell 
viability assays of Rh4 and Rh30 cells treated with increasing concentrations of fenretinide in 
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combination with the Dynamin inhibitor Dyngo 4a in increasing concentrations as depicted. c 
Relative Mean fluorescence index analysis of the flow cytometry data of fenretinide (3/4µM) 
treated Rh4 and Rh30 cells (left and right panel) in combination with the Dynamin inhibitor 
dynasore (30µM), stained with Acridine Orange (2.7µM) using two different bandpass filters 
530/30 and 670/30 (See Fig.5 C) d Mean fluorescence index analysis of the flow cytometry data 
of fenretinide (3/4µM) treated Rh4 and Rh30 cells (left and right panel), dynasore (30µM) was 
added as depicted and stained with MitoSox (10µM). e Cell viability assay of Rh4 cells treated 
with a custom-made small compound and drug containing library comprising 206 agents (each 
0.5µM, except fenretinide 3µM) in combination with Vitamin C (50µM) or dynasore (30µM). 
Depicted is the difference of cell viability of only library treated cells and cells treated with either 
Vitamin C (50µM) or dynasore (30µM). The table on the right shows the top twenty Vitamin C 
rescued compounds. 
 
Supplementary Figure 6. a Western Blot using whole cell lysates from Rh4 and Rh30 cells in 
which either Dynamin 1 or Dynamin 2 was knocked out using the CrisprCas 9 system. In each 
case three different guides (#1, 2, and 3) are shown. Dynamin 1 respectively Dynamin 2 and 
GAPDH activity was assessed. b Mean fluorescence index analysis of the flow cytometry data of 
fenretinide (3/4µM) treated Rh4 and Rh30 mutants (upper and lower panel), stained with Acridine 
Orange (2.7µM) using two different bandpass filters 530/30 and 670/30 (See Fig 6 A). c Mean 
fluorescence index analysis of the flow cytometry data of fenretinide (3µM) treated Rh4 and Rh30 
mutants (upper and lower two panels), stained with Acridine Orange (2.7µM) using two different 
bandpass filters 530/30 and 670/30 (right and left panel). d Cell viability assay of Rh4 and Rh30 
Dynamin mutants (two left respectively two right graphs) treated with different concentrations of 
fenretinide 
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Supplementary Tables 
Compound Name Product information 
3-Methyladenine (3-MA) M9281, Sigma-Aldrich 
Deferoxamine Mesylate (Deferoxamine, DFO) D9533, Sigma-Aldrich 
Hydroxy- dynasore (Dyngo 4a)  SML0340 Sigma-Aldrich 
Dynasore hydrate (dynasore) D7693, Sigma-Aldrich 
Ethylisopropylamiloride (EIPA) A3085, Sigma-Aldrich 
Ferrostatin-1 (FS) A4371, APExBIO 
Genistein G6649, Sigma-Aldrich 
Filipin complex from filipinensis F9765, Sigma-Aldrich 
Chlorpromazin hydochloride C8138, Sigma-Aldrich 
L-Ascorbinsäure (Vitamine C) A4403, Sigma-Aldrich 
MitoTempo (MT) SML0737, Sigma-Aldrich 
Necrostatin-1 (NS-1) A4213, APExBIO 
Retinoic acid p-hydroxyanilide (Fenretinide, Fen) H7779, Sigma-Aldrich 
Z-VAD-FMK  A1902, APExBIO 
Carboxine 45371, Sigma-Aldrich 
2-Thenoyltrifluoroacetone T27006, Sigma-Aldrich 
Rotenone R8875, Sigma-Aldrich 
Antimycin A8674, Sigma-Aldrich 
Carbonyl cyanide 3-chlorphenyl-hydrazone (CCCP) C2759, Sigma-Aldrich 
Sodium Azid S2002, Sigma-Aldrich 
 
Table 1 Compounds used for WST-1 cell viability assays and Flow Cytometry 
 
Stain Product information 
Acridine Orange (hemi zinc chloride salt) 158550, Sigma-Aldrich 
CellRox Deep Red Reagent C10422, ThermoFisher 
Lucifer Yellow L453, ThermoFisher 
MitoSox Red M36008, ThermoFisher 
Propidium Iodide 4170, Sigma-Aldrich 
 
Table 2 Fluorescent stains for flow cytometry and fluorescence microscopy 
 
Antibody Product information 
Mouse anti-caspase 8  Cell Signaling, Cat# 9746 
Rabbit anti-Bak  Cell Signaling, Cat #3792 
Rabbit anti-Bax  Cell Signaling, Cat# 2774 
Rabbit anti-cleaved caspase-7  Cell Signaling, Cat# 9491 
Mouse anti-caspase 9  Cell Signaling, Cat#9508 
Rabbit anti-PARP  Cell Signaling, Cat# 9542 
Rabbit anti-GAPDH  Cell Signaling, Cat#2118 
Mouse anti-RIP1  BD Biosciences, Cat# 51-6559 
Rabbit anti-RIP3  Abnova, Cat# PAB0287 
Rabbit anti-dynamin1  ThermoFisher, Cat# PA1-660 
Rabbit anti-dynamin 2  GeneTex, Cat# C2C3 
Horseradish peroxidase-conjugated goat anti-mouse Cell Signaling, Cat# 7076 
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Horseradish peroxidase-conjugated goat anti-rabbit Cell Signaling, Cat# 7074 
 
Table 3 Antibodies used for WB 
 
Gene Name Primer Sequence 
RIPK1-1 ACACCTCCCGAAGCCTCCGCTGTCT 
RIPK1-2 ACACCTGTGAAAGTCACGATCAACG 
Scrambled GCACTACCAGAGCTAACTCA 
Bak ACGGCAGCTCGCCATCATCG 
Bax CAAGCGCATCGGGGACGAAC 
Dynamin 1 #1 ACACCGCAGGTCGAGGTCCGCGTTC 
Dynamin 1 #2 ACACCCATTGTCACCCGACGTCCCC 
Dynamin 2 #1 ACACCCCCGCTGGTCAACAAACTGC 
Dynamin 2 #2 ACACCGTGACGATTCCTGAACCGCG 
Dynamin 1 #3 AAGGCGCACCTCCTCGAAGT 
Dynamin 2 #3 CGTGTGGCGAGTAGACTCGA 
 
Table 4 Lenti-CRISPR primers (insert sequences) 
 
Product Name Target 
Veliparib (ABT-888) PARP 
Axitinib VEGFR, PDGFR, c-Kit 
Saracatinib (AZD0530) Src, Bcr-Abl 
FG-4592 HIF 
Afatinib (BIBW2992) EGFR 
Bortezomib (PS-341) Proteasome 
Bosutinib (SKI-606) Src 
Dovitinib (TKI-258, CHIR-258) c-Kit, FGFR, Flt, VEGFR, PDGFR 
Dasatinib Src, Bcr-Abl, c-Kit 
Erlotinib HCl (OSI-744) EGFR 
Gefitinib (ZD1839) EGFR 
Lapatinib (GW-572016) EGFR, HER2 
Lenalidomide (CC-5013) TNF-alpha 
Nilotinib (AMN-107) Bcr-Abl 
Pazopanib HCl VEGFR, PDGFR, c-Kit 
Rapamycin (Sirolimus) mTOR 
Sorafenib Tosylate VEGFR, PDGFR, Raf 
Sunitinib Malate VEGFR, PDGFR, c-Kit, Flt 
Vandetanib (ZD6474) VEGFR 
Vorinostat (SAHA, MK0683) HDAC 
VX-680 (Tozasertib, MK-0457) Aurora Kinase 
Y-27632 2HCl ROCK 
Elesclomol (STA-4783) HSP 
Entinostat (MS-275) HDAC 
Enzastaurin (LY317615) PKC 
Olaparib (AZD2281, Ku-0059436) PARP 
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GDC-0941 PI3K 
SB431542 TGF-beta/Smad 
Crizotinib (PF-02341066) c-Met, ALK 
AUY922 (NVP-AUY922) HSP 
PHA-665752 c-Met 
SB216763 GSK-3 
MK-2206 2HCl Akt 
Vismodegib (GDC-0449) Hedgehog, P-gp 
KU-55933 (ATM Kinase Inhibitor) ATM 
GSK1904529A IGF-1R 
MLN8054 Aurora Kinase 
Danusertib (PHA-739358) Aurora Kinase, FGFR, Bcr-Abl, c-RET, Src 
GSK690693 Akt 
JNJ-38877605 c-Met 
Palbociclib (PD-0332991) HCl CDK 
Cabozantinib (BMS-907351) VEGFR, c-Met, Flt, Tie-2, c-Kit 
Everolimus (RAD001) mTOR 
BMS-754807 IGF-1R 
YM155 (Sepantronium Bromide) Survivin 
Alisertib (MLN8237) Aurora Kinase 
AT9283 Bcr-Abl, JAK, Aurora Kinase 
Barasertib (AZD1152-HQPA) Aurora Kinase 
Roscovitine (Seliciclib,CYC202) CDK 
Lenvatinib (E7080) VEGFR 
Valproic acid  GABA Receptor, HDAC 
CYC116 Aurora Kinase, VEGFR 
XAV-939 Wnt/beta-catenin 
Thalidomide Others 
Decitabine DNA/RNA Synthesis 
PIK-75 PI3K, DNA-PK 
2-Methoxyestradiol (2-MeOE2) HIF 
Vemurafenib (PLX4032, RG7204) Raf 
Rigosertib (ON-01910) PLK 
Ruxolitinib (INCB018424) JAK 
Resveratrol Sirtuin 
Ispinesib (SB-715992) Kinesin 
AEE788 (NVP-AEE788) EGFR, Flt, VEGFR, HER2 
PHA-793887 CDK 
Ponatinib (AP24534) Bcr-Abl, VEGFR, FGFR, PDGFR, Flt 
AT7519 CDK 
MK-1775 Wee1 
Quizartinib (AC220) Flt 
AZD7762 Chk 
R406 (free base) Syk 
Org 27569 Cannabinoid Receptor 
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EX 527 (Selisistat) Sirtuin 
Pomalidomide TNF-alpha, COX 
KU-60019 ATM 
BIRB 796 (Doramapimod) p38 MAPK 
RO4929097 Y-Secretase 
Tie2 kinase inhibitor Tie-2 
Azacitidine  DNA/RNA Synthesis 
Acadesine AMPK 
Nicorandil Others 
PF-573228 FAK 
Lovastatin HMG-CoA Reductase 
LDE225 (Erismodegib) Smoothened 
PF-4708671 S6 Kinase 
MLN2238 Proteasome 
MLN9708 Proteasome 
SGI-1776 free base Pim 
AZ 960 JAK 
Apatinib VEGFR 
Volasertib (BI 6727) PLK 
Degrasyn (WP1130) DUB, Bcr-Abl 
BKM120 (Buparlisib) PI3K 
Imatinib (STI571) PDGFR,c-Kit, v-Abl 
Mifepristone Estrogen/progestogen Receptor 
LY2603618 Chk 
NU7441 (KU-57788) DNA-PK, PI3K 
MK-0752 Gamma-secretase 
Trametinib (GSK1120212) MEK 
Ibrutinib (PCI-32765) Src 
NVP-BSK805 2HCl JAK 
GDC-0980 (RG7422) mTOR, PI3K 
A-769662 AMPK 
AMG-900 Aurora Kinase 
Crenolanib (CP-868596) PDGFR 
AZ 3146 Kinesin 
PHA-767491 CDK 
CUDC-907 HDAC, PI3K 
NVP-BVU972 c-Met 
SB705498 TRPV 
Tofacitinib (CP-690550) JAK 
Dabrafenib (GSK2118436) Raf 
GDC-0068 Akt 
Torin 2 mTOR 
TAE226 (NVP-TAE226) FAK 
TPCA-1 IKK 
Carfilzomib (PR-171) Proteasome 
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T0070907 PPAR 
WZ811 CXCR 
IOX2 HIF 
Evacetrapib (LY2484595) CETP 
Pazopanib VEGFR 
Rimonabant Cannabinoid Receptor 
Cabozantinib malate  c-met, VEGFR2 
Spironolactone Androgen Receptor 
JNK-IN-8 Free Base 
QNZ (EVP4593) NF-κB 
Tofacitinib (CP-690550) Citrate JAK 
GDC-0152 IAP 
AZD3514 Androgen Receptor 
AZ20 ATM/ATR 
GSK126 Histone Methyltransferase 
EPZ5676 Methyltransferase 
GSK J4 HCl Others 
LDK378 ALK 
IWP-2 Wnt/beta-catenin 
GSK2334470 PDK-1 
PF-3758309 PAK 
HSP990 (NVP-HSP990) HSP (e.g. HSP90) 
AZD3463 ALK 
EPZ-6438 Histone Methyltransferase 
PYR-41 E1 Activating 
PR-619 DUB 
P5091 (P005091) DUB 
BMS-833923 Hedgehog/Smoothened 
AZD1080 GSK-3 
C646 Histone Acetyltransferase 
10058-F4 c-Myc 
AVL-292 BTK 
IOX1 Histone demethylases 
OG-L002 Histone demethylases 
SGC-CBP30 Epigenetic Reader Domain 
CNX-774 BTK 
MM-102 Histone Methyltransferase 
JIB-04 Histone demethylases 
PFI-2 Histone Methyltransferase 
CPI-203 Epigenetic Reader Domain 
GSK2606414 PERK 
6H05 Rho 
K-Ras(G12C) inhibitor 9 Rho 
SH-4-54 STAT 
OTX015 BET 
LEE011 CDK 
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LDC000067 CDK 
PI-1840 Proteasome 
JNK Inhibitor IX JNK 
GNF-5837 Trk receptor 
Afuresertib (GSK2110183) Akt 
GDC-0994 ERK 
UNC0379 Histone Methyltransferase 
GSK-LSD1 2HCl Histone Demethylase 
GSK J1 Histone Demethylase 
INCB024360 IDO 
BRD4770 Histone Methyltransferase 
BV-6 IAP 
EI1 Histone Methyltransferase 
MI-2 (Menin-MLL Inhibitor) Histone Methyltransferase 
LDC1267 Axl 
CPI-360 Histone Methyltransferase 
CH5183284 (Debio-1347) FGFR 
YK-4-279 DNA/RNA Synthesis 
AZD6738 ATM/ATR 
Verdinexor (KPT-335) CRM1 
EPZ015666 Histone Methyltransferase 
Pexmetinib (ARRY-614) p38 MAPK 
Pexidartinib (PLX3397) CSF-1R 
BI-847325 MEK 
PFI-4 Epigenetic Reader Domain 
Epacadostat (INCB024360) IDO 
NSC 23766 Rac 
BMS-345541 IκB/IKK 
Pacritinib (SB1518) JAK 
Idasanutlin MDM2/p53 
iBet762 BET 
ABT-263 BCL2, BCL-XL, BCL-w 
ABT-199 BCL2 
Obatoclax BCL2-family 
dynasore Dynamin 
Dyngo4a Dynamin 
GDC-0973 MEK 
Fenretinide Retinoid Acid Receptor 
JQ-1 BET 
Birinapant IAP 
Doxorubicine DNA  
Vincristine Microtubuli 
Etoposide Topoisomerase 
 
Table 5 Compounds of the drug screen library 
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Abstract 
Alveolar rhabdomyosarcomas (aRMS) are highly aggressive childhood malignancies that are 
mainly treated by conventional chemotherapy, surgery and radiotherapy. Since radiotherapy is 
associated with a high burden of side effects, addition of radio-sensitizers would be beneficial.  
Here, we thought to assess the role of fenretinide, a potential agent for aRMS treatment, as radio-
sensitizer for aRMS treatment. 
Survival of human aRMS cells was assessed after combinatorial treatment with fenretinide and 
ionizing radiation (IR) by cell viability and clonogenic assays. Further, the underlying mechanisms 
of action and cell death modality were studied.  
The combinatorial treatment with fenretinide and IR significantly reduced cell viability further 
compared to single agent treatment. Mechanistically, this was accompanied by enhanced 
production of reactive oxygen species, initiation of cell cycle arrest and induction of apoptosis. 
Interestingly, the combinatorial treatment also triggered a new form of dynamin-dependent 
macropinocytosis, which was previously described in fenretinide-only treated cells.  
Our data suggest that fenretinide acts in combination with IR to induce cell death in aRMS cells 
and might act as novel radio-sensitizer for the treatment of this disease. 
 
  
 122 
Results – Manuscript II 
Introduction 
Radiation therapy (RT) applying ionizing radiation (IR) is along with chemotherapy and surgery 
part of the standard therapeutic regiment for many malignancies. In the pediatric patient population 
this treatment is used e.g. in neuroblastoma, medulloblastoma, Ewings and soft tissue sarcomas 
(1). Rhabdomyosarcoma (RMS) is the most common soft tissue malignancy in children and young 
adolescents. Especially the alveolar rhabdomyosarcoma subgroup (aRMS) is associated with a 
poor outcome due to its aggressiveness and a high risk of relapse (2-5).  
Earlier, we identified the small molecule fenretinide (retinoic acid p-hydroxyanilide) as a potential 
additional treatment option for this malignancy, as it was found to have strong cytotoxic effects 
on aRMS cells (6). In follow-up experiments, we further elucidated the underlying mechanism of 
cell death which depends on enhanced production of reactive oxygen species, an increased 
accumulation of cytoplasmic vesicles resembling the characteristics of macropinocytosis (First 
manuscript), a recently described new form of cell death (7, 8). 
The effectiveness of ionizing radiation is well studied and has direct and indirect effects on cancer 
cells. As direct action, IR damages DNA, proteins and lipids, which eventually results in genomic 
instability, cell cycle arrest and cell death (9). Indirect effects occur through radiolysis of water 
and the production of reactive oxygen species (ROS). The unpaired electrons in ROS are highly 
reactive and can induce DNA single- and double-strand breaks (10-13). Further, they act as a 
signaling molecules driving cells towards cell death.  
On the other hand, ionizing radiation is associated with considerable side effects and induces 
damages to non-diseased tissues and organs depending on the dose administered and absorbed. 
This may cause relevant side effects especially in pediatric patients which become apparent only 
later in life such as growth retardation, reduced neurocognitive development, infertility, and most 
importantly the risk to develop secondary malignancies (14, 15). One current goal in radiobiology 
is therefore to minimize these side effects, while at the same time maximizing radiation benefits 
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against tumor cells. Image-guided and intensity-modulated RT for example have led to significant 
improvements in the field (16, 17).  
Another well recognized option to achieve this goal is the simultaneous administration of 
radiosensitizers (18). Drugs are defined as radiosensitizing agents when they render cancer cells 
more vulnerable to radiation therapy. Wang et al categorizes radiosensitizers based on their 
structures into three categories: small-molecule chemicals, nanostructures, and macromolecules 
(19). Bentzen and colleagues explained the different mechanisms by using the term cytotoxic 
enhancement, where the combinatorial treatment in general modulates response to DNA damage 
(20).  
Fenretinide is a small-molecule compound that is well established in the treatment for multiple 
malignancies during adulthood and is also already in clinical use in children (Clinicaltrials.gov ID 
NCT02163356) (21, 22). Moreover its side-effect profile is very favorable with no limiting 
toxicities (23).  
Multiple studies suggest that the fenretinide induced cell death occurs mainly through apoptosis 
in most of the cell lines. This is achieved either through the production of reactive oxygen species 
(ROS) or the involvement of lipid second messengers (24-28).  
So far, fenretinide has not been investigated together with RT in the treatment of 
rhabdomyosarcoma. However, fenretinide combined with radiation therapy is currently under 
investigation for the treatment of diffuse intrinsic pontine glioma (DIPG) and suggests promising 
results in mice (29).  
In the current study we therefore aimed to characterize the potential use of the fenretinide as 
radiosensitizer. Additionally, we described the underlying mechanisms of cell death occurring 
during combination treatment in more detail. The study highlights this combination as potential 
novel treatment option for aRMS.  
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Material and Methods  
Gamma Irradiation 
Irradiation was performed using an Xstrahl 200 kV X-Ray unit (Ratingen, Germany) at 100 
cGy/minute. Depending on the question, different intensities of radiation was applied to the cells.  
 
Cell Culture 
The alveolar rhabdomyosarcoma cell line Rh4 (provided by Peter Houghton, Greehey Children’s 
Cancer Research Institute, San Antonio, Texas, USA) was maintained in high glucose Dulbecco's 
Modified Eagle Medium (DMEM, Sigma-Aldrich, Buchs, Switzerland), supplemented with 100 
U/mL penicillin/streptomycin (Invitrogen, ThermoFisher, Waltham, Massachusetts, USA), 2 mM 
L-glutamine (BioConcept, Allschwil, Switzerland) or Glutamax (Gibco, ThermoFisher, Waltham, 
Massachusetts, USA) , and 10% fetal bovine serum (FBS, Sigma-Aldrich, Buchs, Switzerland), in 
5% CO2 at 37°C. ARMS cell lines were regularly tested for Mycoplasma infection, authenticated 
by short tandem repeat analysis (STR profiling) in 2011/2014 and positively matched with 
reference data (30).  
 
Cell viability assay 
80000 Rh4 cells/ml were seeded in 96 well format (TC-Plate, Standard F, Sarstedt, Nümbrecht, 
Germany) in 100µL medium. The studied compounds (see Table 6) were added for 72hours. For 
measurement of cell viability, 10µl WST-1 reagent (Sigma-Aldrich-Aldrich, Buchs, Switzerland) 
was added. After 30 minutes incubation at 37°C in the dark, absorbance at 440 and 640 nm were 
measured with a Synergy™ HT multi-detection microplate reader (BioTek, Winooski, Vermont, 
USA). The difference of the two values was calculated (delta optical density; ΔOD) and values 
from pure medium were subtracted as background.  
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Clonogenic cell survival assays 
Clonogenic cell survival was determined by the ability of single cells to form colonies in vitro 
(31). 50000 cells were seeded in 10cm dishes format (TC-Dish, 100, Standard, Sarstedt, 
Nümbrecht, Germany). The following day, the cells were treated with the desired concentration of 
fenretinide in DMEM, high glucose supplemented with 100 U/mL penicillin/streptomycin ,2 mM 
Glutamax and 10% FBS, and irradiated with the desired intensity. After 12 days of culturing in 
5% CO2 at 37°C the medium was removed and the cells fixed with glutaraldehyde (6.0%) and 
stained with crystal violet (0.5%).  
 
Flow Cytometry 
For all flow cytometry experiments, 150000 Rh4 cells were seeded per well in Corning Costar 6-
well plates (Sigma-Aldrich-Aldrich, Buchs, Switzerland).  After treatments, cells were detached 
from the plates using Trypsin, washed once with PBS and re-suspended in 0.5 ml indicated buffer. 
Data was acquired with the LSRII Fortessa (BD Biosciences, San Jose, California, USA) flow 
cytometer or the BD FACS Canto system (BD Biosciences, San Jose, California, USA). Acquired 
data was analysed with FlowJo Software, Version 9.9.6 (Tree Star Inc., Ashland, Orlando, USA). 
All used fluorescent stains are listed in Table 7 in Supplementary Material and Methods.  
 
Pan ROS measurement 
Cells were seeded and treated with the desired compounds according to table 6 (in the 
Supplementary Material and Methods). Simultaneously 4µM CellRox Deep red (ThermoFisher, 
Waltham, Massachusetts, USA) solution was added to the medium. One hour after drug treatment, 
cells were irradiated with the desired intensity. After 18 hours cells were collected, washed in PBS 
and re-suspended in FluoroBrite live cell fluorescence imaging medium DMEM (ThermoFisher, 
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Waltham, Massachusetts, USA). CellRox signal (50’000 events per sample) was acquired with 
excitation laser 640 nm and Emission filter 670/14.  
 
Mitochondrial ROS measurement 
Cells were seeded and treated with the desired compounds according to table 7. One hour after 
drug treatment, cells were irradiated with the desired intensity. After 18 hours, cells were collected, 
washed in PBS and re-suspended in MitoSox (ThermoFisher, Waltham, Massachusetts, USA) 
Solution (10µM MitoSox in PBS) for 30min at 37°C in the dark. MitoSox signal (50’000 events 
per sample) was acquired with excitation laser 561 nm, and Emission filter 570 LP, 525/50. 
 
Cell cycle Analysis 
Cells were seeded and treated with the desired concentration of fenretinide. One hour after drug 
treatment, cells were irradiated with the desired intensity. After 24h and 48h, cells were, collected, 
washed with PBS and fixed with ice cold 70 % ethanol for four hours at -20°C. Then cells were 
washed with PBS three times and incubated for 30 min with propidium iodide 20 mg/ml (Sigma-
Aldrich, Buchs, Switzerland) and RNAse A (200mg/ml) (Qiagen, Hilden, Germany) in TritonX-
PBS 0.1% (Sigma-Aldrich, Buchs, Switzerland). PE signal (50’000 events per sample) was 
acquired with excitation laser 488 nm, and Emission filter 585/42.  
 
Acridine Orange (AO) Staining 
Acridine Orange (Sigma-Aldrich-Aldrich, Buchs, Switzerland) (AO) was used to measure fluid-
phase endocytic uptake induced by fenretinide treatment and IR after 48h. Cells were seeded and 
treated with the desired compounds according to table 6 in Supplementary Material and Methods. 
One hour after drug treatment, cells were irradiated with the desired intensity. After 48 hours 
Acridine Orange (2.7 μM) in FluoroBrite DMEM live cell fluorescence imaging medium 
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(ThermoFisher, Waltham, Massachusetts, USA) was added to the cells 4 h prior to their 
preparation for flow cytometry. Cells were collected, washed in PBS and re-suspended in PBS. 
AO signal (50’000 events per sample) were acquired with excitation laser 488 nm and 561, 
emission filter 505 LP, 530/30 and 635LP, 670/30.  
 
Epifluorescence microscopy 
All images were taken with the Zeiss Axio Observer (Zeiss, Oberkochen, Germany) equipped with 
a Hamamatsu Orca Flash 4.0 V2, sCMOS cooled fluorescence camera (Hamamatsu, Hamamatsu 
City, Japan) and an objective with 20x magnification. All fluorescent stains used can be found in 
table 2 in Supplementary Material and Methods. For data processing, images were exported as 
TIFF files and the mean integrated density was quantified with the image processing software Fiji 
(32). The integrated density value of an image was divided by the number of cells (counted on the 
phase image). Per treatment a minimum of four pictures was taken.  
 
LY fluorescence microscopy 
50000 cells/ml were seeded in Falcon™ chambered cell culture slides (4 wells, Corning) (Thermo 
Scientific, ThermoFisher, Waltham, Massachusetts, USA) and treated with 3µM fenretinide. One 
hour after drug treatment, cells were irradiated with the desired intensity. After 48h, cells were 
subsequently stained with Lucifer Yellow (820µM) in FluoroBrite DMEM for 4 h at 37°C, 5% 
CO2 after removal of the culturing medium. Afterwards, cells were washed with PBS and fixed 
with 4 % PFA for 15 min at room temperature. After three PBS washes, the chamber was removed, 
and the cells were mounted in Vectashield mounting medium with 4′,6-Diamidin-2-phenylindol 
(Vector Laboratories, Burlingame, California, USA). 
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Immunoblot 
Whole cell extracts were prepared from cells lysed with RIPA buffer (50 mM Tris-Cl (pH 7.5), 
150 mM NaCl, 1% NP-40, 0.5% Na-deoxycholate, 1 mM EGTA, 0.1% SDS, 50 mM NaF, 10 mM 
sodium β-glycerolphosphate, 5 mM sodium pyrophosphate, 1 mM sodium orthovanadate and 
supplemented with Complete Mini Protease Inhibitor cocktail (all from Sigma Aldrich, Buchs, 
Switzerland).  P Proteins were separated using NuPAGE™ Novex™ 4-12% Bis-Tris gels 
(ThermoFisher, Waltham, Massachusetts, USA) and transferred to nitrocellulose membranes (GE 
Healthcare Life Sciences). Membranes were blocked with 5% milk powder in TBS/0.05% Tween 
and subsequently incubated with respective primary antibodies overnight at 4°C. After three time 
washing in TBS-0.05% tween, membranes were incubated with horseradish peroxidase (HRP)-
linked secondary antibody for 1h at RT. A 
Following antibodies were used: Rabbit, anti-phospho-Histone H2A.X (Ser139) (Cat# 9718), 
rabbit anti-cleaved-Caspase 7 (Cat# 9491), rabbit anti-cleaved PARP (Cat# 5625), rabbit anti-
GAPDH (Cat#2118) all from Cell Signaling (Cell Signaling Technology, Danvers, Massachusetts, 
USA). Horseradish peroxidase-conjugated goat anti-rabbit from Cell Signaling (Cat# 7077) were 
used as secondary antibodies. After three additional washing steps with TBS/0.05% Tween, 
proteins were detected by chemiluminescence using either the Pierce™ ECL Western Blotting 
Substrate (ThermoFisher, Waltham, Massachusetts, USA) or Supersignal Western blotting reagent 
(ThermoFisher, Waltham, Massachusetts, USA) and a ChemiDoc MP (BioRad Laboratories AG, 
Cressier, Switzerland) imager. The images were analysed with the software Image Lab Version 
6.0. (BioRad Laboratories AG, Cressier, Switzerland). 
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Statistics 
The software GraphPad Prism (La Jolla, California, USA) was used for all statistical analyses. 
Comparisons of differences between two groups were analysed by parametric paired t-test. The 
data were considered significant when p ≤ 0.05. 
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Results  
We previously demonstrated that fenretinide alone efficiently induces a novel dynamin-dependent 
cell death in aRMS cells (Manuscript 1), which we also confirmed here (Figure 1A, left panel, 
Table 1). As radiotherapy is part of the aRMS standard treatment regimens, we questioned if the 
combination radiotherapy with fenretinide would enhance the anti-tumor effect on aRMS cells. In 
a first step, we therefore co-treated Rh4 cells with different single doses of radiation (5 and 10Gy) 
and two low doses of fenretinide (IC10 and IC20, equals to 1.9 and 2.6µM) and assessed cell 
viability after 72h by WST-1 assay. Indeed, for all combination treatments, cell viability decreased 
significantly at this time point. We found a dose dependent combinatorial effect of fenretinide with 
IR, whereby the combination at the lower radiation dose reduced cell viability to levels comparable 
to cells treated at higher radiation doses alone (Figure 1A, Table 1 and 2). Next, we assessed the 
combinatorial effect on clonogenic cell survival. In this setting, we observed a strong 
combinatorial effect already at lower concentrations of fenretinide (0.5µM) together with low 
radiation doses of 2Gy (Figure 2B). 
In a next step, we investigated the mechanisms of cell death that were induced by the combination 
treatment. Western blot analysis of cleaved Caspase 7 and cleaved PARP revealed induction of 
apoptosis in single treated cells, which was enhanced by the combination treatment. The addition 
of Z-vad, a pan-caspase inhibitor abolished both caspase 7 and PARP cleavage (Figure 2C). Next, 
we were interested to see whether the combination would induce enhanced phosphorylation of the 
histone H2AX (γH2AX) as a well-established marker for DNA double-strand breaks (33).Western 
blot analysis showed enhanced phosphorylation of γH2AX in the combinatorically treated cells, 
most prominently after 30 minutes and rapidly decreasing over the next four hours (Figure 1D). 
Based on these findings, we further investigated the effect of fenretinide and IR on cell cycle 
distribution. Fenretinide alone did not change the cell cycle distribution after 24 hours. In contrast, 
single treatment of IR induced a dose-dependent G2/M arrest (Figure 1F, left panel) which was 
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further increased by the combination in a dose-dependent manner. After 48h, we still saw a slight 
G2/M arrest but also an emerging Sub-G1 peak, which indicates the induction of cell-death after 
that treatment period (Figure 1F, right panel). These data suggest that fenretinide combined with 
IR enhances a G2/M cell cycle arrest which eventually leads to cell death.  
 
Next, we wanted to see whether the combination treatment affected reactive oxygen species (ROS) 
production. Indeed, increasing concentrations of fenretinide and increasing doses of IR 
significantly enhanced ROS production (pan-ROS) compared to the control cells. This was also 
significantly more prominent in the combination treatment (Figure 2A, Table 3). To confirm 
specificity, we co-treated cells with the hydrogen-peroxide scavenger N-Acetylcysteine (NAC) 
and observed a significant reduction of ROS production (Figure 2A, Table 3). Since we previously 
found mitochondrial derived ROS to be the main source of ROS under fenretinide treatment, we 
also analyzed cells with the specific MitoSox staining. We observed a significant dose-dependent 
increase of mitochondrial ROS both upon fenretinide treatment alone, as well as a further increase 
under combination treatment. Interestingly, radiation alone, did not enhance mitochondrial ROS 
production (Figure 2B, Table 4).  
To further characterize and validate the impact of ROS species on cell death, we treated the cells 
additionally with Vitamin C as a well-recognized pan-ROS scavenger and MitoTempo, a 
mitochondrial-specific ROS Scavenger. We observed an almost complete rescue from cell-death 
by both Vitamin C and MitoTempo (Figure 2C, Table 5).  
Taken together, fenretinide and IR induce the production of reactive oxygen species whereas 
mitochondrial derived superoxides are mainly produced by fenretinide.  
 
Previously, we could demonstrate that fenretinide induced the formation of large phase lucent 
cytoplasmic vesicles, which derive from increased macropinocytosis. Therefore, our next aim was 
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to clarify whether fenretinide would also enhance accumulation of those cytoplasmic vesicles 
when combined with IR. Hence, we co-treated cells either with dynasore, Vitamin C or Z-vad and 
measured Acridine Orange (AO) staining to assess endocytosis (Figure 3, A-C and Supplementary 
Figure 1, A-C). These experiments revealed a significant increase in dye uptake in the fenretinide-
only treated cells which was further enhanced by IR treatment. Interestingly, IR treatment alone 
only minimally affected the uptake of AO. In addition, co-treatment of the cells with Vitamin C 
and dynasore decreased the dye uptake in treated cells (Figure 3A+B, Supplementary Figure 1 
A+B). No change was observed in the IR-only treated cells (Figure 3A and 3B, Supplementary 
Figure 1 A+B). As expected, the addition of Z-vad did not change the levels of endocytosis as 
measured by AO dye uptake (Figure 3C, Supplementary Figure 1A).  
Finally, to validate these findings we used the fluid phase dye Lucifer Yellow and performed 
fluorescence microscopy. We confirmed a non-significant increase of dye uptake when cells were 
treated with IR alone, whereas a significant increase was observed in the combination treatments 
(Figure 3D). These findings suggest that the combination of IR with fenretinide significantly 
enhanced the uptake of fluid phase dyes whereas IR alone does not. Further, enhanced endocytosis 
might depend on mitochondrial ROS production and involve dynamin GTPases as most likely 
triggering factors. 
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Discussion  
The aim of this study was to evaluate the potential of fenretinide as a radiosensitizer for co-
treatment of aRMS cells. In radiation therapy, timing, duration, and dose are crucial factors for its 
effectiveness and to minimize long term side effects. Therefore, identification of combinations of 
agents and treatment modalities that act synergistically is most desirable. Radiosensitizing agents 
are capable to broaden the therapeutic window and selectively augment radiation effects in tumour 
cells while also sparing the surrounding tissue. Fenretinide combined with radiation therapy is 
under investigation for the treatment of diffuse intrinsic pontine glioma (DIPG) and shows 
promising results in mouse experiments (29). However, up-to-now there are only few other studies 
exploring this combinatorial effect in additional tumors. 
We already showed that fenretinide has a strong anti-tumour effect in aRMS cells through the 
production of mainly mitochondrial derived reactive oxygen species, which induced a new form 
of a dynamin-dependent vesicular cell death (manuscript one). Here, first experiments 
demonstrated an increased dose-dependent combinatorial anti-tumor effect. This enabled us to 
reduce both treatment dosages with a persisting effect already at 2Gy which also impaired 
clonogenic growth.  
The underlying cell death mechanism was identified in part as apoptosis. However, it also led to 
induction of ROS and subsequent DNA damage. Radiation therapy is known to induce G2 cell 
cycle arrest following DNA damage (34), which was confirmed in our findings. It is also known 
that fenretinide can induce cell cycle arrest (35). Our results also showed impaired cell cycle 
progression with mainly G2/M arrest most pronounced in the combination treatment. This is an 
important finding as it is one of the hallmarks of cancer that tumour cells sustain proliferative 
signalling even after DNA damage (36), and therefore restoration of a normal physiological 
response – induction of cell death - is desirable.  
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Our experiments using a pan-ROS detectant, further revealed a significant increase of ROS 
production in irradiated cells. In our previous experiments we were able to show that fenretinide 
alone induces mitochondrial derived ROS. Here, irradiation mainly induced the production of 
hydrogen peroxide, as we were able to scavenge them with NAC. Hence triggering different ROS 
species in our treatment combination is important in the context of resistance development, as 
cancer cells are known to upregulate antioxidant pathways (37). 
To identify the cell death mechanism in more detail we evaluated whether IR would also trigger 
dynamin-dependent increased macropinocytosis as found previously as the prominent mode of 
action of fenretinide. As shown above, we were able to identify increased macropinocytosis in the 
co-treated cells. In the irradiated-only cells, this increase was minimal when assessed by flow 
cytometry and a bit more prominent when assessed with light microscopy. The discrepancy 
between flow cytometry and light microscopy might actually be an analysis bias and explained by 
the fact that ionizing irradiation induces cell cycle arrest and senescence (as observed on 
microscopy imaging) and subsequently a morphologically apparent change of cells. As they 
become bigger, they are capable to take up more dye and the analysis will show an increased 
integrated mean density index per cell. Due to the gating strategy applied in flow cytometry, the 
cell size is not relevant. However, in the irradiated-only cells the dye uptake could be inhibited 
neither with a Dynamin Inhibitor nor a ROS-scavenger, as was the case for fenretinide treated 
cells. Based on these findings it is unlikely that radiation induced cell death is a result of increased 
macropinocytosis, however this cell death mode can be triggered and enhanced upon additional 
fenretinide treatment, most likely from the interaction of a distinct population of ROS.  
 
Taken together our findings support the hypothesis that fenretinide acts as a promising radiation 
sensitizer in co-treatment of alveolar rhabdomyosarcoma cells. Different modes of cell death 
mechanism are activated and enhanced by these two treatment modalities. Reactive oxygen species 
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and DNA damage are the main underlying triggering factors, whereas macropinocytosis as seen 
in fenretinide treatment plays only a minor role in IR-only treated cells. A combinatorial treatment 
with both modalities however may help to reduce development of resistances and increases the 
therapeutic window in the local treatment. Hence, it might be a promising treatment regimen in 
paediatric patients with alveolar rhabdomyosarcoma. 
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Figure 1: The combinatorial treatment of fenretinide and radiation therapy leads to an 
enhanced cell death. A) Cell viability of Rh4 cells treated with fenretinide alone (left panel) and 
cell viability assay of fenretinide and ionizing radiation at the indicated concentrations and dosages 
as determined by WST assay (right panel). B) 12 days clonogenicity assay of Rh4 cells treated 
with fenretinide and ionizing radiation at the indicated concentrations and dosages C) Western 
Blot using whole cell lysates from Rh4 cells treated with 0.5µM fenretinide and 2Gy radiation. 
Cleaved PARP, Caspase 7 and GAPDH activity was assessed D) Western Blot using whole cell 
lysates from Rh4 cells treated with 0.5µM fenretinide and either 2Gy or 5Gy radiation. Phosph-
H2X and GAPDH activity was assessed (upper panel). Quantification of individual band 
intensities assessed by BioRad Software: Depicted are the normalized ratios of yH2X and GAPDH 
(lower panel). E) Cell cycle analysis determined by Flow Cytometry of Rh4 cells after 24h and 
48h treated with fenretinide and radiation at the indicated concentrations and dosages. Staining 
with propidium iodid (20mg/ml). 
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Figure 2 
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Figure 2: The combination of fenretinide and ionizing radiation enhances the production of 
reactive oxygen species. A+B: Mean fluorescence index analysis of the flow cytometry data of 
Rh4 cells treated with fenretinide (0.5/1.4µM) and ionizing radiation (2/5Gy), further co-treatment 
with N-Acetylcysteine 15mM. Cells were stained with CellRox (4µM) (A) and MitoSox (10µM) 
(B) C) Cell viability of Rh4 cells treated with fenretinide (1.4µM) and ionizing radiation (2Gy) in 
presence or absence of the mitochondria specific ROS scavenger MitoTempo (300µM) or Vitamin 
C (50µM) as determined by WST assay.  
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Figure 3 
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Figure 3: The combinatorial treatment of fenretinide and radiation therapy leads to an 
enhanced uptake of phase lucent dyes. A-C) Mean fluorescence index analysis of the flow 
cytometry data of fenretinide (1.4/3µM) and gamma radiation (2Gy/5Gy) treated Rh4 cells and 
co-treatment with dynasore (30µM) (A), Vitamin C (50µM) (B) or Z-VAD (100µM) (C), stained 
with Acridine Orange (2.7 µM) using two different bandpass filters, here 530/30 (Bandpass filter 
670/30 Supplementary Figure 1 A-C) D) Light fluorescence images of Rh4 cells treated or 
untreated with fenretinide (1.4µM) and gamma radiation (5Gy), stained with Lucifer Yellow 
(820µM). Quantification of the Relative Mean Density Index assed with Fiji software: Total 
integrated density value of an image was divided by the number of cells.  
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Supplementary Figure 1 
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Supplementary Figure 1: The combinatorial treatment of fenretinide and radiation therapy 
leads to an enhanced uptake of phase lucent dyes. A-C) Mean fluorescence index analysis of 
the flow cytometry data of fenretinide (1.4/3µM) and gamma radiation (2Gy/5Gy) treated Rh4 
cells and co-treatment with dynasore (30µM) (A), Vitamin C (50µM) (B) or Z-vad (100µM) (C), 
stained with Acridine Orange (2.7µM) using two different bandpass filters, here 670/30 (Bandpass 
filter 530/30 Figure 3 A-C). 
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Supplementary Tables 
Statistical Analysis 
 
Table 1 Statistical analysis with paired Students t-test of cell viability assay using the software 
Prism 7 
 
Treatment A Treatment B p-Value Significance 
DMSO, 0Gy Fen 1.9µM, 0Gy 0.0018 ** 
DMSO, 0Gy Fen 2.6µM, 0Gy 0.0079 ** 
 
Table 2 Statistical analysis with paired Students t-test of cell viability assay using Prism 7 
 
Treatment A Treatment B p-Value Significance 
DMSO, 0Gy DMSO, 5Gy 0.1313 ns 
DMSO, 0Gy DMSO, 10Gy 0.0826 ns 
DMSO, 5Gy Fen 1.9µM, 5Gy 0.0150 * 
DMSO, 5Gy Fen 2.6µM, 5Gy 0.0001 *** 
DMSO, 10Gy Fen 1.9µM, 10Gy 0.1813 ns 
DMSO, 10Gy Fen 2.6µM, 10Gy 0.4102 ns 
Fen 1.9µM, 0Gy Fen 1.9µM, 5Gy 0.0365 * 
Fen 1.9µM, 0Gy Fen 1.9µM, 10Gy 0.0033 ** 
Fen 2.6µM, 0Gy Fen 2.6µM, 5Gy 0.0190 * 
Fen 2.6µM, 0Gy Fen 2.6µM, 10Gy 0.1132 ns 
 
Table 3 Statistical analysis with paired Students t-test of MFI analysis using Prism 7  
 
Treatment A Treatment B p-Value Significance 
PAN-ROS NAC 
DMSO, 0Gy DMSO, 2Gy 0.0343 * 
DMSO, 0Gy DMSO, 5Gy 0.0300 * 
DMSO, 2Gy Fen 0.5µM, 2Gy 0.0042 ** 
DMSO, 2Gy Fen 1.4µM, 2Gy 0.0125 * 
DMSO, 5Gy Fen 0.5µM, 5Gy 0.0114 * 
DMSO, 5Gy Fen 1.4µM, 5Gy 0.0045 ** 
Fen 0.5µM, 0Gy Fen 0.5µM, 2Gy 0.0053 ** 
Fen 0.5µM, 0Gy Fen 0.5µM, 5Gy 0.0062 ** 
Fen 1.4µM, 0Gy Fen 1.4µM, 2Gy 0.0099 ** 
Fen 1.4µM, 0Gy Fen 1.4µM, 5Gy 0.0119 * 
DMSO, 0Gy NAC, DMSO, 0Gy 0.0043 ** 
 149 
Results – Manuscript II 
Fen 0.5µM, 0Gy NAC, Fen 0.5µM 0.0403 * 
Fen 1.4µM, 0Gy NAC, Fen 1.4µM 0.0123 * 
DMSO, 2Gy NAC, DMSO, 2Gy 0.0018 ** 
Fen 0.5µM, 2Gy NAC Fen 0.5µM, 2Gy 0.0405 * 
Fen 1.4µM, 2Gy NAC Fen 1.4µM 2Gy 0.0123 * 
DMSO, 5Gy NAC, DMSO, 5Gy 0.0148 * 
Fen 0.5µM, 5Gy NAC Fen 0.5µM 5Gy 0.0308 * 
Fen 1.4µM, 5Gy NAC Fen 1.4µM, 5Gy 0.0182 * 
 
Table 4 Statistical analysis with paired Students t-test of MFI analysis using Prism 7 
 
Treatment A Treatment B p-Value Significance 
MitoSox 
DMSO, 0Gy DMSO, 2Gy 0.5531 ns 
DMSO, 0Gy DMSO, 5Gy 0.0249 * 
Fen 0.5µM, 0Gy Fen 0.5µM, 2Gy 0.0523 ns 
Fen 0.5µM, 0Gy Fen 0.5µM, 5Gy 0.0289 * 
Fen 1.4µM, 0Gy Fen 1.4µM, 2Gy 0.1624 ns 
Fen 1.4µM 0Gy Fen 1.4µM, 5Gy 0.0036 ** 
 
Table 5 Statistical analysis with paired Students t-test of cell viability assay using Prism 7 
 
Treatment A Treatment B p-Value Significance 
Different Inhibitors 
DMSO, 0Gy 1.4µM Fen, 0Gy 0.5022 ns 
DMSO, 0Gy DMSO, 2Gy 0.1198 ns 
DMSO, 0Gy Fen 1.4µM, 2Gy 0.0459 * 
Fen 1.4µM, 0Gy VitC, Fen 1.4µM, 0Gy 0.3080 ns 
Fen 1.4µM, 0Gy MT, Fen 1.4µM, 0Gy 0.9648 ns 
DMSO, 2Gy VitC, DMSO, 2Gy 0,1674 ns 
DMSO, 2Gy MT, DMSO, 2Gy 0,3227 ns 
Fen 1.4µM, 2Gy VitC, Fen 1.4µM 2Gy 0,2351 ns 
Fen 1.4µM, 2Gy MT, Fem 1.4µM, 2Gy 0,8130 ns 
VitC, DMSO, 0Gy VitC, Fen 1.4µM, 0Gy 0,2199 ns 
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VitC, DMSO, 0Gy VitC, DMSO, 2Gy 0,9317 ns 
VitC, DMSO, 0Gy VitC, Fen 1.4µM, 2Gy 0,6376 ns 
MT, DMSO, 0Gy MT, Fen 1.4µM, 0Gy 0,1270 ns 
MT, DMSO, 0Gy MT, DMSO, 2Gy 0,6383 ns 
MT, DMSO, 0Gy MT, Fen 1.4µM, 2Gy 0,1036 ns 
 
 
Drugs and Stains 
 
Table 6 Drugs used during the experiments 
 
 Product information 
dynasore hydrate (dynasore) D7693, Sigma 
L-Ascorbinacid (Vitamine C) A4403, Sigma 
MitoTempo (MT) SML0737, Sigma 
Retinoic acid p-hydroxyanilide (fenretinide, Fen) H7779, Sigma 
Z-vad-FMK  A1902, APExBIO 
N-Acetylcysteine  A7250, Sigma 
 
Table 6 Fluorescent stains for flow cytometry and fluorescence microscopy 
 
 Product information 
Acridine Orange (hemi zinc chloride salt) 158550, Sigma 
CellRox Deep Red Reagent C10422, Thermo Fisher 
Lucifer Yellow L453, Thermo Fisher 
MitoSox Red M36008, Thermo Fisher 
Propidium Iodide 4170, Sigma 
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III. Discussion 
Sarcomas form the third biggest group of childhood malignancies. Within this group, aRMS is a 
rare but highly malicious subtype. The occurrence of metastasis already at early stages and high 
recurrence rates demand a multimodal and aggressive treatment approach comprising surgery, 
chemotherapy and radiotherapy. Despite this aggressive treatment, survival rates remain poor and 
therapy-related side effects still have a great impact on the children’s quality of life [42]. Despite 
abundant research on new anti-cancer agents for treatment of aRMS, only few new compounds 
are permanently established in the international treatment trials [48]. Reasons for the failure of 
new agents are mainly high toxicity and side-effects, unsatisfying tumour responses and 
development of resistances.  
Hence it remains one of the biggest challenges to overcome intrinsic or acquired resistances 
towards conventional treatment, which is responsible for the high recurrence rates seen in aRMS 
[411, 412].  
Along these lines, drugs that re-sensitize cells towards chemotherapy induced apoptosis or activate 
alternative, non-apoptotic cell death pathways, while exhibiting a low toxicity profile are highly 
desirable [412, 413].  
ARMS is characterised by its chromosomal translocation, which leads to the expression of the 
chimeric transcription factor PAX3-FOXO1 [31]. It is believed that PAX3-FOXO1 is the main 
tumorigenic driver in aRMS and tumour cell survival is dependent on its expression [35]. 
However, as a transcription factor it is considered undruggable and so alternative treatment 
strategies have to be exploited.  
In this thesis, we characterized the cytotoxic effect of fenretinide on aRMS cells in great detail.  
In a previous work and in an attempt to find new compounds with an improved therapeutic 
selectivity, we screened a small compound library thereby focusing on compounds which affected 
the transcriptional activity of PAX3-FOXO1. During this screen fenretinide was identified as the 
Discussion 
top hit affecting PAX3-FOXO1 activity levels without exhibiting a broad and unspecific toxicity 
[99].  
The work presented in the first manuscript focused on the mode of action of fenretinide in aRMS 
cells and described and characterized a new form of cell death induced in response to fenretinide 
treatment. In the second manuscript we presented data of fenretinide combined with ionizing 
radiation, assessed the effectiveness of this combinatorial treatment on cancer cell survival 
pointing out a role of fenretinide as radiosensitizer. 
 
1. Activation of a distinct and non-classical cell death pathway 
As expression of PAX3-FOXO1 is essential for aRMS and the previous screen had revealed that 
fenretinide affected PAX3-FOXO1 transcript levels, we first studied this interrelation in more 
detail. By using an inducible lentiviral vector system directed against endogenous PAX3-FOXO1 
together with one overexpressing PAX3-FOXO1 in Rh4 cells, we demonstrated that, upon 
fenretinide treatment, apoptosis was induced which was accompanied with a reduction of PAX3-
FOXO1 protein levels. However, ectopic PAX3-FOXO1 did not protect from fenretinide induced 
cell death indicating that Fenretinide might induce an alternative mode of cell death.  
Interestingly, further studies showed that the fenretinide induced cell death was distinct from 
apoptosis, necroptosis, autophagy and ferroptosis, as neither pharmacological inhibition of these 
death pathways nor their genetic ablation rescued cell survival after fenretinide treatment. 
However, inhibitors directed against reactive oxygen species completely abrogated the fenretinide 
mediated toxicity, indicating the importance of ROS in fenretinide induced cell death.  
 
2. Trigger to the production of reactive oxygen species 
As previously shown in other cellular systems, fenretinide is capable to induce production of 
different kinds of reactive oxygen species, which are responsible for the observed cell death [67, 
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80, 90, 414]. In our cell system, we found that fenretinide treatment led to the production of 
mitochondria derived ROS as an early event, preceding the induction of cell death. Further, rescue 
experiments clearly showed that these mitochondrial ROS also mediated cell death. This 
observation was not surprising, since the mitochondrial respiratory chain (MRC) is on the one 
hand the major sources of ATP production, but on the other hand also the major source of ROS 
production and so depicts a vulnerable system when the equilibrium is disturbed [110, 111, 130, 
154, 238, 240]. Our results are in accordance with the findings of Cuberus et al [79] who also 
suggested that fenretinide-induced ROS production occurred via complex II of the MRC, which is 
further in agreement with our own findings, which indicate that the main target of fenretinide to 
cause ROS production lies downstream of complex II of the MRC.  
However, in contrast to our data where an uncoupling of the MRC with CCCP at complex V had 
no influence on ROS production, Suzuki et al. [75] suggested that fenretinide inhibits the MRC at 
complex V in cervical carcinoma cells. Nevertheless, while at this point it is not exactly clear how 
fenretinide induces ROS production, their role in triggering cell death is undebatable.  
 
3. Accumulation of cytoplasmic vesicles and uptake of fluid phase dyes 
induction 
On electron microscopy images, we observed that fenretinide treatment induced formation and 
accumulation of cytoplasmic vesicles. This phenomenon has been previously described in multiple 
other cellular systems in the context of paraptosis, oncosis, methuosis and autophagy [298, 310, 
415, 416]. During paraptosis as well as during oncosis, the ER shows distinct vacuolization and 
the mitochondria are swollen [415, 417], both features that we did not observe in our fenretinide 
treated cells. Moreover, the vesicles observed in aRMS cells are surrounded by a single membrane 
and therefore did not originate from autophagy, which gives rise to double membrane 
autophagosomes [298]. The cytoplasmic vesicles are of variable size with diameters of up to 7μm, 
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which is comparable to the described diameter of macropinosomes which reach a diameter up to 
5μm [361]. Morphologically the vesicles mostly resembled endosomes, an interpretation which 
was further verified by increased fluid phase dye uptake stimulated by fenretinide treatment. 
Interestingly co-treatment with ROS scavengers abolished vesicle formation substantiating an 
effect downstream of ROS. Further inhibition of apoptosis by Z-vad, led to enhanced accumulation 
of vesicles, which suggests that alternative death pathways can be engaged if the classical ones 
like apoptosis are impaired. Moreover, this is in accordance with a delay in the onset of cell death 
in presence of Z-vad by about 10 hours as seen in our time lapse experiments. 
 
4. Accumulation of early and late endosomes in a dynamin-dependent manner 
Attempts to block the fenretinide mediated cell death with commonly used endocytosis inhibitors 
like chlorpromazin, filipin and genistein revealed an independence of the clathrin and caveolin-
mediated endocytosis. However, in contrast to other published descriptions on vesicular mediated 
cell death, we observed that pharmacologic as well as genetic interference with the Dynamin 
GTPases completely abolished vesicle accumulation and rescued from fenretinide induced cell 
death. The Dynamin family of GTPases are profoundly involved in endosome fission at the plasma 
membrane, both during clathrin-dependent and -independent endocytosis. More recent studies also 
suggest a role of dynamins during circular dorsal ruffle (CDR) formation, which is considered a 
specific type of the macropinocytosis pathway [343, 418, 419]. In this context, Orth et al was able 
to show, that formation of CDR at the plasma membrane mainly serves the internalization of 
EGFRs, following stimulation of TRKs and proceeds in a highly organized manner [418]. Here, 
dynamin and its binding partner cortactin, as well as multiple other cytoskeleton associated 
proteins are involved in vesicle formation [419]. Interestingly, tumor cells seem to form less CDR 
than normal cells, which might lead to unchecked growth [419], and so stimulation of CDR in 
tumor cells might have a negative influence on their growth which could be exploited.  
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Reactive oxygen species are known to activate PTEN and MAPK phosphatases and so act as 
negative regulators of tyrosine kinase receptor signaling cascades [133, 144-146, 420-422], which 
might be a possible link to the formation of CDRs after fenretinide treatment.  
Also very interesting in this context is the observation that induction of ROS-dependent cell death 
with other drugs including the proteasome inhibitors MLN2238 and MLN9708, the microtubule-
destabilizing agent rigosertib or the tyrosine-kinase inhibitor bosutinib neither induced the 
formation of cytoplasmic vesicles nor was the cells’ demise blocked by Dynamin inhibitors.  
When comparing our findings with other similar cellular phenotypes that have been described in 
the literature, the greatest resemblances are found in a cell death form termed methuosis [310, 415, 
416]. Since the description and denomination of methuosis by Overmayer et al [310] in 
glioblastoma cells, several different stimuli have been described that induce this phenotype and 
are associated with a disturbance of the endosomal maturation. These stimuli include various small 
molecules with different pathways involved, including activation of Ras, as well as ectopic Ras 
expression per se, which stimulates marcopinosmome formation via over-activation of Rac1 and 
at the same time impedes their recycling (for review see Maltese et al [423])[317]. While Ras 
activation seems to be crucial in vesicle formation of several cell types including glioblastoma, 
Ewing sarcoma and epithelial cells [310, 317, 338], Ras pathway mutations are not associated with 
aRMS [424]. Further pharmacological inhibition as well as knock-out of Rac1 and Arf6 in aRMS 
cells neither affected fenretinide mediated cell death nor dye uptake (data not shown in the thesis), 
indicating that this pathway does not seem to play a role in these cells. 
However similar to methuosis, we also observed an impaired recycling of endosomes with a 
maturation stop at the level of early/late endosome formation, as the vesicles acquire markers such 
as Rab5 and Rab7 but not the lysosomal marker LAMP-1. However, the exact mechanisms leading 
to a maturation stop of the endosomes has not yet been understood and needs further elucidation. 
Nevertheless, the different studies suggest that various upstream pathways might be engaged to 
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induce a similar vesicular phenotype associated with cell death, while none of the studies were 
able to draw a causal link between vesicle accumulation and cell death. Further very important in 
this context is the fact, that none of the compounds used in the mentioned studies is yet in clinical 
use. So clinical and pharmacological data regarding bio distribution, tolerability, side-effects and 
also efficacy are not available. However, due to the long clinical experiences with fenretinide and 
also the fact that it is already FDA approved sets it apart from those other compounds. The finding 
that fenretinide engages a new form of cell death which is not exploited by conventional 
chemotherapy agents makes it as a promising combinatorial partner for the treatment of aRMS 
patients, as resistance development against two different death pathways is much less likely than 
the development against only one. Agents for a potential combination treatment might either be 
stimuli that further enhance ROS production to trigger cell death even further or stimuli that induce 
other forms of cell death like canonical apoptosis or necroptosis.  
 
5. Fenretinide and radiation therapy combination enhances cell death 
We considered ionizing radiation as potential combination therapy for fenretinide treatment. 
Moreover, radiotherapy is already in use as the third pillar in the standard treatment plan for 
patients with aRMS along with chemotherapy and surgery and therefore represents a rational 
choice [401-404]. But viewed from the other side, it seems even more important to identify 
radiosensitizers to potentially reduce radiation doses. Fenretinide which has a low toxicity profile 
and promising anti-cancer activity, therefore represents an ideal candidate.  
RT is associated with significant late effects in survivors [425]. Depending on the treatment site, 
the side effects comprise neurocognitive sequelae, growth restriction through growth hormone 
deficiency, infertility and secondary malignancies [388-390]. In this context, duration and dose 
administered is crucial and based on the patient's risk-group. While in low risk patients RT can be 
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omitted, high risk patients have a far worse prognosis and addition of RT to the treatment regimen 
has substantially improved EFS and overall survival [401, 426].  
So far multiple strategies have been investigated to reduce RT-related morbidity in aRMS patients, 
including intensity-modulated RT (IMRT) and hyperfractioned radiation [396, 397]. While 
hyperfractionation did not bring a benefit in local nor regional control [43, 406], IMRT resulted in 
an excellent local tumor control in parameningial aRMS, with comparable side-effects than 
conventional RT [407]. Radiosensitizing agents are capable to broaden the therapeutic window 
and selectively augment radiation effects in tumor cells while also sparing the surrounding tissue. 
In pediatric trials, radiosensitizers are so far not implemented. Several chemotherapeutic agents as 
anthracyclines and actinomycin D are known to render the tumor tissue more radiosensitive, cause 
however a significant toxicity so that these chemotherapeutic agents must indeed be avoided in 
conjunction with radiotherapy. Other agents like platinum-derivates or 5-fluoruracil also potentiate 
the radiation effect but have not yet been studied in the context of radiotherapy and aRMS.  
Tumor hypoxia is a commonly found feature in tumor masses, which becomes more severe with 
increasing size of the mass. Hypoxic tumor cells are not only more chemotherapy-resistant but 
also often resistant to radiation therapy. Further, hypoxia leads to a more malignant phenotype and 
increases metastasis [427]. To target tumor hypoxia and increase radiosensitivity has been a major 
focus of radiobiologists over the last years and different approaches to increase radiosensitivity 
have been made. These include hyperbaric oxygen, nitroazole sensitizers and hypoxic cytotoxins 
like tirapazamine [428]. However, none of these strategies was proven effective in clinical trials. 
Hydrogen peroxide is currently under intense investigation as a potential radiosensitizer in 
multiple malignancies (ClinicalTrials.gov NCT02757651). When hydrogen peroxide is injected 
into the tumor, it is degraded into water and oxygen and decreases tumor hypoxia [429]. As 
fenretinide induces superoxides which might be reduced to hydrogen peroxide by SODs an anti-
 158 
Discussion 
hypoxic effect might also be seen with fenretinide treatment. This question has not been addressed 
yet and opens the possibility of further investigations.  
 
Fenretinide combined with radiation therapy is under investigation for the treatment of diffuse 
intrinsic pontine glioma (DIPG) and suggest promising results in mice [430]. Up-to-date, there are 
only few other studies exploring the combinatorial effect of fenretinide with radiation therapy and 
so far, radiosensitizing agents for the treatment of aRMS, are not established in international 
treatment trials. Therefore, new treatment strategies are needed to better exploit the benefits of RT 
while reducing their side-effects.  
During our first experiment with RT combined with fenretinide, we saw an increasing, dose-
dependent combinatorial effect on cell-viability. This effect was so strong, that almost no colonies 
survived. Subsequently, we were able to reduce both treatment dosages with a persisting effect at 
2 Gy on clonogenic growth.  
We saw a strong enhancement of induction of apoptosis in the combination treatment. The 
underlying cause for the induction of apoptosis most likely result from DNA damage and 
consequently induction of cell cycle arrest. Cell cycle arrest is frequently observed following DNA 
damage and radiotherapy [431], and is also observed after fenretinide treatment [432]. Our results 
also showed an impaired cell cycle progression with a G2/M arrest with a clear combinatorial 
effect. This is an important finding as it is one of the hallmarks of cancer that tumor cells sustain 
proliferative signaling even after DNA damage [6], and hence restoration of the normal response 
– induction of cell death - is desirable. 
In the context of those findings and when taking toxicities in consideration, fenretinide with its 
low toxicity profile seems the perfect drug in the combination with RT.  
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6. Combination with ionizing radiation, ROS-production and vacuolizing cell 
death 
In the first manuscript, we were able to show that fenretinide triggers mitochondrial ROS 
(superoxides). In the combination treated cells, we identified further increase in ROS production. 
Interestingly however, we saw that RT alone mainly triggered the production of hydrogen 
peroxide. So obviously in the combined treated cells, two different kinds of ROS species are 
responsible for the enhanced cell death. This finding, to trigger different ROS species, is important 
in the context of resistance development, as cancer cells are known to upregulate antioxidant 
pathways and different ROS species are scavenged by their own antioxidants [433].  
Also interesting in this context are studies that use hydrogen peroxide as a radiosensitizer [429]. 
Here hydrogen peroxide serves indirectly as an oxygen donor in the tumor cell during its 
dismutation to H2O and O2. As superoxides are also reduced to hydrogen peroxide, fenretinide 
might serve in the same way as an indirect oxygen donor for tumorous tissues. However, this has 
not been investigated yet.  
In summary, we were able to show that downstream of ROS, the combination of RT and 
fenretinide triggered increased macropinocytosis, as assessed via fluid phase dye uptake 
experiments by flow cytometry.  
In contrast, single treatment with RT did not induce macropinocytosis and scavenging with 
Dynamin inhibitors had no influence. In contrary, by light microscopy only a non-significant 
increase in macropinocytosis was seen. This minor increase in dye uptake might however exhibit 
an analysis bias as the mean integrated density value of an image sums all of the pixels within a 
region and gives you a total value. This value is then divided by the number of cells counted on 
the phase image. This analysis does not take into consideration the size of the cell.  
RT however induces cell cycle arrest and senescence and subsequently a morphological 
appearance-change of the cells with an increased cell size. This eventually will lead to an increased 
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integrated density value for the enlarged cell as they are capable to uptake more dye per cell and 
the evaluation is expected to show an increased mean density index per cell, compared to smaller 
cells. Due to the gating strategy applied in the flow cytometry analysis, the cell size is not relevant. 
However, in the irradiated-only cells neither a Dynamin Inhibitor nor a ROS-scavenger could 
inhibit the dye uptake, as was the case for fenretinide treated cells. Based on these findings it is 
unlikely that irradiation induced cell death is a result of an increased macropinocytosis. 
These findings suggest that a distinct population of ROS are responsible for the induction of 
macropinocytosis through fenretinide, which is not induced by RT alone. Hence, while the exact 
mechanism leading to the increased macropinocytosis remains to be elucidated, the fact that 
fenretinide engages this new form of vesicular cell death which is neither exploited by 
conventional chemotherapy agents nor RT defines them as promising combinatorial partners. 
Moreover, our data clearly show that addition of fenretinide to RT enhances cell death, meaning 
that a reduction of the administered doses could be possible, while maintaining the same anti-
cancer response. In the context of normal tissue toxicity and radiation related side-effects this is 
an encouraging finding to translate the combination into clinics.  
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7. Conclusion  
Taken together our results provide evidence that fenretinide induces mitochondrial ROS through 
an interference with the MRC downstream of complex two. Further, these distinct ROS species 
induce dynamin-dependent macropinocytosis leading to an enormous vesicle formation and 
accumulation in the cytoplasm. These vesicles have a strong and effective cytotoxic potential in 
aRMS cells.  
Further our findings support that fenretinide acts as a promising radiation sensitizer in alveolar 
rhabdomyosarcoma cells. Here, different modes of cell death mechanism are activated and 
enhanced by these two treatment modalities.  
Since fenretinide is already in clinical use in children (Clinicaltrials.gov ID NCT02163356) with 
a promising toxicity profile [66, 434], a combinatorial treatment of both may help to reduce the 
development of resistances and increases the therapeutic window in the local radiotherapy 
treatment and so is a promising treatment regime in pediatric patients with alveolar 
rhabdomyosarcoma. 
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